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Structure And Metal Binding Properties Of A Poxvirus Resolvase
Abstract
Poxviruses, including smallpox virus, replicate their linear genomes by forming concatemers that must be
resolved into monomeric units in order to produce new virions. Poxviruses encode a resolvase enzyme
that cleaves 4-way junctions extruded at the concatemer junctions, a process that is essential for viral
replication. Given its important role in the viral life cycle, the resolvase is an attractive target for identifying
small molecule inhibitors of poxvirus infection. To provide a platform for interpreting and designing
experiments and to establish a framework for inhibitor design, we have determined the crystal structure
of the canarypox virus (CPV) resolvase. CPV resolvase is a RuvC-like dimer composed of RNaseH family
folds, with an active site lined by highly conserved, acidic, metal-binding residues. However, there are a
number of intriguing structural differences between resolvase and RuvC. A model of the CPV
resolvase•HJ complex provides insights into the likely consequences of these changes, including a
plausible explanation for the weak sequence specificity exhibited by the poxvirus enzymes. The model
also explains why the poxvirus resolvases are more promiscuous than RuvC, cleaving variety of branched,
bulge, and flap-containing substrates. Comparing to bacterial RuvC, poxvirus resolvase has one additional
aspartic acid (Asp130) at the A site in the active site pocket, which locates at a well-structured α helix.
Asp130 side chain carboxylates hydrogen bonds to a water molecule that coordinates the bound A site
metal. Thus, Asp130 contributes indirectly to metal binding and could be important for resolvase activity.
Based on the unique active site structure observed for CPV resolvase, we have carried out a series of
experiments designed to test divalent ion usage and preferences. We find that the two resolvase metal
binding sites have different preferences for Mg2+ vs. Mn2+ relative to their expected physiological
concentrations. Optimal resolvase activity is maintained with 5 �M Mn2+ and 100 �M Mg2+,
concentrations that are well below those required for either metal alone. The additional Asp130 increases
the affinity for divalent ions by 10-15 folds and increases resolvase enzymatic activity. Biochemistry
studies on the resolvase inhibitor demonstrated that it inhibits resolvase activity in uncompetitive manner.
Together, our findings provide biochemical insights and structural models that will facilitate studying
poxvirus replication and the search for efficient poxvirus inhibitors.
We developed one novel method (Metal&EDTA) to purify RNaseH family members. This method takes full
advantage that RNaseH family members have different binding affinities to cationic exchange
chromatography column in the presence of EDTA and divalent ions. High purity of enzymes could be
obtained in a two-step purification using one SP-sepharose chromatography column. Metal&EDTA
method has the potential to purify all types of metal dependent nucleic acids enzymes and
metalloproteinases.
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ABSTRACT
STRUCTURE AND METAL BINDING PROPERTIES OF A POXVIRUS RESOLVASE
Huiguang Li
Gregory D. Van Duyne

Poxviruses, including smallpox virus, replicate their linear genomes by forming
concatemers that must be resolved into monomeric units in order to produce new virions.
Poxviruses encode a resolvase enzyme that cleaves 4-way junctions extruded at the concatemer
junctions, a process that is essential for viral replication. Given its important role in the viral life
cycle, the resolvase is an attractive target for identifying small molecule inhibitors of poxvirus
infection. To provide a platform for interpreting and designing experiments and to establish a
framework for inhibitor design, we have determined the crystal structure of the canarypox virus
(CPV) resolvase. CPV resolvase is a RuvC-like dimer composed of RNaseH family folds, with an
active site lined by highly conserved, acidic, metal-binding residues. However, there are a
number of intriguing structural differences between resolvase and RuvC. A model of the CPV
resolvase•HJ complex provides insights into the likely consequences of these changes, including
a plausible explanation for the weak sequence specificity exhibited by the poxvirus enzymes.
The model also explains why the poxvirus resolvases are more promiscuous than RuvC, cleaving
variety of branched, bulge, and flap-containing substrates. Comparing to bacterial RuvC,
poxvirus resolvase has one additional aspartic acid (Asp130) at the A site in the active site pocket,
which locates at a well-structured α helix. Asp130 side chain carboxylates hydrogen bonds to a
water molecule that coordinates the bound A site metal. Thus, Asp130 contributes indirectly to
metal binding and could be important for resolvase activity.
Based on the unique active site structure observed for CPV resolvase, we have carried
out a series of experiments designed to test divalent ion usage and preferences. We find that the
two resolvase metal binding sites have different preferences for Mg2+ vs. Mn2+ relative to their
expected physiological concentrations. Optimal resolvase activity is maintained with 5 µM Mn2+
and 100 µM Mg2+, concentrations that are well below those required for either metal alone. The
v

additional Asp130 increases the affinity for divalent ions by 10-15 folds and increases resolvase
enzymatic activity. Biochemistry studies on the resolvase inhibitor demonstrated that it inhibits
resolvase activity in uncompetitive manner. Together, our findings provide biochemical insights
and structural models that will facilitate studying poxvirus replication and the search for efficient
poxvirus inhibitors.
We developed one novel method (Metal&EDTA) to purify RNaseH family members. This
method takes full advantage that RNaseH family members have different binding affinities to
cationic exchange chromatography column in the presence of EDTA and divalent ions. High
purity of enzymes could be obtained in a two-step purification using one SP-sepharose
chromatography column. Metal&EDTA method has the potential to purify all types of metal
dependent nucleic acids enzymes and metalloproteinases.
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CHAPTER 1: Poxvirus resolvase Introduction
Poxvirus and poxvirus resolvase
Poxviruses are a large group of viruses which infects a very broad range of eukaryotic
hosts, including mammals, birds, reptiles and insects. These viruses have long, linear and
double stranded DNA genomes that are replicated in the cytoplasm of infected cells (1), shown in
Figure 1-1A. The best known example is variola, the virus responsible for smallpox. The
vaccinia virus (VV), which had been used for many years as a naturally attenuated vaccine to
eliminate smallpox, has served as the prototype poxvirus for laboratory research. The VV
genome is ~200 kb in length and encodes ~200 genes. During poxvirus replication (Figure 1-1B),
a viral DNA polymerase and several auxiliary factors generate concatemers of the linear genome
using a rolling hairpin replication mechanism (2-4). The concatemer junctions between unit
genomes contain inverted repeat sequences which can be extruded as 4-way DNA junctions (5).
These cruciform structures are cleaved by a viral resolvase, resulting in monomeric genomes that
can ultimately be packaged into new virions (6,7).

Figure 1-1. Poxvirus replication. Figure A shows vaccinia virus replication in human cell cytoplasm. This Figure is
adopted from reference (8). Figure B shows the vaccinia virus genome replication. Black lines are single-stranded DNA.
Half- arrows denote repeated sequences at the genome termini. Bulges are unpaired DNA at the termini. The replication
has four steps: 1) genome replication and concatemer formation. 2). Concatemer isomerizes to form cruciform extrusion.
3). the cruciform DNA is recognized and cleaved by resolvase. 4). DNA ligation seal the DNA ends.

The VV resolvase (named A22) was originally identified based on weak similarity to
1

bacterial RuvC proteins (Figure 1-2) and is a member of the RNaseH superfamily (6). Vaccinia
virus A22 was the first poxvirus resolvase to be investigated. Initial studies demonstrated that
A22 binds Holliday Junction (HJ) substrates and cleaves them in a Mg2+ dependent manner in
vitro (6). In infected cells, A22 expression is required for concatemer resolution, viral replication,
and production of virions, supporting an essential role in concatemer resolution for this enzyme
(7). Subsequent studies showed that A22 fusion with maltose-binding protein (MBP) is a stable
dimer and that the enzyme has only weak sequence-specificity compared to E.coli RuvC (9,10).

Figure 1-2. Multiple sequence alignment of HJ resolvases from RNaseH family. Only five conserved motifs are shown.
The lengths of the poorly conserved spacers between the motifs are indicated by italic numbers. The positions of the first
and the last of the aligned amino acid residues in each sequence are also indicated. The protein designation consists of
the gene, an abbreviated species name, and the GenBank identification number (separated by underlines). The multiple
alignment is based on existing or predicted secondary structure. E indicates β-sheet, and H indicates α-helix. Species
abbreviations: Bacteria: Ct, Chlamydia trachomatis; Ec, E.coli; Hp, Helicobacter pylori; Mtu, Mycobacterium tuberculosis;
Rp, Rickettsia prowazekii; Ssp, Synechocystis sp; Tm, Thermotogamaritima; Tp, Treponemapallidum. Eukaryotic
mitochondrial: Sc, Sac. cerevisiae; Sp, Sch.pombe.Viruses: biL66, LBPc2, Lactococcus lactis bacteriophages; CIV, Chilo
iridescent virus; MCV, molluscum contagiosum virus; MSEPV, Melanoplus sanguinipes entomopoxvirus; Myx, myxoma
virus; RFV, rabbit fibroma virus; VACC, vaccinia virus; YMV, Yaba monkey virus. Two arrows point to E.coli RuvC and
vaccinia virus resolvase. This figure is adopted from reference (6).

The RuvC-like resolvases use Mg2+ ions as co-factors, where two metal ions bind in an
active site lined with conserved aspartic and glutamic acid residues (11). During catalysis, the
metals coordinate the scissile phosphate and the A site metal activates a water molecule for
hydrolytic attack of the phosphodiester, leaving 5'-phosphate and 3-hydroxyl groups (12,13). B
site metal participates in transition state stabilization. This two-metal ion mechanism is used in a
broad range of nucleotidyl transfer reactions, including the RNaseH-like nucleases, transposases,
retroviral integrases, DNA/RNA polymerases, and group I & II ribozymes (14,15).
Historically, smallpox has been a major threat to human health. The virus is highly
transmissible with infection typically resulting in 20%-30% mortality. According to the World
Health Organization (WHO), it has been estimated that 500 million people died of smallpox
2

infection in 20th century (16). Although the smallpox virus has been eradicated, several reasons
may cause the smallpox virus to come back. First, terrorists may use smallpox as a weapon.
Second, smallpox has been found in frozen mummies in Siberia and it is still infective (17). When
global warming intensifies, the contagious virus may infect humans. Another concern is that
cross-species virus transmission may infect humans such as monkeypox virus and cowpox virus
(18). There are few viral protein targets available for developing small molecule inhibitors as
drugs except the poxvirus DNA polymerase (19). Cidofovir has been developed as a inhibitor to
poxvirus DNA polymerase (19), however, the poxvirus soon acquires the resistance the cidofovir
(20). It is clear that we still need other poxvirus enzymes to work as targets to develop drugs.
Since humans have no homologue of poxvirus resolvase, it is a promising target to develop drugs
against poxvirus. Large scale inhibitor screens have been carried out, and several small
compounds have shown promising inhibiting effect (21).

RNaseH family members and RNaseH folding pattern
In 1990, the crystal structure of E.coli RNaseH was determined by two research groups
independently at same time (22,23). The RNaseH shows a novel folding pattern with five beta
strands sandwiched between alpha helices. In the next several years, crystal structures for two
other enzymes (HIV integrase and E.coli RuvC) involved DNA recombination have been
determined (24,25). Surprisingly, they share a similar folding pattern as RNaseH, although they
function as dimers and do not show primary sequence homology. Therefore, the folding pattern
of RNaseH is called “RNaseH folding pattern” and this group is called the RNaseH family. Since
then, more crystal structures of enzymes involved in cleaving nucleic acid have been determined
with the similar fold pattern. Important members include transposase (26) which catalyzes
transposon moving in host genome, argonaute (27) which plays critical role during RNA mediated
gene silence and cas9 (28) which could introduce double stranded DNA break. In general,
RNaseH families are a large group of nucleases which digest double stranded nucleic acid,
including double stranded DNA (examples is RuvC), double stranded RNA (examples is
argonaute) and double stranded DNA/RNA duplex (examples is RNaseH). Typical RNaseH
family member structures are shown in Figure 1-3. The oligomeric status of RNaseH family
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members could be monomer or dimer depending on the number of cleavage sites on the
substrate. RNaseH needs only one cleavage thus it adopts a monomeric structure; RuvC and
argonaute need two cleavages on their substrates, therefore, RuvC and argonaute adopt dimeric
structures.

Figure 1-3. Catalytic core domain of RNaseH family members. The central β-sheet (with numbered strands) and the
conserved α-helix are shown in orange and yellow, respectively. More divergent parts of the fold are shown in grey. The
active-site residues are shown in ball-and-stick representation. The two metal ions observed in the Tn5 and RNaseH1
structures are shown in purple. The sites of insertions into the RNaseH fold are shown as dashed lines. The direction of
the last helix is indicated with an arrow. HIV, human immunodeficiency virus; PDB, Protein Data Bank code; Tn5,
transposon 5. This figure is adopted from reference (29).

RNaseH binds to RNA/DNA hybrids in a sequence nonspecific manner and degrades the
RNA strand. Two groups of RNaseH have now been identified: RNaseH1 and RNaseH2
enzymes. RNaseH1 enzymes are present in all forms of life from bacteria to animals, as well as
in retroviruses where they constitute a domain of reverse transcriptase. RNaseH1 enzymes have
been implicated in the removal of the RNA primers that are used to start the synthesis of Okazaki
fragments during DNA replication (30). RNaseH2 enzymes have different substrate specificity
and biochemical properties. Most importantly, RNaseH2 enzymes cleave preferentially at the 5'
end of RNA in chimeric DNA–RNA–DNA/DNA hybrids. They can hydrolyze this substrate even if
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it contains only a single ribonucleotide, whereas RNaseH1 enzymes require at least four
ribonucleotides (31). Therefore, RNaseH2 enzymes are thought to be involved in the removal of
single ribonucleotides misincorporated into DNA during replication(32).
Although there is no detectable homology between the members of the RNaseH family,
the structure of their catalytic RNaseH domains is highly conserved (33). The central and most
invariant element of this domain is a five stranded β-sheet and one α helix. The first three
strands are anti-parallel and usually run without any insertions. The shorter fourth and fifth
strands run parallel to the first strand. In addition to the central β-sheets, the fold contains αhelices of variable position and arrangement. The most conserved α-helix is located immediately
after strand 3. It is adjacent to one face of the β-sheet and runs across it.
Table 1-I. Enzymes that use two metal mechanism and possess an RNaseH folding pattern
Enzymes activity
Two-metal-mechanism
RNaseH folding pattern
Transferase activity
DNA polymerase (34)
Yes
RNA polymerase (35)
Yes
Reverse transcriptase (36)
Yes
Yes (RNaseH domain)
Hydrolase activity
Restriction enzyme(37)
Yes
RNaseH (23)
Yes
Yes
Bacteria Resolvase (24)
Yes
Yes
Dicer (38)
Yes
Argonaute (27)
Yes
Yes (RNaseH domain)
Cas9 (28)
Yes
Yes (RNaseH domain)
Poxvirus resolvase
Yes
Yes
Bacteria UvrC (39)
Yes
Yes
Prp8 (40)
Yes
Yes (RNaseH domain)
Alkaline phosphatase (41)
Yes
Ligase activity
DNA ligase (42)
Yes
RNA ligase (43)
Yes
Combined activity
Transposase (26)
Yes
Yes
Retroviral integrase (25)
Yes
Yes (RNaseH domain)
Divalent ions are essential for catalysis. The preferred ion is Mg2+, but Mn2+ also
supports catalysis. The crystal structures solved in the presence of nucleic acid (RNaseH1
enzymes) indicated the involvement of two ions (12,44) and a general two-metal ion mechanism
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(45). In this mechanism, metal ions are located on two sides of the scissile phosphate: the A site
Mg2+ ion activates the nucleophile; and the B site Mg2+ coordinates and stabilizes the transition
state and the leaving group (Figure 1-4C). The two-metal-ion mechanism is not only used by
RNaseH family members, but also for most of the divalent ion dependent nucleic acid enzymes.
Table 1-I lists the typical nucleic acid enzymes using a two-metal-mechanism to carry out their
biological functions and possessing an RNaseH folding pattern. The active sites of RNaseH
members are composed predominantly of negatively charged carboxylate residues that
coordinate the metal ions.

Figure 1-4. Crystal structure of RNaseH and RNaseH•DNA/RNA complex. A) shows the E.coli RNaseH. PDB code:
1RNH. The critical amino acids are shown as sticks. Conserved motifs are colored green, while divergent parts are
colored purple. B) shows the Human RNaseH•DNA/RNA complex. PDB code: 2QKK. The critical amino acids are shown
as sticks. RNA strand is colored in red, while the DNA strand is colored in blue. Two Mg2+ ions at the active site are
shown as blue spheres. Three water molecules interacting with A site metal are shown as red spheres. C) shows the
detail structure at the active site of panel B, adopted from reference (29).

Two residues (two aspartates or one aspartate and one glutamate) are particularly
important and are well conserved, as shown in Figure 1-4A. The position of these two residues is
also highly conserved: the first is in the middle or at the end of the first β-strand and the second is
at the end of the fourth strand, adjacent to strand 1. The first carboxylate is the only one that
coordinates directly both metal ions and is located at the heart of the active site (12). The second
6

residue coordinates metal ion B. The third residue of the active site—the most C-terminal of the
three coordinates metal ion A. This residue is comparatively variable and can be an aspartate, a
glutamate or a histidine (46). Members possessing a histidine at the last C-terminal are often
either located in the cytoplasm or are from archaea. This residue is always located in a less
conserved part of the core structure, after strand 5 of the central β-sheet. This region usually
forms a α-helix that is adjacent to the β-sheet, but in some species it exists as a loop. The
number of residues interacting with metal ion A also varies from two to four(24,47,48).
Crystal structures of bacterial and human RNaseH1 enzymes bound to RNA/DNA hybrids
have been determined (12,44). The crystal structure of human RNaseH1•RNA/DNA complex is
shown in Figure 1-4B. In both cases, the nucleic acids adopt B from and were seen to interact
with the active site. Both bacterial and human RNaseH1 enzymes contain two grooves on their
surface, each of which accommodates one strand of the RNA/DNA hybrid. The RNA-strand
groove contains the active site, and the RNA is specifically recognized by interactions with 2'-OH
groups. Two metal ions have been observed at the active sites of both bacterial and human
RNaseH1 enzymes, which are coordinated not only by carboxylates from the active site but also
by the backbone of the RNA.

RuvC and HJ resolution
Homologous recombination is a fundamental cellular process that rearranges genes
within and between chromosomes, promotes DNA repair, and guides segregation of
chromosomes at division. More than 50 years ago, Holliday proposed a meiotic recombination in
which homologous chromatids exchanges single DNA strands to form a joint molecule with a
four-way junction at the point of exchange (49). The four-way DNA strand exchange is reciprocal
and generates a HJ. Since then, enzymes responsible for resolving the four-way junction DNA
have been identified in all kind of organisms, including bacteriophage T7 endonuclease I (endo-I)
(50) (51), bacteriophage T4 endonuclease VII (endo-VII) (52), bacteria RuvC (53) and eukaryote
Mus81-EME1 (54). Among these junction resolvases, RuvC was extensively studied. In early
1990’s, the crystal structure of E.coli RuvC was determined (24). It functions as a dimer, and
shows a similar folding pattern to E.coli RNaseH, although they do not have primary sequence
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homology, shown in Figure 1-5A

Figure 1-5. Crystal structure of E.coli RuvC and mechanism of RuvABC recognizing and cleaving HJs. Figure A shows
the crystal structure. Critical amino acids are shown as sticks. Figure B shows the cartoon diagram of RuvABC
recognizing and cleaving HJ. RuvA is colored in yellow, RuvB is color in blue and RuvC is colored in magenta. Left
Figure the top view and right Figure shows the side view. Figure B was adopted from reference (55). Two opposite
Junction arms are pumped in from RuvAs, and the other two opposite arms are pumped out from RuvB.

RuvC functions as a dimer, and each monomer has 5 conserved beta sheets sandwiched
between alpha helices. Four of critical amino acids comprise the active site. The dimeric RuvC
resolves the HJ into duplex products by the introduction of symmetrically related nicks in two of
the four DNA strands. It shows a preference for cleavage between the third and fourth positions
of a tetra-nucleotide sequence with the consensus 5’-(A/T)TT↓(G/C)-3’ (56). In the early study of
the ruv gene region, scientists identified two other genes, RuvA and RuvB (57). These two gene
products are also involve in the homologous DNA repair pathway in E.coli. Crystal structures of
RuvA and RuvB have been determined (58,59), and RuvA has been further determined as a
crystal structure with HJ (60). A tetramer of the RuvA protein forms a grooved platform on which
the HJ is held in a square planar configuration. Each subunit binds one HJ arm and the four arms
adopt a crossed configuration. RuvB is an AAA enzyme (ATPase associated with various cellular
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activities). It functions as a hexamer, forming a ring shape with a central hole to hold HJ arms.
Piecing these data together, researchers gradually formed a clear model to explain how
RuvABC recognizes and cleaves the HJ in a concerted manner (55,61). When RuvABC complex
carries out its function, it uses a sequential process. DNA HJ is first recognized and bound by
RuvA. Then one RuvB molecule is loaded on opposing arms of the junction via contacts with
RuvA; five extra RuvB molecules polymerize to form a hexamer and wrap around the HJ arm.
Finally, RuvC is loaded on the opposite side of RuvA. Branch migration of the HJ is achieved by
the RuvB helicase motor drawing the DNA through the complex, with each duplex arm rotating
within the channels on the surface of RuvA. DNA arms perform continuous open and anneal
process at the junction center. Meanwhile, RuvC scans the HJ to search for preferred sequence
and carry out the cleavage. This model is shown in Figure 1-5B.
For two decades, the attempt to crystallize E.coli RuvC with HJ was not successful. In
recent years, researchers switched their interests from E.coli to Thermus Thermophilus
(T.thermophilus) and successfully obtained one high resolution crystal structure (1.28 Å) of RuvC
alone (62) and one low resolution crystal structure of RuvC•HJ complex (3.75 Å) (63), as shown
in Figure 1-6A, 1-6B. The overall structure of T.thermophilus RuvC is similar to E.coli RuvC.
Comparing the T.thermophilus RuvC structure between apo and complex forms, it adopts
similar structural conformations. The only differences locate at the β4-α2 loop and the α3-α4 loop
region. The β4-α2 loop adopts an asymmetric conformation in the apo form; however, it adopts a
distinct conformation when RuvC forms a complex with HJ. RuvC forms a symmetric
conformation, moving along the junction center region to determine the substrate sequence
specificity. The α3-α4 loop region is flexible in the complex form. The junction DNA in the
complex is in an unfolded 2-fold symmetrical conformation, in which the four arms point toward
the vertices of a tetrahedron. The two arms during HJ resolution to be cleaved extend to the
bottom two vertices, where they form numerous interactions with RuvC active sites and flanking
regions. The two uncleaved arms in the HJ resolution do not interact with RuvC, and extend to
the upper two vertices.
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Figure 1-6. Structure of T.thermophilus RuvC and RuvC•HJ complex. A) shows the crystal structure of T.thermophilus
RuvC (PDB code: 4EP4). B) shows the crystal structure of T.thermophilus RuvC•HJ complex. (PDB code: 4LD0). Uarm
denotes the HJ arm which is not cleaved during HJ resolution; Carm denotes the HJ arm which is cleaved during HJ
resolution. C) shows the crystal structure of endonuclease VII•HJ complex. (PDB code: 2QNC). D) shows the crystal
structure of endonuclease I•HJ complex (PDB code: 2PFJ). Critical amino acids are shown as sticks. RuvC are shown in
cyan while HJ DNA as colored in magenta. Two monomers in endo-I and endo-VII are colored in green and red
respectively. HJ are shown as yellow ribbons in endoI•HJ and endoVII•HJ complex.

Two other resolvase•HJ complexes have been reported. They adopt different
conformations to recognize and cleave HJ substrates. One of them is bacteriophage T4 endoVII•HJ (Figure 1-6C). In this complex, the HJ adopts a planar, un-stacked “X” conformation, and
runs over one surface of endo-VII resolvase. Endo-VII only approaches HJ from minor groove,
and forms interactions with the sugar and phosphate moieties of HJ. Another resolvase•HJ
complex is bacteriophage T7 endo-I•HJ complex. In this complex, the HJ adopts a different
conformation from the HJ in bacteria RuvC and T4 endo-VII (Figure 1-6D). Two adjacent arms
stack together by aromatic interactions, and two halves of the junctions twist at 90° degree. The
HJ is recognized by two channels at the endo-I surface. Similar to T4 endo-VII, endo-I only
contacts HJ by sugar and phosphate moieties, which results in sequence non-specific cleavage.

Purification of nucleic acid enzymes
Purifying protein is labor and time consuming work since different proteins have different
10

properties and need different protocols. Nowadays, hundreds of nucleic acid enzymes have been
cloned, expressed, purified and commercialized, which include DNA/RNA polymerases,
nucleases, ligases and other (64). Several general methods have been developed to purify
nucleic acid enzymes (65,66). The most often used chromatography resins are cellulose
phosphate, SP-sepharose, heparin and hydroxyapatite (HAP) (65,67,68). In general, multiple
chromatography steps are required for one protein to reach high purity. Fusing the protein of
interest with an affinity tag could greatly facilitate downstream purification. However, adding tags
may alter protein properties and cause some negative affects (69). Furthermore, adding a tag
may also cause crystallization difficulty that hinders further structural study (70). Several cases
have been reported where nice crystals could be only obtained from non-tag proteins (62,71).
Thus, it is a general rule that the affinity tag should be removed before the protein of interest goes
to crystallization trial (70).
Nucleic acid enzymes use nucleic acids as substrate. Nucleic acids are negatively
charged molecules. To carry out their biological function, the interface of nucleic acid enzymes to
bind nucleic acid is heavy positively charged (72). This usually involves numerous positively
charged residues, such as lysine and arginine (73). For the divalent ion dependent nucleic acid
enzymes, there are several negative charged residues at the active site which are surrounded by
positive charged residues. Electrostatic potential maps of typical nucleic acid enzymes are shown
in figure 1-7.

Figure 1-7. Electrostatic potential map of typical nucleic acid enzymes. Negatively charged areas are colored red while
positively charged areas are colored blue. A) shows Klenow enzyme (the large fragment of E.coli DNA polymerase I). B)
shows the restriction enzyme BamHI. C) shows T7 DNA ligase.

According to the two-metal-ion mechanism, two divalent ions, Mn2+ or Mg2+, bind at the
active site (14). Two metal ions at the active site play different roles in the catalysis process. One
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metal ion activates the attacking water or sugar hydroxyl, while the other metal ion coordinates
and stabilizes the oxyanion leaving group (12,14,44). This mechanism was first observed in the
crystal structure of DNA polymerase I from E.coli (74). Later, it was found that most divalent ion
dependent nucleic acid enzymes, such as polymerases (75), nucleases (37) and ligases (42) use
a the similar mechanism to carry out their biological functions. The shared surface and active site
properties may help develop a universal protocol to purify this group of enzymes.
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CHAPTER 2: Resolvase structure
Contribution of this chapter pertaining to cell culture of Selenomethionine CPV resolvase were
prepared by Young Hwang, a staff scientist in the Bushman lab. The initial phasing and structure
of CPV resolvase were obtained by Kay Perry, a stall scientist of Beamline NE-CAT at Advanced
Photon Source. Gregory Van Duyne carried out final stage refinement of CPV resolvase structure
and constructed the resolvase•HJ model.

Abstract:
Poxviruses encode a resolvase enzyme that cleaves 4-way junctions extruded at the
concatemer junctions, a process that is essential for viral replication. In this chapter, we solved
crystal structure of canarypox virus (CPV) resolvase. CPV resolvase crystals were obtained by
micro-dialysis method and crystal structure were solved by combination of single wavelength
anomalous dispersive and molecular replacement method. CPV resolvase is a RuvC-like dimer
composed of RNaseH family folds, with an active site lined by highly conserved, acidic, metalbinding residues. Comparison of CPV resolvase with E.coli RuvC reveals several structure
differences. CPV resolvase has two shorter α2 helices than RuvC which constitute the major
dimerization motif. CPV resolvase has no α3 helix as RuvC, but has a much longer α4 helix than
RuvC. CPV resolvase has one additional aspartic acid in the active site. A model of the CPV
resolvase•HJ complex was constructed to study the effects of structure differences on CPV
resolvase functions. The long α2 helix in RuvC causes β4-α2 loop interacting with HJ center thus
determines the HJ sequence specificity. In CPV resolvase, the short α2 helix leads to distance
between β4-α2 loop and HJ center thus explains the lack of sequence specificity. The N-terminal
of CPV resolvase long α4 helix was docked into minor groove of HJ arm, suggesting that CPV
primarily recognize HJ by four arms. In contrast, RuvC recognize HJ by two arms and junction
central region. An additional aspartic acid (Asp130) was identified in the CPV resolvase active
site. Asp130 help anchor Mg2+ ion at the active site through a water molecule, therefore, Asp130
may increase resolvase activity by increasing Mg2+ binding affinity. Further studies on the
nucleases which are located in cytoplasm and digest double stranded nucleic acid indicated that
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all of them have special structures features to maintain high metal affinity.

Introduction
Poxviruses carry out their life cycles in the host cytoplasm. Replication of poxvirus the
genome involves formation of concatemers, and poxvirus resolvase plays an essential role to
cleave the s to monomeric genome. Based on secondary structure prediction and critical amino
acid mutation assays, poxvirus resolvase has a similar structure to bacterial RuvC and belongs to
the RNaseH family.
Compared to bacterial RuvC, poxvirus resolvase has low substrate specificity. The
substrate specificity includes substrate structure specificity and substrate sequence specificity.
Earlier studies on E.coli RuvC and phage T4 endo-VII demonstrated that RuvC has strict
substrate specificity, and only cleaves four-way junction DNA (76), while endo-VII cleaves has
much wider substrate specificity including four-way junction DNA, three-way junction (Y junction)
and bulged DNA. The substrate structures are in Figure 2-1A, B and D. Recent work on poxvirus
resolvase by Culyba et al indicated that poxvirus resolvase has even wider range of substrates
similar than those of T4 endo-VII (77). In addition to the DNA substrates cleaved by endo-VII,
The authors further found poxvirus resolvase was able to cleave flap DNA, as shown in Figure 21C. These alternative nuclease activities led to the suggestion that A22 could also participate in
the initiation of replication and/or double-strand break repair pathways (78).

Figure 2-1. Structure diagram of poxvirus resolvase substrates. Figures from left to right are: A) 4-way Holliday Junction;
B), 3-way Holliday Junction; C), flap DNA; D), Bulged DNA. T4 endo-VII cleaves substrates in Figure A, B and D. E.coli
RuvC only cleave HJ shown in Figure A.

It is known that E.coli RuvC only recognizes and cleaves specific HJ DNA sequences
(Figure 2-2A). RuvC shows a preference for cleavage between the third and fourth positions of a
tetra-nucleotide sequence with the consensus 5’-(A/T)TT↓(G/C)-3’ (53,56,79). In contrast,
vaccinia A22 weakly favors cleavage at the sequence 5’-(G/C)↓(A/T)-3’ (Figure 2-2B), and is
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much less sequence specific than E.coli RuvC. These two properties make poxvirus resolvase
unique: it is structurally similar to RuvC but functionally similar to T4 endo-VII. Although
considerable progress has been made in poxvirus studies, our understanding of poxvirus
resolvase is still very limited because lacking of structural information.

Figure 2-2. Substrate sequence specificity comparison among E.coli RuvC, phage T4 Endo-VII and fowlpox virus
resolvase. Figure A is adopted from reference (80), and it shows the HJ cleavage by RuvC and endo-VII. In the middle
column, migratable HJ was cleaved by RuvC and endo-VII. RuvC generates several distinct bands while endo-VII
generates smear bands. Both enzymes do not cleave linear DNA. Figure B is adopted from reference (10), and it shows
the HJ cleavage by RuvC and vaccinia resolvase A22R fused with maltose binding protein. From left to right, the Figure
shows the cleavage results on four DNA strands.

RNaseH family members need different concentrations of Mg2+ to carry out their
enzymatic functions. Poxvirus resolvase is active when Mg2+ concentration reach 0.2 mM (10)
(Figure 2-3A), while E.coli RuvC shows activity when Mg2+ reaches 1 mM (79) (Figure 2-3B) .
HIV integrase needs a much higher concentration of Mg2+ (5 mM) to be functional (81) (Figure 23C). The Mg2+ concentration requirement is arranged in the order: poxvirus resolvase<bacteria
RuvC<HIV integrase. It is important to note that RNaseH family members often function in
different cellular compartments. The poxvirus life cycle, for example, is fully carried out in the
host cell cytoplasm. The HIV genome is integrated into the host genome in the nucleus. RuvC
functions in the bacterial cell. Divalent ions are not evenly distributed in the eukaryotic cell. Most
divalent ions are located in the nucleus, and mitochondria, where they loosely associate with
negatively charged macromolecules such as DNA. According to Thiers’ study, the Mg2+
concentration in the nucleus is 60% higher than that in the cytoplasm in term of mass ratio of
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magnesium/nitrogen (82). In these three types of locations, the eukaryotic cell nucleus has the
highest concentration of Mg2+; the bacterial cell is the next and eukaryotic cell cytoplasm has the
lowest concentration of Mg2+. The relative Mg2+ concentration distribution is: poxvirus
resolvase<bacterial RuvC<HIV integrase. It seems likely that the different concentration
requirements of RNaseH family members adapt to their working environment. It will be very
interesting to know the structural basis of different RNaseH family members having different
affinities to Mg2+.

Figure 2-3. The divalent ion requirement for RNase family members. A) shows the poxvirus resolves cleavage of HJ
substrate at the different concentration of Mg2+; B) shows the RuvC activity in the presence of different concentration of
divalent metal ions. C) shows the enzymatic activity of HIV integrase in the presence of Mg2+. Figure A is adopted from
reference (10). Figure B is adopted from reference (79). Figure C is adopted from reference (81).

Despite the substantial biochemical data now available for the VV and FPV resolvases,
there are no structural models available for these proteins that could facilitate interpretation of
existing data, guide new experiments, or enable structure-based poxvirus inhibitor design.
Although crystal structures of bacterial RuvC and a yeast mitochondrial resolvase are known
(24,48,62), the limited sequence similarities and distinct biochemical activities of the poxvirus
enzymes have made it difficult to utilize homology-based models. Determination the crystal
structure of poxvirus resolvase will not only answer these questions, but also provide a platform
for the design of drugs against poxviruses.
In my thesis, I have determined the crystal structure of poxvirus resolvase, and
established a structural basis for poxvirus resolvase possessing low substrate specificity and high
metal binding affinity, and provided a solid platform for structure-based drug design against
poxviruses.
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Results
CPV resolvase protein purification
To initiate biochemical and structural studies of a poxvirus resolvase, we performed
extensive crystallization of fowlpox virus (FPV) resolvase either alone or as a complex with 4-way
junction DNA. All of our attempts were unsuccessful. Although FPV resolvase has improved
solubility properties compared to the vaccinia virus (VV) resolvase, we found that FPV resolvase
precipitated upon incubation at 4°C and 20°C, which may have contributed to the difficulties in
obtaining crystals. The selection of FPV resolvase as a model system was based on a
comparison of five different poxvirus resolvase homologs that had been cloned and expressed
(77). We therefore expanded the search to include resolvases from five additional poxviruses
(canarypox, crocodilepox, pseudocowpox, sheeppox, and swinepox) in an attempt to identify an
ortholog that could be crystallized. Each gene was codon optimized, synthesized by IDT
(Integrated DNA Technologies) and cloned into pET21a between for bacteria expression. We
found that canarypox virus (CPV) resolvase could be over-expressed in BL21(DE3) cells. CPV
resolvase functions as a dimer with a molecular weight of 35 kDa and pI (isoelectric point) of 8.5.
Detailed CPV resolvase properties are shown in appendix file. We worked out one initial protocol
to purify CPR resolvase by combining of two ion-exchange chromatography and one gel-filtration
chromatography steps. This protocol yielded CPV about 99% purity by SDS-PAGE. The results
are in shown in Figure 2-4.
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Figure 2-4. Initial protocol to purify CPV resolvase. (A) and B) show the results of SP-sepharose chromatography. A)
shows the salt gradient elution profile. B) shows the SDS-PAGE results of different fractions. Lane 1: Ladder marker;
Lane 2: lysate; Lane 3: supernatant; Lane 4: flow through; Lane 5 to 13 are evenly sampled from 44 ml to 84 ml. C) and
D) show the results of MonoS chromatography. C) shows the salt gradient elution profile. D) shows the SDS-PAGE
results of different fractions. Lane1: Ladder marker; Lane 2 to 12 are evenly sampled from 25 ml to 36 ml. E) and F)
show the results of gel-filtration chromatography. E) shows the gel-filtration elution profile. F) shows the SDS-PAGE
results of different fractions. Lane1: Ladder marker; Lane 2 to 7 are evenly sampled from 15 ml to 20 ml. Arrows show a
unknown protein tightly associated with CPV resolvase.

We noticed that there is an unknown protein band with molecular weight around 20 kDa
tightly associated with CPV resolvase. This band could not be removed during ion exchange
chromatography and gel-filtration chromatography.
Large scale crystallization screens were performed using purified CPV resolvase protein
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with lab-made and commercial available kits by hanging drop vapor diffusion. One condition
(0.16 M MgCl2, 0.08M Tris-HCl, pH8.5 24% PEG4000, 20% glycerol) gives needle crystals,
shown in Figure 2-5A. Based on this condition, we varied MgCl2, PEG4000, and glycerol
concentration, and tried buffers with different pH. However, this result is not easily reproducible
with only occasional success. We picked up the best crystal (Figure 2-5B) and tested its
diffraction at room temperature by capillary mounting. The crystal diffracts to 7~8 Å, with some
spots that could be observed at 3.5 Å, as shown in Figure 2-5C.

Figure 2-5. Characterize CPV resolvase crystals. A) shows the CPV resolvase crystals obtained from initial screen. B)
shows the optimized CPV resolvase crystal. An arrow points to the crystal. C) shows the diffraction pattern of CPV
resolvase crystal. D) shows the SDS-PAGE results of CPV resolvase crystal and purified CPV resolvase.

Since the final purified protein has two components, we did further experiments to
characterize the crystals. We spun down the crystal, dissolved them in SDS-PAGE loading buffer
and ran electrophoresis to identify the crystal composition. The result is shown in Figure 2-5D.
This result confirms that the crystals we obtained are CPV resolvase. Then it leaves us the
question, what is the unknown band tightly associated with CPV resolvase?
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Figure 2-6. Protocol to purify CPV resolvase. A) and B) show the results of SP-sepharose chromatography. A) shows
the salt gradient elution profile. B) shows the SDS-PAGE results of different fractions. Lane1: Ladder marker; Lane 2:
before induction; Lane 3: Ladder marker; Lane 4: lysate; Lane 5: supernatant; Lane 6: flow through; Lane 7 to 15 are
evenly sampled from 64 ml to 96 ml. C) and D) show the results of MonoS chromatography. C) shows the salt gradient
elution profile. D) shows the SDS-PAGE results of different fractions. Lane1: Ladder marker; Lane 2 to 11 are evenly
sampled from 25 ml to 34 ml. E) and F) show the results of gel-filtration chromatography. E) shows the gel-filtration
elution profile. F) shows the SDS-PAGE results of different fractions. Lane1: Ladder marker; Lane 2 to 8 are evenly
sampled from 15 ml to 21 ml.

We did further experiments to characterize both bands to determine their primary
sequences by mass spectrometry. These results indicated that the lower band is full length CPV
resolvase. To our surprise, the band with larger molecular weight is also CPV resolvase, but only
matches the N-terminal 147 amino acids. The additional residues are not resolvase-derived. We
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noted that there are 8 adenosine bases in a row after the F147 (AAA-AAA-AAC, coding for KKN),
suggesting that a translational frameshift could occur here. A similar translational frameshift of
adenosine repeats occurs in HIV Gag-Pol translation (83). Therefore, we changed the codon
AAA-AAA-AAC to AAG-AAG-AAC without affecting the primary protein sequence and repeated
the expression and purification. The purification results are shown in Figure 2-6. The protein
tightly associated with CPV resolvase was gone, and the purity was greatly improved.
The removal of the higher molecular weight band generated an immediate effect. When we
crystallized CPV resolvase with the same conditions as described above, each drop contained
several to several dozen resolvase crystals. In addition, the crystal quality improved: the crystal
size increased and the crystals were more single.
Structure determination
After we removed the CPV resolvase impurity band, we optimized crystallization
condition in an attempt to obtain more single and bigger crystals. Crystals with a larger size could
be obtained with conditions around 0.15~1.20 M MgCl2, pH7.0~9.0, and 10%~20% PEG4000.
However, we encountered another problem. There were several cracks on the crystal surface,
and some cracks ran through the crystals, as shown in Figure 2-7A and 2-7B. When we tried to
cryo-protect crystals by adding glycerol, they broke into thousands of small pieces in seconds.
We could not even perform a capillary mounting and test its diffraction at room temperature. The
observation that glycerol could not be used to cryo-protect these crystals suggests that high
concentration of glycerol may also have a negative effect on crystal growth, such as crack
formation. However, we must keep a high concentration of glycerol to make CPV resolvase
soluble. The micro-dialysis method allows more control over the crystallization condition.
Therefore, we switched from the hanging drop vapor diffusion method to the micro-dialysis
method.
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Figure 2-7. Crystal images of CPV resolvase. Figures A, B show the CPV resolvase crystals obtained by hanging drop
evaporation method. Cracks are visible on crystal surfaces and edges. Figure C shows the CPV resolvase crystals
obtained by micro-dialysis method.

The final crystallization condition of the micro-dialysis method is determined by the
reservoir/dialysis solution. Therefore, we decreased NaCl concentration to 0.35 ~ 0.50 M, and
removed glycerol. We further found that adding sodium potassium tartrate could help crystal
growth through an additive screen. The final condition to grow CPV resolvase crystal was: 10μl
of 10mg/ml resolvase in 20 mM Tris-HCl (pH 7.4), 15% glycerol, 1 M NaCl and 0.01% NaN3
dialyzed against 1.5 ml of 50 mM Tris-HCl (pH 8.5), 180 mM MgCl2, 150 mM sodium-potassium
tartrate, 0.35-0.50 M NaCl at 22°C. CPV resolvase crystals usually appear in one week and
continue to grow for another week. Crystals have the shape of long pyramids, and typical
crystals reached dimensions of 0.1x0.1x0.5 mm, as shown in Figure 2-7C.
Various cryo-protectants were tested their effects; however, most of them did not work.
Resolvase crystals tended to crack or break to pieces. Fortunately, we found that sucrose could
effectively cryo-protect CPV resolvase crystals without damaging the diffraction quality. The
results of testing different cryo-protection buffers and their effects are listed in Table 2-I.
Table 2-I. Summary of cryo-protection of CPV resolvase crystals
Cryo-protectant

5%

10%

15%

20%

25%

Glycerol

OK

OK

Crack

Crack

Broken

EG

OK

OK

OK

Crack

Broken

PEG400

OK

OK

OK

Crack

Broken

30%

50%

MPD

OK

Broken

EG/PEG400

OK

OK

OK

Broken

Sucrose

OK

OK

OK

OK

OK

OK

2.5 M

3.0 M

OK

Almost OK Crack

Salt concentration

0.5 M

1.0 M

1.5 M

2.0 M

Malonate

OK

OK

Crack

Broken

NaCl

OK

OK

OK

OK
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OK
3.5M

We collected one Se-Met dataset and one high resolution native dataset at Advanced
Photon Source. Typical images are shown in Figure 2-8. Se-Met CPV resolvase crystals decay
quickly during data collection. The resolvase crystals have the shape of long pyramids, and this
feature has the advantage that we could shoot crystals along the long dimension without
changing the crystal orientation. Therefore, we were able to collect a full dataset using one single
crystal by translating the crystal. Native crystals could last longer during data collection, and one
full dataset could be collected by one single crystal. The native resolvase diffraction data
exhibited anisotropy with diffraction limits of 2.3 Å along c* but 2.7 Å along a* and b*. The data
were ellipsoidally truncated, anisotropically scaled, and used at 2.6 Å for final refinement. There
is one resolvase dimer in asymmetric unit. CPV resolvase crystals have a Matthews coefficient of
3.3, and solvent comprises 63% of total cell volume.

Figure 2-8. Diffraction pattern of CPV resolvase crystals. The left panel shows the SeMet CPV resolvase, and the right
panel shows the native CPV resolvase diffraction pattern. SeMet CPV resolvase diffracts to 3.2Å, and native CPV
resolvase diffracts to 2.6Å.

The SeMet dataset extend to 3.2 Å, however, the anomalous signal could only be used to
5 Å. Two Se sites were located, and a phased map was calculated. But, the resulting SADphased map could not be readily interpreted. We used the HJ resolvase from S.pombe
mitochondria as a model (Protein Data Bank code: 1KCF), and combined the phasing from
molecular replacement and Se-Met SAD to obtain an interpretable map. The diffraction data
collection and final structure statistics are shown in Table 2-II. Canarypox virus resolvase has
152 amino acids. In our final structure, the N-terminal methionine, and the C-terminal amino
acids after 145 were disordered. Residues 114-127 of both subunits are also disordered, but
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were fit into weak density to provide approximate locations for modeling studies.
Table 2-II. Summary of data collection and refinement statistics
Crystal
Native resolvase
Se-Met(Peak)
Space Group
P43212
P43212
Unit Cell
a=b=89.1Å, c=117.9Å
a=b=89.3Å, c=118.2Å
α=β=γ=90°
α=β=γ=90°
Wavelength (Å)
0.97918
0.97947
Resolution (Å)
50-2.6
50-3.2
Completeness (%)
99.7(99.9)
99.9(100)
Rmerge
0.09(0.99)
0.156(0.922)
Mean I/σ
14.5(1.4)
23.9(3.3)
Redundancy
3.4(3.2)
13.6(11.7)
Unique Reflections
18685
8250
SAD phasing
Se sites
2
Resolution (Å)
5.0
SeMet/Model Phase combination
Figure of merit
0.669
Final total log likelihood gradient map
-86084
Molecular replacement
Model
1KCF
Resolution (Å)
2.9
Refinement
Rfree*
0.264
Rwork
0.198
Number of atoms
Protein
2342
Mg2+
2
Tartrate
10
Solvent
35
RMSD
Bond length (Å)
0.008
Bond Angles (°)
1.270
Ramachandran plot (%)
Favored
94.4
Allowed
5.6
Rmerge=Σ|Ih - <Ih>|Σ Ih, where <Ih> is the average intensity over symmetry equivalent measurements; R-factor, Σ|Fobs –
Fcalc|/ ΣFobs, where summation is data used in refinement. Numbers in parentheses represent values in the highestresolution shell. *Rfree was calculated with 5% of the data.

Overall architecture of CPV resolvase
CPV resolvase is an elongated dimer with a dimension of 40x44x74Å, as shown in Figure
2-9A. Each subunit has five beta sheets and four alpha helices. Five beta sheets are
sandwiched between two pairs of alpha helices. β1 to β3 strands run anti-parallel and β1, β4 and
β5 strands run parallel. α1 and α2 helices are located in the middle of the dimer forming the
dimerization motif, while α4 are located at the outside regions. The active site, defined by a
cluster of conserved acidic residues, is located in a cleft formed between the β-sheet and the
α4/α5 helices. There is one Mg2+ ion identified in the active site pocket. The dimer has two-fold
24

symmetry, generated by interactions between the α1 and α2 helices. However, their
conformations are not exactly identical. The overall rmsd between the two subunits is 0.330 Å.
The β4-α2 loop region (residues 60-67) adopts different conformations, and has a higher rmsd of
1.471 Å (Figure 2-11H). The asymmetric structure at these loop regions is also observed in
RuvC from E.coli and T.thermophilus. They are involved the sequential cleavage of HJ substrates
at the two cleavage sites (62,63).
The electrostatic potential of CPV resolvase is unevenly distributed. One side bearing
the active sites is rich in positively charged residues, making it a positively charged. This face
binds HJ substrate. Only the active site forms a small patch of negatively charged area, with a
function to bind divalent ions as cofactor. The opposite side is rich in negatively charged residues,
making it a negatively charged surface. The electrostatic potential map is shown in Figure 2-9B.

Figure 2-9. The overall structure of poxvirus resolvase and its electrostatic potential map. A), Resolvase structures are
shown in cartoon. Left panel shows the side view of CPV resolvase and right panel shows the top view (bearing the
active sites). The critical amino acids at the active site pocket are shown in sticks. Mg2+ ions are shown as blue spheres.
B) shows the surface electrostatic potential map. Negatively charged area is colored in red and positively charged area is
colored in blue. Left panel shows the surface without active sites and right panel shows the surface bearing active sites.

Poxvirus resolvase belongs to the RNaseH family. We performed a primary and
secondary structure alignment with other resolvases from the RNaseH family, including fowlpox
virus resolvase, vaccinia virus resolvase, S.pombe mitochondria resolvase (Ydc2), and
T.thermophilus and E.coli RuvC, shown in Figure 2-10. The results show that they have a similar
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number of secondary structure elements. All of them have 5 beta sheets and several alpha
helices. Importantly, the critical amino acids for enzyme activity are well conserved (22-24,47).

Figure 2-10. Secondary structure alignment of RuvC family resolvases. Active site residues are shaded yellow, and
residues identical in three or more of the sequences are shaded gray. α helices are shown as pink rectangles and β
strands are shown as green arrows. Ydc2, Schizosaccharomyces pombe; Tth, T. thermophilus; Ec, E.coli

Comparison between poxvirus resolvase and RuvC from E.coli
When CPV resolvase and E.coli RuvC dimers are compared, several differences stand
out (Figure 2-11). First, the α1 and α2 helices are both longer in RuvC, resulting in a more
extensive dimerization interface. For the RuvC, the dimer interface has total area of 953 Å2. In
the dimer, the α2-α2 interface only contributes 429 Å2 (45%), while the interface between α1-α1,
α1-α2 contributes 524Å2 (55%). Non-polar interaction comprises 22.5% and polar interaction
comprises 77.5% of total interactions. The interface comprises numerous of hydrophobic side
chains, such as A74, A77, L78, L80, L44, L40, I88, L47, and V89. The only aromatic stacking
comes from Tyr 48 of two subunits, shown in Figure 2-11F. The overall shape of the RuvC
dimerization domain resembles a reversed “V” where the vertex goes into and contacts DNA HJ.
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Figure 2-11. Structure comparison between CPV resolvase and E.coli RuvC. A). Cartoon expression of canarypox virus
resolvase. B). Cartoon expression of E.coli RuvC. Critical amino acids for the catalysis are shown as sticks. In all panels,
poxvirus resolvases are colored in green, RuvCs are colored in cyan. The critical amino acids in resolvase are shown as
red sticks, and the critical amino acid in RuvC are shown as yellow sticks. Two Mg2+ ions in the active sites are shown as
blue spheres. C) and D). Superimposition of resolvase and RuvC. Resolvase and RuvC were aligned as dimer. E).
Zoom in the dimerization motif of resolvase and alpha helix from two monomers are colored in green and light green
respectively. Amino acids involved in the dimerization are shown as sticks. F). Zoom in the dimerization motif of RuvC
and structures from different monomers are colored as cyan and light cyan. G), Superimposition of poxvirus resolvase
monomer and RuvC monomer. H), Superimposition of two monomers in CPV resolvase. Side chains of β4-α2 loop are
shown as sticks.

In poxvirus resolvase, dimerization is primarily contributed by α2 helix. We calculated the
total interface area between two monomer of resolvase is 663 Å2, and 594 Å2 (90%) of them is
located at α2-α2 interface. The α1-α2 interface only contributes 69 Å2 (10%). In this case, polar
interactions comprise 75%, while non-polar comprise 25%. The major non-polar interaction is
aromatic ring contacts with a side chain from other subunit. The hydrophobic interactions include
from top to bottom: R64(A, molecule A)-R64(B, Molecule B), P66(A)-Y63(B), K69(A)-Y72(B),
Y72(A)-K69(B), F73(A)-K75(B), K75(A)-F73(B), F77(A)-Y79(B) and F79(A)-Y77(B), shown in
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Figure 2-11E. The overall shape of poxvirus resolvase dimerization domain also resembles a “V”
with two α2 fragments meeting at the bottom. Despite the modest self-interaction surface, CPV
resolvase elutes as a single dimeric peak on size exclusion columns, consistent with the dimeric
properties of VV resolvase when expressed as a maltose-binding protein fusion (9).
A second conspicuous difference between the viral and bacterial resolvases is that CPV
resolvase does not have the α3 helix found in RuvC, and the α4 helix is longer than the similarly
positioned helix in RuvC. As discussed below, the shorter α2 and extended α4 helices in CPV
resolvase suggest that different structural elements may be used to recognize branched DNA
substrates compared with RuvC.
Superimposition was performed to compare CPV resolvase and RuvC, as shown in
Figure 2-11C and 2-11D. When we compare resolvase and RuvC homology as dimer, it gives a
rmsd of 8.5 Å, and even the active sites could not be nicely aligned. However, if we only align the
core domain (five beta sheet and α4 helix), the rmsd drops to 1.4 Å (Figure 2-11G), suggesting
that the active site pockets of RuvC and poxvirus resolvase are quite similar.
Comparison of a bacterial RuvC•HJ structure with a poxvirus resolvase•HJ model
The crystal structure of T.thermophilus RuvC bound to a DNA four-way junction has
provided a framework for considering how the bacterial enzyme recognizes this branched
substrate (63). Given the common features of the dimeric E.coli (and T. thermophilus) RuvC and
CPV resolvase structures, we reasoned that the modes of substrate recognition are also likely to
be similar. However, there are also some important differences between the two enzyme dimer
structures, as discussed previously and highlighted in Figure 2-11. To help visualize the potential
consequences of these differences in the context of substrate binding, we constructed a model of
the CPV resolvase•HJ complex by superposition of the CPV resolvase dimer onto the
T.thermophilus RuvC dimer in the RuvC•HJ complex structure. For both models, we extended
the four-way junction arms to lengths of 10 bp using standard B-DNA, leaving the core DNA
structure unchanged.

28

Figure 2-12. Comparison of RuvC•HJ complex (PDB code: 4DL0) and resolvase•HJ complex model. A), T.Th crystal
structure of RuvC•HJ complex. RuvC are colored in cyan and synthetic HJ molecule is colored in magenta. Critical
amino acids located at the active pocket are shown as yellow sticks. B), Model of poxvirus resolvase and HJ complex.
The resolvase was shown in green and HJ was shown in magenta. Critical amino acids at the active pocket are shown as
sticks.

The CPV resolvase•HJ model and RuvC•HJ structure are compared in Figure 2-12. The
DNA junction arms extend in directions that approximate tetrahedral geometry, but the four DNA
strands are not stereo chemically equivalent. The two “continuous” strands have a B-DNA-like
backbone conformation at the branch point, whereas the two “crossing” strands have a sharp kink
at the branch point, similar to that seen in the Cre•HJ complex (84). The continuous strands of
the HJ substrate are positioned near the enzyme active sites, consistent with the established
strand cleavage preference for RuvC (85). Overall, the enzyme-bound DNA junction adopts a
confirmation that is distinct from the planar, 2-fold symmetric form found in the Cre•HJ complex
(84), the stacked-X form found in the T7 endonuclease I•HJ complex (86), and the 2-fold
symmetric unstacked X form found in the T4 endonuclease VII•HJ complex (87).
The RuvC/resolvase dimers engage the minor grooves of the DNA arms as they
converge at the center of the junction, consistent with biochemical data for FPV resolvase (88).
The most extensive interactions are with the DNA duplex arms that will be cleaved, which we
refer to here as the “C arms.” RuvC makes very few contacts to the DNA arms that are not
cleaved (the “U arms”), except at the very center of the junction (63). Here, HJ nucleotides in a
given strand are numbered -10...-1, 1...10, where the branch point phosphate is indicated by 1:+1.
An obvious difference between the two complexes shown in Figure 2-12 involves the
protein-DNA interactions present at the center of the junction. The α2 helix in RuvC extends into
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the center of the junction, where side chain from α2 and the β4-α2 loop are well positioned to
interact with both the backbone and the +1 and +2 base pairs of each arm. In the CPV resolvase
model, the α2 helix is shorter, and the enzyme can only contact the sugar and phosphate
backbone at the junction center. These observations are consistent with and may explain the
relative lack of sequence specificity near the junction branch point for the poxvirus enzymes
(9,10), compared with the strong preferences observed for E.coli RuvC (56,89).

Figure 2-13. Arg100 and Lys101 are conserved throughout poxvirus resolvase. Critical amino acids at the active pocket
are shown as sticks. Mg2+ ions are shown as blue spheres. Arg100 and Lys101 are shown as red spheres.

A second difference involves the α4 helix, which is longer in CPV resolvase compared
with RuvC. The α3-α4 region of RuvC makes only minimal contact with the DNA junction,
although the disordered loop connecting these helices could potentially form backbone contacts
to the U arm. In the CPV resolvase•HJ model, the N terminus of α4 is docked at the minor
groove of the extended U-arm in each subunit, where resolvase-DNA backbone interactions
involving both α4 and residue in the β5-α4 loop can be formed. Arg100 and Lys101 are located
on the DNA binding surface of α4 and are highly conserved among the poxvirus enzymes, shown
in Figure 2-13. Lys101 is essential for activity in FPV resolvase (88), supporting the importance
of these inferred protein-DNA contacts. Indeed, Lys101 is also strongly conserved among the
RuvC-like enzymes (Figure 2-10). Unlike RuvC, the model predicts that poxvirus resolvases
make substantial interactions with all four arms of the four-way junction.
The third difference we observed involves the extent of enzyme-DNA interactions on the
C-arms of the junction. RuvC makes a relatively small number of DNA backbone interactions
after the +1 and +2 nucleotides, with contacts possibly extending to the +6 and +7 positions.
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CPV resolvase, however, docks in the major groove of the C-arm adjacent to the cleavage site,
where a complex network of interactions could potentially be formed. In addition, the disordered
α4-α5 loop is positioned where it could form backbone interactions in the adjacent minor groove,
extending potential C-arm contacts to +8/+9 base pairs from the branch point. The more
extensive C-arm contacts predicted for the poxvirus enzyme may explain the broad range of
branched substrates that can be efficiently cleaved (77). Unlike RuvC, which interacts primarily
with the center of the four-way junction, resolvase is predicted to interact primarily with the
junction arms. Bulged, flap-containing, and alternative junction substrates could each adopt
conformations in which two duplex segments are bent into a structure resembling the C-arms
shown in Figure 2-12. This observation may explain why activity-based screens for poxvirus
resolvase inhibitors work so well with bulged DNA substrates (21).
Active site organization
Two active sites are located at the clefts of the resolvase dimer. Each active site
comprises of five conserved negatively charged amino acids (Appendix A), as shown in Figure 214A. In which, Asp8 is located at the C-terminal end of β1, and Glu59 is located at the C-terminal
end of β4. These two negatively charged amino acids are conserved throughout the RNaseH
family enzymes. Three other aspartic acids Asp130, Asp131, Asp134 are located at the Nterminus of the α4 helix. There is a huge electron density between Asp8 and Asp131, which
corresponds to one Mg2+ and three water molecules. The Mg2+ ion forms interactions with the
carboxyl oxygen of Asp8 and Asp131. It further interacts with three water molecules in the active
site pocket. Water 1 forms a bridge between Asp130, Asp134 and Mg2+. Waters 2, 3 and 4 only
forms interaction with Mg2+ and fill the metal coordination sites. One of waters functions as a
nucleophile to perform the nucleophilic attack of the scissile phosphate. The B site (as defined in
Chapter 1, Figure 1-4 ), where Glu59 is expected to coordinate a second metal ion in the
presence of substrate, is not occupied in the crystal structure despite the high concentration of
Mg2+ that is present. This suggests that the resolvase B site has a low affinity for divalent metal
ions.
Yang and co-workers (12,13,44) have crystallized a series of RNase H1•DNA-RNA
31

complexes and visualized snapshots of active sites thought to represent the two-metal ion
catalytic mechanism in progress. A comparison of the CPV resolvase active site with the active
site from the RNase H1 complexes provides useful insights into how a DNA substrate strand
could be engaged for hydrolytic attack by resolvase (Figure 2-14B and C). One of the Mg2+
coordinated water molecules in the CPV resolvase structure (W3 in Figure 2-14B) may serve as a
surrogate for the scissile phosphate oxygen atom that bridges between the A site and B site
bound metals in an active resolvase-substrate complex.

Figure 2-14. Active site of CPV resolvase. A), stereo view of active site electron density (2mFo-DFc; contoured at 1 )
showing theMg2+ water cluster bound at site A and the five acidic active site residues. B) and C), active sites of CPV
resolvase B) and RNase H1 C) bound to a DNA-RNA hybrid (PDB code 2QKK). Metal coordination and Asp-water
hydrogen bonds are drawn as dashed lines. The substrate scissile phosphate is expected to displace one of the water
molecules coordinated to Mg2+ in the CPV resolvase A site. Asp130 and Asp134 stabilize a Mg2+ bound water through
hydrogen bonding.

Resolvase has an additional aspartic acid in the active site
We compared the active sites among CPV resolvase and other typical RNaseH family
members, including E.coli RuvC, T.thermophilus RuvC, S.pombe Ydc2, HIV integrase and E.coli
RNaseH, shown in Figure 2-15. RNaseH family members have different critical residues in their
active sites. The numbers range from three to five. HIV integrase only has three residues; E.coli
RuvC has four residues while CPV resolvase have five residues. The critical residues numbers
have an inverse correlation with Mg2+ concentration requirements for enzyme activity as
described in the introduction.
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For each of the four HJ resolvases, three residues are involved in the B site metal binding.
The difference in active site residues is located at the A site. CPV resolvase has one extra
aspartic acid in the A site compared to E.coli RuvC. Which one is the extra, Asp130 or Asp131?
In Figure 2-14, it seems amino acid Asp131 is the extra one. The Bushman lab has
systematically studied the function of amino acids function in the active site of the related fowlpox
virus resolvase (88). Their results suggested that Asp8, Glu59, Asp131, and Asp134 (numbers
refer to CPV resolvase) are critical amino acids which are required for the resolvase activity. Our
enzymatic studies also showed that the D131A mutation abolished the resolvase function (The
experiment is shown in Appendix A). We believe Asp130 is the extra aspartic acid in the active
site, since Mg2+ directly interacts with Asp131, but indirectly interacts with Asp130. Four residues
in CPV resolvases form a shape of square, in which the Mg2+ interacts with Asp8 and Asp131,
and indirectly interacts with Asp130 and Asp134 through a well-anchored water molecule. This
H-bond and salt bond network does not work for Ydc2, since the corresponding residues adopts
the shape of a rhombus.
RNaseH has 4 critical amino acids in the active site pocket, where the orientation of
active pocket arrangement rotates by 90° (Figure 2-15F). E48 is unique to RNaseH and it
provides enzyme the ability to recognize the RNA strand in an RNA/DNA duplex (44).

Figure 2-15. Active sites of typical RNaseH family members. Amino acids in red dashed line box are the amino acids
forming the A sites, while the amino acids in green dashed line box are the amino acids forming B sites.
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Double stranded nucleic acid nucleases in the cytoplasm have special structural features
to maintain high metal binding affinity to Mg2+
Poxvirus resolvase has one extra Asp in the active site, and this increases metal binding
affinity by 10-15 fold. Considering that divalent ions are not evenly distributed in eukaryotic cells
and most ions are located in the nucleus (82), we suggest that Asp130 enhances poxvirus
resolvase function and is required for poxvirus resolvase to functions efficiently in the cytoplasm.
To seek support for this idea, we looked for examples of double stranded nucleases in the
cytoplasm possessing high metal binding affinity.
These nucleases should satisfy three requirements: 1) they should cleave double
stranded nucleic acids. These substrates could be double-stranded DNA, RNA or DNA/RNA
duplex; 2) the enzymes should be divalent ion dependent; 3) They should carry out their
biological function in the cytoplasm. The ideal candidates should either have a different folding
pattern to achieve high affinity binding to divalent ion, or have structures like CPV resolvase
which possesses an extra aspartic acid to provide high metal affinity, or have other special
structural features to reach high metal affinity. Unfortunately, not many double stranded nucleic
acid nucleases are located at the cytoplasm. The most well-studied example, bovine pancreatic
ribonuclease, is located in the cytoplasm. However, it is not divalent ion dependent, and it only
digests singe-stranded RNA (90).
Two enzymes involved in the RNA interference digest double stranded RNA. One is
Dicer, and the other is Argonaute (27). Dicer cleaves double stranded pre-microRNA into short
double stranded RNA fragments called micro-RNAs. The exact Mg2+ concentration requirement
for Dicer has not been reported. However, from the Provost et al study (91), when Mg2+ reaches
1 mM, the Dicer reaches its maximum velocity, suggesting the real Mg2+ requirement is much
lower than 1 mM (Figure 2-16C). The crystal structure of human Dicer has been solved (92).
Dicer has a very different folding pattern than RNaseH, suggesting that different folds also
support high affinity biding to metal ions (Figure 2-16A and B). Interestingly, the Dicer crystals
were obtained in the presence of 20 mM MgCl2, much lower than CPV resolvase crystals (180
mM MgCl2). We also noticed that in the A site, Mg2+ coordinates with three negatively charged
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amino acids, and three water molecules. Together, these data support the idea that Dicer uses
different folding pattern to obtain high metal affinity in cytoplasm.

Figure 2-16. Human dicer has a special folding pattern to obtain high metal affinity. A) shows the crystal structure of
human Dicer (92). B) shows the active site of human Dicer (PDB: 2EB1). Mg2+ are shown as blue spheres, water
molecules are shown as red spheres and negatively charged amino acids are shown as sticks. Salt or hydrogen bonds
are shown as dashed lines. C) shows human Dicer enzymatic activity in the presence of different concentration of Mg2+.
Figure C is adopted from reference (91).

Next we carefully studied the structure of the PIWI domain of human argonaute. The
PIWI domain shares a similar folding pattern as RNaseH, and is responsible for the double
stranded RNA cleavage in RNA interference. We found that the last critical amino acid, located in
an alpha helix, is a histidine, not an aspartic acid as in E.coli RNaseH (93) (Figure 2-17A and B).
Since divalent ions could be coordinated by the δ-1 nitrogen atom of histidine, this suggests that
histidine in the PIWI domain serves a similar role as an aspartic acid in RNaseH. This finding
inspired us to search all eukaryotic species and compare the primary sequences of argonautes It
is very interesting that all eukaryotic argonautes have a histidine at the last alpha helix of the
PIWI domain (Figure 2-17D). As a comparison, most prokaryotic species have an aspartic acid at
the same position (94) (Figure 2-17C). Interestingly, some extreme thermophiles also have a
histidine in the argonaute active site, as shown in the Figure 2-17D. The histidine in this position
may help stabilize Mg2+ at higher temperature.
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Figure 2-17. PIWI domain of Argonautes from eukaryotes and some thermophile prokaryotes have special structure
composition to get high metal affinity. A) shows the crystal structure of PIWI domain of human argonaute. B) shows the
crystal structure of E.coli RNaseH. Box with red dashed lines shows the A site and boxes with green dashed lines shows
the B site. C) shows the primary sequence of argonaute from Cyanobacteria Calothrix sp. D) shows primary sequence
alignment of PIWI of typical eukaryote Argonautes and some thermophile species of some prokaryotes. Protein ID in the
alignment: Calothrix sp: WP_019497030; Methanotrorris Formicius: WP_007044032; Pyrococcus furiosus: 62738879;
Thermococcus barophilus: WP_013468138; Arabidopsis-thaliana: AEE32289; Caenorhabditis-elegans: NP_500994;
Danio rerio: NP_001289151; Drosophila melanogaster: NP_730054; Homo sapiens: NP_004755; Mus Musculus:
DAA00372; Schizosaccharomyces P: CAA19275; Xenopus laevis: ACA52290. Critical amino acids form active sites are
shadowed in yellow.

Metalloproteinases use two histidines and one glutamate to achieve high affinity for
divalent ions
We found that the number of histidines in the active site, is correlated with the affinity to
metal that they bond. Examples are divalent ion dependent metalloproteinases (Figure 2-18).
Unlike nucleic acid enzymes, which use two metal ions at their active sites, metalloproteinases
only need one divalent ion at their active sites (95). Three critical amino acids form the active site.
One of them is glutamate, and the other two amino acids are histidines. These three amino acids
form one salt bond and two dipolar bonds with Zn2+. One water molecule also binds to Zn2+,
which is activated by Zn2+, and performs nucleophilic attack against the substrate peptide bond.
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Most metalloproteinases use Zn2+ as their cofactor, but some metalloproteinases prefer to use
other divalent ions, such as Mn2+, Cu2+, or Co2+ based on the subtle difference at the active site
(96). Metalloproteinases have extremely high affinity for their cofactor, which could often reaches
nano-molar levels (97).

Figure 2-18. The active site of bovine pancreas carboxypeptidase (BPC) has special structural feature to maintain high
affinity to Zn2+. A) shows the overall structure of BPC at 1.2 Å resolution (PDB: 1M4L). B) shows the active site
composition. Salt bonds or dipolar bonds are shown as dashed lines.

The affinity of metalloproteinases to metal is so strong that once the metalloproteinase
has been activated, divalent ion is always sitting at the active site, and ready for the nucleophilic
attack. The divalent ion could only be removed by harsh conditions, such as adding EDTA to
chelate the metal, or changing pH from neutral to acidic conditions.
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CHAPTER 3: Resolvase biochemistry
This chapter focuses on poxvirus resolvase biochemistry study. Young Hwang, a staff scientist in
the Bushman lab, made various contributions which included providing fluorescence labeled
bulged and Holliday Junction DNA, helping enzymatic experiment and providing resolvase
inhibitors.

Abstract
The structure of CPV resolvase and the model of CPV resolvase•HJ complex have
important implications for understanding how CPV resolvase recognizes and cleaves HJ
substrate. In this chapter, we carried out serial experiments to study the how the resolvase
structure adapts to its function. The structure model of CPV resolvase•HJ suggests that Nterminal α4 helix docks into minor groove of HJ arms. Our truncation assay demonstrated that α4
helix increases HJ binding affinity by 1000 folds. This result supports that CPV resolvase
recognizes HJ primarily by four arms, while RuvC recognizes HJ primarily by two arms and
junction central region. We symmetrically studied the metal binding property of CPV resolvase
and the effect of Mg2+ and Mn2+ as cofactors. When using Mn2+ as cofactor, resolvase is much
more active than Mg2+. When both Mg2+ and Mn2+ are present, optimum activity could be
reached at low concentration of both Mg2+ and Mn2+. The additional aspartic acid in the active
site, Asp130, increases resolvase activity by 10-15 folds. This property likely adapts to low Mg2+
concentration in cytoplasm. Preliminary studies on resolvase inhibitor indicated that it does not
bind resolvase alone, but binds resolvase•HJ complex. These results suggest that the resolvase
inhibitor may inhibit resolvase activity in an uncompetitive manner.
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Results
α4 helix enables resolvase to preferentially bind HJ substrates
Based on the CPV resolvase and HJ structural model, the N-terminal end of the α4 helix
likely interacts with the HJ substrate arms. To study the contribution of the α4 helix to HJ binding,
we made a truncated version that we call ∆7-resolvase (the first seven amino acids at the Nterminal of α4 helix were deleted: YSDRKKQ), and compared its affinity for HJ substrates with
wild-type resolvase. The N-terminus of α4 helix comprises residues frequently observed to
interact with DNA (98). We first determined the binding affinity of wild-type resolvase to HJs by
electrophoretic mobility shift assay (EMSA). CPV resolvase has a Kd value of about 50 nM for
the immobile HJ substrate used in our studies (shown in Figure 3-1A). We then determined the
binding affinity of ∆7-resolvase to HJ, as shown in Figure 3-1B. The maximum concentration of
∆7-resolvase in the experiment resulted in shifting only one fourth of the total HJ. We estimated
that ∆7-resolvase has a HJ-binding Kd value of about 50 μM. These experiments indicate that α4
increases the binding affinity of resolvase to HJs by 1000-fold, strongly suggesting that the α4
helix interacts directly with the HJ DNA. These experiments support the idea that CPV resolvase
recognizes HJs by interacting with all four arms of the junction rather than just two.
We next measured the wild-type resolvase and ∆7-resolvase affinities for duplex DNA.
These results are shown in Figure 3-1C and 3-1D. Wild-type resolvase has a binding affinity of 1
μM (Kd) to DNA duplex, while ∆7-resolvase has an estimated binding affinity of 10 μM (Kd) to
duplex DNA. (The maximum concentration of ∆7-resolvase in the experiment could only bind
roughly half of total DNA, so this Kd is an estimate). The binding affinity of resolvase to DNA
duplex is only 10 times higher than ∆7-resolvase. Considering the binding affinity of resolvase to
HJ is 1000 times higher than ∆7-resolvase, we suggest that α4 provides poxvirus resolvase the
capability to preferentially to recognize HJ substrates. We also tested the enzymatic activity of
∆7-resolvase. The results indicated that ∆7-resolvase does not cleave bulged DNA or only has
very weak enzymatic activity, suggesting α4 helix is essential to resolvase function (shown in
Appendix A). Truncation of N-terminal of α4 helix does not change resolvase property. ∆7resolvase could be over-expressed and purified as wild resolvase.
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Figure 3-1. Electrophoretic mobility shift assay to determine the binding affinity of wild resolvase or ∆7-resolvase to HJ or
DNA duplex. Figure A shows the structural model of wild CPV resolvase•HJ complex, and Figure B shows the structural
model of ∆7-resolvase•HJ complex. Resolvase is shown in green, aphla4 helix is colored in red. HJ DNA are shown in
magenta. Figure C shows the result of HJ affinity to resolvase, while the Figure D shows ∆7-resolvase affinity to HJ.
Fluorescein labeled HJ was fixed at 5 nM. Resolvase and ∆7-resolvase concentration are 0 nM, 10 nM, 100 nM, 1 μM
and 10 μM through lane 1 to lane 5. Figure E shows the result of resolvase affinity to DNA duplex, while the Figure F
shows ∆7-resolvase affinity to DNA duplex. Fluorescein labeled DNA duplex was fixed at 5 nM. Resolvase and ∆7resolvase concentration are 0 nM, 10 nM, 100 nM, 1 μM and 10 μM through lane 1 to lane 5.

Metal binding properties of CPV resolvase
The observation of a bound Mg2+ ion, together with a potential role for Asp130 in
stabilizing the A site metal, prompted us to investigate Mg2+ and Mn2+ binding to CPV resolvase.
We used isothermal titration calorimetry (ITC) to measure the binding affinities, where metal ions
were titrated into a solution of resolvase. These results are shown in Figure 3-2. CPV resolvase
has affinities of 108±27 mM (estimated value) and 1.19±0.03 mM to Mg2+ and Mn2+ respectively.
These results are quite surprising, since the cellular concentration of Mg2+ and Mn2+ are at submilli and micro-molar level (99). These values would appear to be too high for resolvase to
function if metal binding to the apo-enzyme is required. Therefore, poxvirus resolvase must have
a way to deal with the low concentration of divalent ion. One possible strategy is that metal
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affinity is higher to the enzyme-HJ complex and metal binds following the binding of HJ substrate.

Figure 3-2. ITC experiment to determine the CPV resolvase metal affinity. Figure A shows the result of titration of
resolvase buffer with Mn2+; Figure B shows the result of titration of resolvase with Mn2+; Figure C shows the result of
titration of resolvase buffer with Mg2+; Figure D shows the result of titration of resolvase with Mg2+. Kd of Mg2+ for CPV
resolvase is a estimated value, since titration profile is not sigmoidal.

We next used ITC to measure the binding affinities of metal ions to the resolvase•HJ
complex. We limited metal binding to a single site and eliminated cleavage activity by using sitespecific resolvase catalytic mutants. The resolvase E59A mutant was used to measure metalbinding affinity at A site, since Glu59 is remote from the A site and does not participate in A site
metal binding (Figure 2-14). The D131A mutant was used to measure the metal affinity at B site,
based on similar reasoning. Both mutants have been previously shown to eliminate cleavage
activity but bind HJ substrates with wild-type affinities (Kd< 50 nM) for the nearly identical FPV
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resolvase (88). As a negative control, we titrated metal ions into a resolvase
E59A/D130A/D131A/D134A•HJ complex where both metal binding sites were eliminated. This
mutant still binds HJ substrates tightly, but the complex does not bind Mg2+ or Mn2+, indicating
that there are no high affinity binding sites located outside of the enzyme active site. These
results are shown in Figure 3-3 and a summary of binding data is given in Table 3-I.

Figure 3-3. ITC experiment to determine the CPV resolvase•HJ complex metal affinity. Figure A shows the result of
titration of Tetra-Mut•HJ with Mg2+; Figure B shows the result of titration of E59A•HJ with Mg2+; Figure C show the results
of titration of D131A•HJ with Mg2+; Figure D shows the result of titration of Tetra-Mut•HJ with Mn2+. Figure D shows the
result of titration of Tetra-Mut•HJ with Mn2+; Figure E shows the result of titration of E59A•HJ with Mn2+; Figure C show the
results of titration of D131A•HJ with Mn2+; Figure D shows the result of titration of Tetra-Mut•HJ with Mn2+. Figure BE
measure the metal affinity at A site of poxvirus resolvase to bind metal; Figure CF measure the metal affinity at the B site
of poxvirus resolvase to bind metal.

Mn2+ binds to the A site with Kd=24.7±0.8 μM and to the B site with Kd=5.8±0.2 μM. The
surprisingly high affinity of Mn2+ for the metal binding sites of CPV resolvase suggests that this
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metal ion could be used in vivo, if present at micro-molar concentrations in the cytoplasm of
poxvirus-infected cells. When we titrated Mg2+ into the same complex, we found weaker binding,
with Kd values of 277±14 and 392±16 μM for sites A and B, respectively. In these experiments,
the stoichiometries were fixed at N=2 sites per dimer and the affinities were determined from
standard hyperbolic binding curves, since sigmoidal binding (allowing experimental determination
of N) would require using concentrations of resolvase•HJ complex greater than 1 mM (79 mg/ml).
Table 3-I. Summary of Mn2+ and Mg2+ affinity to apo-poxvirus and resolvase*HJ complex
Mg2+
Mn2+
Wild-type resolvase (A site)
108±26.7
1.185±0.031
Kd (mM)
∆H (kcal/mol)
-8.75±0.19
-6.14±0.05
Wild-type resolvase (B site)
N.D.
N.D.
Kd (μM)
E59A•HJ complex (A site)
277 ± 14
24.7±0.8
Kd (μM)
∆H (kcal/mol)
3.93±0.08
2.76±0.02
D131A•HJ complex (B site)
392±16
5.75±0.21
Kd (μM)
∆H (kcal/mol)
4.52±0.08
8.11±0.04
Cellular Concentration (mM)
0.2~0.7 (100-102)
0.01~0.04 (103,104) (105)
Surprisingly, CPV resolvase has different metal-binding enthalpies for apo vs
resolvase•HJ complex. Mn2+ binds to resolvase with Kd=1.19±0.03 mM and with ∆H=-6.14±0.05
kcal/mol. Mg2+ binding to resolvase alone was too weak to be measured under the buffer
conditions, but we estimated that it has Kd=108±26.7 mM and with ∆H=-8.75±0.19 kcal/mol.
These results are consistent with other RNaseH family members (106-108). We discuss the
implications of these binding enthalpies below in the context of a resolvase•HJ model.
Another interesting phenomenon is that Mg2+ and Mn2+ have distinct affinity pattern at the
A site and B Site. Mn2+ has a 4.3 fold higher affinity to B site than A site, while Mg2+ has a
roughly similar affinity to A site and B site (A site is little bit higher, 1.4 fold). The titration of
resolvase to other divalent ions (Fe2+, Co2+, Ni2+, Cu2+ and Zn2+) could not be performed since the
all of them will precipitate the resolvase•HJ complex.
Catalytic efficiencies of Mg2+ and Mn2+
The results of ITC experiments suggest that Mn2+ should be an effective co-factor for
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resolvase cleavage at much lower concentrations than Mg2+. This is consistent with previous
findings that Mn2+ is effective at 0.5 mM in HJ-cleavage assays for FPV resolvase. To
characterize metal utilization further, we measured Km values for Mg2+ and Mn2+ using a bulged
DNA substrate (Figure 3-4A and B). Unlike HJ substrates, which suffer from slow product
dissociation rates, bulged DNA substrates are both efficiently cleaved and rapidly released by
resolvase (14, 16). Therefore, bulged DNA was used as substrate for enzymatic assays.

Figure 3-4. Determination of Vmax and Km value of poxvirus resolvase using Mg2+ or Mn2+ as cofactor. A), using Mg2+ as
the cofactor to determine the resolvase maximum velocity and Km value of substrate. B), using Mn2+ as the cofactor to
determine the resolvase maximum velocity and Km value of substrate. C), using Mg2+ as cofactor to determine the Km
value of Mg2+. D), using Mn2+ as cofactor to determine the Km value of Mn2+. In Figure C and D, the substrate levels
were fixed at 268nM and 395nM respectively.

Using a fluorescence polarization assay previously developed for screening small
molecules for inhibitory activity against FPV resolvase (16), we first determined approximate Km
values for the bulged substrate in the presence of saturating Mg2+ and Mn2+. The maximum
velocity measured for CPV resolvase was slightly higher when Mn2+ vs. Mg2+ was used as cofactor, with kcat(Mn2+)/kcat(Mg2+) ~ 1.7 and substrate Km values of 395±91 nM and 268±58 nM,
respectively. Basically, when Mg2+ and Mn2+ concentrations are not limiting factor, resolvase has
the similar enzymatic activity. We then measured Km values for Mg2+ and Mn2+ using fixed
concentrations of bulged substrate at their Km values (Figure 3-4C and D). As anticipated from
the ITC experiments, the Km values are quite different for the two metals, with Km=50±17 μM for
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Mn2+ and Km=750±330 μM for Mg2+. Mn2+ is more than 10 times as active than Mg2+. These
results suggested that when Mg2+ and Mn2+ are limiting factor, their concentrations have
considerable effects on resolvase activity. Considering that the physiological concentration of
Mg2+ and Mn2+ is below or around Km values (99,103), the concentrations Mg2+ and Mn2+ will play
a critical role in cleavage of the HJ substrate.
Resolvase activity in the presence of both Mn2+ and Mg2+
Our experiments have thus far indicated that Mg2+ and Mn2+ support resolvase cleavage
activity, but Mn2+ requires concentrations that may not be available under physiological conditions
for efficient function at the A site. Our ITC experiments demonstrate that the two sites at poxvirus
resolvase active pocket have different binding patterns to Mg2+ and Mn2+. The A site prefers to
bind Mg2+, while the B site prefers to bind Mn2+. We therefore asked whether a combination of
Mg2+ and Mn2+ would be effective at concentrations lower than are required for either metal ion
alone. To address this, we measured the amount of HJ cleaved in a 30 min reaction by CPV
resolvase using different concentrations of metal ions (Figure 3-5A and B). When they are the
only source of divalent ion, 200 μM Mg2+ and 20 μM Mn2+ are required to cleave half of the
substrate. When both ions are present, however, the requirements for cleavage of half of the
substrate are quite different (Figure 3-5C). At 5 μM Mn2+, the Mg2+ requirement drops to ~100 μM
and at 10 μM Mn2+, 50-100 μM Mg2+ is sufficient. These experiments indicate that a combination
of 5-9 μM Mn2+ and 50-100 μM Mg2+ is sufficient for highly efficient resolvase-mediated HJ
cleavage.
Estimates of free cytosolic Mg2+ range from 0.2-1.0 mM in mammalian cells, suggesting
that use of Mn2+ by poxvirus resolvases may be unnecessary (37). The cellular concentration of
Mn2+ has not been investigated nearly as extensively as for Mg2+, but in rat hepatocytes, the free
and total concentrations have been measured as 0.7±0.1 μM and 34±4 μM, respectively (38). At
these concentrations, Mn2+ would be expected to contribute to poxvirus resolvase catalysis. We
suggest that in some cell types, and/or under some physiological conditions, the free cytosolic
concentration of Mg2+ may be limiting and poxviruses could exploit the μM concentrations of Mn2+
available to maintain high viral replication activity.
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Figure 3-5. Determine the metal concentration requirement for resolvase activity. A), shows the results using Mg2+ as
cofactor; B), Shows the results using Mn2+ as cofactor; C). Shows the different concentration combination of Mg2+ and
Mn2+; S arrow shows the position of HJ before cleavage, and P arrow shows the position of HJ after cleavage.

Asp130 increases metal binding affinity and promotes resolvase enzymatic activity
Poxvirus and mitochondrial resolvases have a fifth acidic active site residue that is not
conserved among the eubacterial RuvC enzymes (Figure 2-15). For CPV resolvase, this is
Asp130. In the CPV resolvase structure, the Asp130 and Asp134 side chain carboxylates
hydrogen bond to a water molecule that coordinates the bound A site metal (Figure 2-14). Thus,
Asp130 contributes indirectly to metal binding and could be important for resolvase activity. To
test this hypothesis, we purified the CPV resolvase D130N mutant and measured HJ cleavage
activities in the presence of Mg2+ and Mn2+. The concentrations of Mg2+ and Mn2+ required to
cleave half of the HJ substrate in a 30 min reaction increase to 3 mM and 200 μM, respectively,
compared to 200 μM and 20 μM for the wild-type enzyme (Figure 3-6B). To directly measure
metal binding to the resolvase A site, we purified the CPV resolvase D130N/E59A protein in
which B-site binding is blocked and carried out ITC experiments on the mutant resolvase•HJ
complex. The Mn2+ Kd for A site increased from 25 μM (Table 3-I) for wild-type resolvase to ~
170 μM (Figure 3-6C) for the D130N/E59A mutant, in broad agreement with the cleavage activity
measurements. Binding of Mg2+ to the resolvase D130N/E59A•HJ complex was too weak to
measure reliably using ITC. We estimated that it is around 5 mM (Figure 3-6D). These results
demonstrated D130 increases metal binding affinity by 10~15 fold.
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Figure 3-6. The effect of Asp130 on resolvase activity and metal binding affinity. A), structure model of D130N resolvase
active site. B), metal concentration requirement of D130N resolvase cleaving substrate. C), ITC titration of Mn2+ binding
affinity of D130N-E59A resolvase at A site at the active pocket. D), ITC titration of Mg2+ binding affinity of D130N-E59A
resolvase at A site at the active pocket.

Crystallization of the resolvase•HJ complex
We made considerable progress in obtaining CPV resolvase•HJ complex and their
crystals. We found that the solubility of resolvase•HJ complex is much better than resolvase
alone. Resolvase is soluble only in high concentrations of salt and glycerol (1 M NaCl and 15%
v/v glycerol). As a comparison, resolvase•HJ complex is highly soluble in 20 mM Tris-HCl (pH
7.4), 0.1 M NaCl. E59A resolvase was used to form a complex with HJ substrate to prevent HJ
cleavage. We screened for CPV resolvase•HJ complex crystals with commercial and lab-made
crystallization screen. Dozens of conditions has shown small crystals, as shown in Figure 3-7.
All of four arms of the HJ DNA are 15 bp. These results provide a good starting point to optimize
crystallization conditions and obtain large single crystals suitable for structure determination.
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Figure 3-7. Resolvase•HJ crystals were obtained by the hanging drop vapor diffusion method. Crystals are shown as the
same relative size. A) was obtained in buffer containing 0.1M Tris-HCl (pH8.5), 3M NaCl; B) was obtained in buffer
containing 0.2 M MgCl2, 0.1M Tris-HCl (pH 8.5), 25% PEG3350; C) and D) were obtained in buffer containing 0.2 M
sodium formate, 20% PEG3350.

Resolvase inhibitor inhibits resolvase activity in an uncompetitive manner
We carried out preliminary experiments on a previously identified poxvirus resolvase
inhibitor (1,4-dihydroxy-3-phenyl-6-(4-(trifluoromethyl)phenethyl)-1,8-naphthyridin-2(1H)-one, DPTPN,
shown in figure 3-8B). The small molecule inhibits HJ cleavage with an IC50 of 4μM (21). We
tried to co-crystallize CPV resolvase with inhibitor, and also soaked resolvase crystals with
inhibitors. However, no extra electron density was observed in the crystal structure
corresponding to inhibitor, although inhibitors clearly diffused into resolvase crystals (inhibitor is
brown colored and crystals changed to dark brown upon adding inhibitors) (Figure 3-8A).
Therefore we carried out ITC experiments to measure the affinity between resolvase and the
inhibitor. No such experiments had been done previously, since the inhibitors were identified in
activity-based screens and were not further characterized (21) .The results are shown in Figure 38B. To our surprise, resolvase does not show measurable affinity to the resolvase inhibitor. An
alternative explanation is that binding is purely entropic, which would lead to no heat changes
during the ITC experiment. Next, we repeated the ITC experiment measuring the affinity between
resolvase•HJ complex and inhibitor. The result is shown in Figure 3-8C. The inhibitor shows
weak binding to the resolvase•HJ complex. Although the dissociation constant and the
stoichiometry value could not be exactly determined, we roughly estimated resolvase•HJ complex
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has Kd about mM level and stoichiometry between 1 and 2. In this experiment, the heat changes
measured during the titration are very small, indicating a small enthalpic contribution to the free
energy and the need to perform the experiment at higher concentration of complex.
Unfortunately, we are limited in the amount of resolvase-HJ complex that we can use. This was
also the case for the weak Mg2+ binding experiments described earlier. ITC therefore does not
explain the IC50 values observed in the in vitro activity assays of resolvase.

Figure 3-8. CPV resolvase interaction with inhibitor. A) shows the CPV resolvase crystals soaked with inhibitor. B) shows
the resolvase inhibitor structure of 1,4-dihydroxy-3-phenyl-6-(4-(trifluoromethyl)phenethyl)-1,8-naphthyridin2(1H)-one, DPTPN. The naphthyridin core structure is dash-line circled. C) shows ITC experiment to determine
the affinity of CPV resolvase to inhibitor and CPV resolvase•HJ complex. Left shows the result of inhibitor to resolvase
and right shows the result of inhibitor.
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Chapter 4: Resolvase discussion and future directions
Discussion
Poxviruses use a special mechanism to replicate their DNA genomes, and this process
needs the involvement of resolvase. In this thesis, I solved the crystal structure of resolvase from
canary poxvirus. Poxvirus resolvase has a similar folding pattern as RuvC and it belongs to the
RNaseH family. However, poxvirus resolvase has considerable functional and structural
differences from RuvC. First, their biological roles are different. Poxvirus resolvases plays an
essential role in the poxvirus life cycle. When resolvase is deleted, the virus particle is not viable
(7). In contrast, RuvC plays a less important role, since it only benefits bacterial growth by
participating in DNA repair pathways, but is not required for bacterial viability (109) and its
function could be replaced by other enzymes, such as RecG (110). Second, their enzymatic
properties are different. Poxvirus resolvase cleaves a variety of nucleic acid substrates aside from
HJs, while RuvC is specific to HJs. Poxvirus resolvase has less substrate sequence specificity
than RuvC. In addition, poxvirus resolvase requires lower concentrations of divalent ions to
function than RuvC. These enzymatic features make poxvirus resolvase one of the most active
enzymes in the resolvase family, and likely adapt to poxvirus resolvase function.
In this thesis, I considered several interesting questions and reached some conclusions
which are unique to CPV resolvase and other poxvirus resolvases. Some of them may also apply
to other nucleic acid enzymes. Here, I discuss them in detail.
Structural basis of CPV resolvase’s low substrate sequence specificity
Of the available resolvase•HJ complex structures, including Endo-VII•HJ from phage T4
(87) and Endo-I•HJ from phage T7 (86,111), both of them have no substrate sequence specificity.
These endo-nucleases exclusively approach HJ from DNA backbones, which explain the lack of
sequence specificity, as shown in Figure 4-1A and 4-1B. The eukaryotic counterpart, Mus81Eme1, was crystallized as complex with flap DNA substrates. Similar to the phage resolvases, it
only interacts with DNA backbones (112). Bacterial RuvC seems to be an exception since it
requires a specific junction sequence for the cleavage. For all the sequence specific
50

recombinases (including Cre recombinase shown in Figure 4-1C, λ integrase, γδ resolvase and
large serine recombinases), they forms numerous interactions with nucleo bases in the DNA
major grooves (84,113-115). In the crystal structure of the RuvC•HJ complex, the β4-α2 loop,
has close contacts with the HJ central region, thus it provides the substrate sequence specificity.
Since RuvC shares a similar folding pattern with poxvirus resolvase, we believe that poxvirus
resolvase should have a similar mechanism to recognize and cleave the HJ.

Figure 4-1. A), the diagram structure of T4 endoVII•HJ. Protein is shown in red and green (different monomer as different
colors). B), the diagram structure of T7 endo-I•HJ. Proteins are shown in red and green (different monomer as different
colors). C), the cartoon expression of Cre•HJ complex. T4 endo-VII and T7 endo-I only contact with HJ at backbone.
Cre forms numerous interactions with DNA bases.

However, poxvirus resolvase has no or very low substrate sequence specificity. In our
resolvase•HJ model, there is about 10Å distance between the β4-α2 loop and HJ. This region
could only contact the backbone sugar or phosphate group, but could not interact with nucleo
bases. Therefore, poxvirus resolvase avoids forming interactions with the bases from the HJ
center, and retains low or no substrate specificity. If this region of the enzyme does not interact
with the HJ, could the affinity between resolvase and HJ substrate be greatly weakened? Earlier
experiments show that poxvirus resolvase has the similar binding affinity to HJ as E.coli RuvC
(77). In our resolvase•HJ complex model, the α4 helices of resolvase are inserted into the minor
groove of HJ DNA and interact with substrate. The extra interaction of α4 with the HJ minor
groove may compensate for the shorter α2 in poxvirus resolvase. The putative α4 interaction with
the HJ may be responsible for very effective HJ cleavage. Two arms of the HJ are engaged by
α4, while the other two arms are bound by the active sites and flanking residues, including the
distant α4-α5 loop. The interaction between the α4 helix and HJ arm is supported by previous a
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mutation study on fowlpox virus resolvase (88) and our α4 truncation assay described earlier. In
the RuvC•HJ complex, the active sites and flanking residues stabilize two arms; the β4-α2 loop
stabilizes the junction center region with the other two arms left free. Therefore, bacterial RuvC
uses a less effective way to recognize and cleave HJs than poxvirus resolvase.
HJs and Mg2+ bind to CPV resolvase in a sequential manner
The binding sequence of HJ and Mg to resolvase has not been carefully studied. It is
generally assumed that HJ and Mg randomly bind to resolvase. Here, we determined the
Mg2+/Mn2+ affinity to apo resolvase and resolvase•HJ complex. Based on our ITC and kinetics
results, I suggest that CPV resolvase recognizes and cleaves HJ substrates in a sequential
manner, as shown in Figure 4-2A -E. Our observed results indicate that apo CPV resolvase
binds to Mg2+ around 100 mM level (only A site binding was observed; B site could not be
detected because of extremely low binding affinity). However, CPV resolvase has an affinity to
HJs around 50 nM in the absence of divalent ions. When resolvase binds to HJs under these
conditions, it has no activity. As we have shown, the resolvase•HJ complex greatly improves the
affinity to Mg2+, and Mg2+ concentration in the cell is high enough so that it could bind at the active
site. When the three components form a tertiary complex, cleavage occurs. After the cleavage,
the affinity of resolvase to DNA drops to that of double-stranded-DNA level, then DNA dissociates.
After DNA dissociates, resolvase affinity to Mg2+ also drops, then Mg2+ leaves. This mechanism
of resolvase recognizing and cleavage HJs substrate is very different from metalloproteinase
cleaving protein or peptide substrates, as shown in Figure 4-2F-H. The affinity of
metalloproteinase to metal is so strong that it must be synthesized as a zymogen (116-118).
Once metalloproteinase is has been activated, the metal is always sitting at the active site, and
ready for the cleavage of substrate.
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Figure 4-2. CPV resolvase and bovine pancreas carboxypeptidase (BPC) use distinct mechanisms to cleave substrates.
Figure A-E show the model of CPV resolvase cleaves HJ substrate. HJ and resolvase form complex, then four Mg2+ ions
join and form tertiary complex. After cleavage, HJ leave first, and then followed by four Mn2+. Figure F to G show the
model of BPC cleaves peptide. BPC and Zn2+ exist as holoenzyme. Substrate peptide comes in, is cleaved, then leaves.

Some nucleic acid enzymes have high affinity for divalent ions, including Cce1, T7 endo-I
and Methanococcus jannaschii RNase HII. The role of high affinity binding is in most cases to
match the free Mg2+ concentration found in the cytoplasm (106-108). However, these examples
only have high affinity to Mg2+ at one metal binding site (the A site). The affinity between
restriction enzyme and substrate DNA has been intensively studied. In the absence of Mg2+,
restriction enzyme has relatively weak non-specific binding to nonspecific DNA in the μM range
(119), and strong specific-binding specific DNA in the nM to pM range (120). The exact affinity to
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divalent ion has not been studied for apo restriction enzyme. I found one example of
endonuclease domain of the influenza virus polymerase PA subunit, which is a member of the
PD-(D/E)XK family of nucleases that use divalent metal ions for nucleic acid cleavage. The PD(D/E)XK structure motif is shared by most of restriction enzymes (64). Endonuclease domain of
the influenza virus polymerase has affinity to Mg2+ at 0.148 and 4mM: suggesting physiological
Mg2+ concentration could saturate one site, but not both sites (121). I did not find examples
which possess sub-millimolar affinity for both the A site and the B site. Physiological
concentrations of Mg2+ or Mn2+ do not saturate both the A site and B site for nucleic acid apo
enzymes as a general rule. In our studies, we found the expected Mg2+ concentration is high
enough for CPV resolvase to carry out its biological function. This conclusion is based on the fact
that CPV resolvase readily forms a complex with its substrate, and the substrate is well
positioned and ready for cleavage. After Mg2+ binds, the nucleophilic water molecule will be
activated for cleavage. This mechanism may help resolvase to find the proper substrate and
prevent wrong or random cleavage of other nucleic acid structures.
Asp130 functions in poxvirus resolvase and poxvirus replication
Poxvirus resolvase belongs to the RNaseH family. Each member has several negatively
charged amino acids located at the active site. The number ranges from 3 to 5: HIV integrase
has only three; E.coli RuvC has four, and poxvirus resolvase has five. It seems that the aspartic
or glutamic acid number closely correlates with enzyme activity. As described in the introduction,
the Mg2+ concentration requirement for these three members is different, with a sequential order:
HIV integrase > E.coli RuvC > poxvirus resolvase. The number of negatively charged amino
acids is inversely correlated with in vitro Mg2+ concentration requirements for high activity and
with the available Mg2+ concentration in their cellular environments.
Comparing to E.coli RuvC, poxvirus resolvase has one extra aspartic acid (Asp130) at
the active site. What’s the function of Asp130 in poxvirus resolvase and in poxvirus life? The best
example to compare with poxvirus resolvase is E.coli RuvC. Both of them have three negatively
charged amino acids at the B site, suggesting that CPV resolvase and E.coli RuvC may have
similar metal affinity at the B site. Our ITC titration results demonstrated that the B site of CPV
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resolvase has a Kd value of 0.392 mM for Mg2+, which is in the range of the physiological level in
eukaryotic cytoplasm. Therefore, we could conclude that Mg2+ concentration in the cell is not a
problem for the B site.
The extra Asp130 is located in the A site. Now, the question narrows down to the A site.
When Asp130 was replaced by asparagine, resolvase is still active, but requires a high
concentration of Mn2+ or Mg2+ to cleave HJ substrate. Wild-type resolvase needs 0.2 mM Mg2+ to
be active, while D130N resolvase needs 2.5 mM Mg2+ to be active. The mutant assay indicates
that Asp130 is not essential amino acid for resolvase activity. There is no doubt that Asp130
increases poxvirus resolvase’s affinity for divalent ion, thus increasing the resolvase’s enzymatic
activity. What we are really interested in is whether this feature is required for poxvirus viability.
Considering that the eukaryotic cell cytoplasm has a lower free divalent ion concentration than in
the nucleus, it seems unlikely that Mg2+ concentration could not reach 2.5 mM in the cytoplasm.
Therefore, Asp130 is likely essential for poxvirus resolvase to function in vivo.
This conclusion is further supported by the observation that available divalent ion
dependent, double nucleic acids enzymes located in eukaryotic cytoplasm have special features
to reach high metal-binding affinity. These features could be different folding patterns or
replacement of aspartic acid with histidine or addition of an extra aspartic acid at the active site.
Poxvirus resolvase is one example of possessing an extra aspartic acid to reach high metalbinding affinity.
Homologues of RuvC accessory proteins may be not required for poxvirus resolvase
In E.coli, RuvC works together with RuvA and RuvB as a complex (122-124). RuvABC is
a very complicated system, where each member plays a different role. RuvA functions as a
sliding frame, supporting four strand of DNA branch-migrating on its surface. RuvB is an ATPase,
which pumps out DNA through the RuvA scaffold by hydrolyzing ATP and drives branch migration.
RuvC scans the HJ DNA sequence and cleaves the substrate when it encounters the preferred
sequence. RuvB and RuvC form direct interaction and could be cross-linked by chemical reagent
(125,126). In poxvirus, no protein associated with resolvase has been identified (127,128). I
doubt that there are resolvase accessory proteins. Several lines of evidences support the idea
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that poxvirus resolvase can accomplish HJ resolution alone.
One line of evidence comes from the simple genome of poxvirus genome. Poxviruses
encode about 200 genes, and most of the gene products have been assigned a biological
function (4). No protein was identified working together with resolvase. The second line of
evidence comes from structural differences between bacterial RuvC and CPV resolvase.
Bacterial RuvC interacts with HJs primarily by two arms and the junction central region, while
poxvirus resolvase interacts with HJs by binding to all four junction arms. Importantly, HJ
recognition is initiated by RuvA in bacteria, which fixes the HJ configuration as the square planar
“cross” shape. We have suggested that poxvirus resolvase first recognizes HJ by the four
junction arms, and converts to a more planar conformation of the arms upon divalent ion binding
(129), as discussed further below. The third line of evidence comes from the fact that poxvirus
resolvase has higher affinity for HJs than bacterial RuvC. From our studies and Culyba’s studies
(77), poxvirus resolvase has an affinity of 20-50 nM (Kd value) in the absence of divalent ions;
Iwasaki measured the affinity of RuvC to HJ greater than 140 nM (Kd value) (53). However, the
affinity of RuvC to HJ could be increased to 20 nM in the presence of 0.5 mM MgCl2 (130). In the
real situation, the RuvABC system is very complicated, for the affinity of RuvC to HJ may be
further strengthened by interacting with RuvB (125).
The HJ conformation in the active resolvase complex
Whereas there has been general agreement regarding the sequence specificity of E.coli
RuvC, the question of where that sequence is positioned on a given branch point isomer that is
cleaved by RuvC has been more difficult. Bennett & West (131) used methylphosphonates to
bias HJ substrates towards specific branch point isomers and concluded that RuvC cleaves the 1:+1 and +1:+2 phosphates, with a small preference for the branch point position. Using
immobile junctions, Fogg et al. (132) found an even higher preference for the branch point
phosphate. In contrast, Sha et al (133) used intramolecular torsional restraints to bias the HJ
isomers formed in solution and concluded that cleavage at the +1:+2 position is strongly preferred.
For the VV resolvase, Garcia et al (9) found that an immobile HJ substrate was cleaved at both
the +1:+2 and +2:+3 phosphates.
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To address this question in the context of CPV resolvase and the model shown in Figure
2-12B, we first marked the expected locations of scissile phosphates in the enzyme active sites,
using the highly conserved DDE residues (Asp8, Asp134, and Glu59) and the corresponding
residues from a high resolution RNaseH1•DNA•RNA complex structure (12), as shown in Figure
2-14B. Based on these positions, the expected distance between scissile phosphates in the CPV
resolvase dimer is 36.4 Å. Assuming that the resolvase dimer remains relatively rigid and the HJ
substrate is remodeled to fit the enzyme during binding and catalysis, a distance of ~36 Å is
required between HJ scissile phosphate positions in order to be engaged by both of the enzyme
active sites. In the HJ conformer observed in the RuvC•HJ crystal structure, the distance
between continuous strand branch point (-1:+1) phosphates is 30.8 Å and the distance between
+1:+2 phosphates is 24.7 A. Thus, the observed HJ conformation cannot be the one that is
cleaved by either CPV resolvase or RuvC, assuming a symmetric or nearly symmetric
mechanism. The branch point and +1:+2 phosphates are each ~6.5 A from the expected scissile
phosphate positions in the CPV resolvase active sites, further indicating that the HJ in this model
does not represent an active conformation.
To estimate the distances that would be available in alternative HJ conformers (134), we
calculated the same inter-phosphate distances in the Cre (84), T4 endo-VII (87), and T7 endo-I
(86) HJ complexes. For continuous strand branch point phosphates in these structures the
values are 31.9, 31.6, and 32.0 A, respectively, leading to the surprising conclusion that the RuvC
enzymes appear incapable of cleaving symmetrically at this position for any known HJ
conformation. For the +1:+2 phosphates, the corresponding distances are 34.9, 37.3, and 35.6 A,
all of which are much closer to the expected distance than that found in the RuvC•HJ complex.
The Cre and T4 endo-VII HJ conformations are closely related to one another, differing primarily
by their inter-arm angles and small out of plane deviations in the T4 endo-VII HJ arms. An HJ
conformation intermediate between the Cre and T4 endonuclease-bound HJ forms could be
obtained by 'flattening' the HJ conformers shown in Figure 2-12, while maintaining general
features of the resolvase-DNA interactions. The resulting Cre/T4-endonuclease HJ conformation
would have the correct inter-phosphate distance, would be more closely related to the HJs
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observed in RuvABC resolvasome studies (135), and would be more consistent with the wellestablished conformation of RuvC•HJ and FPV resolvase•HJ complexes in solution (88,136).
Indeed, the yeast mitochondrial resolvase Cce1 binds to a nearly square planar form of the HJ
(137). Additional work will be required to establish the detailed structure of the active RuvC and
resolvase•HJ complexes.
Thermodynamic signature of a structural reorganization upon metal binding
The metal binding enthalpies summarized in Table 1-III support the idea that the poxvirus
resolvase•HJ complex adopts distinct structural conformations in the presence vs absence of
divalent ions. Previous reports have indicated exothermic binding of Mg2+ and/or Mn2+ to RuvClike resolvases, as expected from the ionic nature of the coordination complexes that are formed
(106-108). Indeed, Mn2+ binding to CPV resolvase is also exothermic. However, I have shown
here that binding of Mg2+ and Mn2+ to the resolvase•HJ complex is endothermic, and is therefore
entropically driven. These observations can be explained by a model in which a substantial
number of solvent molecules are bound within the resolvase•HJ interface upon initial complex
formation but released when divalent ions bind to the complex. The resulting redistribution of
solvent would provide both a positive enthalpic contribution (due to 'melting' of water) and a
favorable entropic contribution. Additional structural changes may contribute as well and would
presumably be revealed by high resolution structural models of resolvase•HJ complexes.

Future directions
Poxvirus resolvase shares a similar folding pattern with bacterial RuvC; however, it
possesses considerable structural differences, such as the ability to bind variety of substrates
preference and high metal-binding affinity. This leaves several unanswered questions regarding
poxvirus resolvase’s mechanism of action. Does the poxvirus resolvase structure adapt to its
biological functions? What is the three dimensional structure of the resolvase•HJ complex? Does
it have a similar conformation as the RuvC•HJ complex prior to divalent metal binding? What is
the nature of the conformational change upon binding of Mg2+? Where do the currently known
resolvase inhibitor binds in resolvase•HJ complex? What is the mechanism of inhibition of
poxvirus resolvase? Can we improve the inhibitory effects of resolvase inhibitors?
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In this section, I have designed serial experiments to address the above questions. This
section is presented in three parts. The first part addresses how the poxvirus resolvase structure
is adapted to its function. The second part aims to determine the three dimensional structure of
CPV resolvase•HJ complex. The final part will address the mechanism and kinetics of current
resolvase inhibitors and develop more efficient inhibitors.
Study the molecular basis of poxvirus resolvase adapting to its biological function
1). The first biochemical assay is to study the mechanism of poxvirus resolvase only
possessing low substrate sequence specificity. Based on the CPV resolvase•HJ model and
RuvC•HJ structure, we found that the RuvC α2 helix is much longer than that of CPV-resolvase,
making the β4-α2 loop deep into the center region of the HJ. I speculate that the loop moves
along the HJ surface to form numerous interaction with the HJ, thus determining the substrate
sequence specificity.
I have designed two strategies to study whether the long α2 helix determines E.coli RuvC
specificity. The first strategy is decreasing the α2 helix at the N terminal end by one turn in the
E.coli RuvC structure (Figure 4-3A and B). Thus the close interactions between β4-α2 loop
region and HJ substrate will be abolished. I expect that RuvC will lose substrate sequence
specificity. EMSAs will be used to determine the affinity change. We expect that the shorter α2
helix will make the loop region unable to interact with HJ center region (becoming more similar to
the interaction between CPV resolvase and HJ), thus it will also weak the RuvC•HJ interaction
affinity. Another experiment will be carried out on CPV resolvase. We will extend the resolvase
α2 helix at the N terminal end by one turn (Figure 4-3C and D), making the β4-α2 loop region
reach closer into HJ central region. Thus, the linker will form interactions with the HJ junction
central region (like the interaction between E.coli RuvC and HJ). In this way, the CPV resolvase
may show a certain level of sequence preference cleavage of HJ DNA. We expect that extension
of the α2 helix will strengthen the CPV resolvase•HJ interaction affinity. EMSA will be used to
measure the affinity change.
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Figure 4-3. Planned experiments on resolvase substrate sequence specificity assay. A) shows the structural model of
E.coli RuvC•HJ complex, and B) shows the structural model of E.coli RuvC•HJ complex with truncated α2 helix. C) shows
the structural model of CPV resolvase•HJ complex, and D) shows the structural model of CPV resolvase•HJ complex with
extended α2 helix. Both α2 helices in RuvC and CPV resolvase are colored in red.

2). Study the interaction between the α4 helix, α4-α5 loop, and HJ DNA arm. Based on
our structural model and our truncation experiment, the N-terminal end of α4 forms interacts with
the HJ uncleaved arm. However, it is not clear how many amino acids are involved in the
interaction. The possible number is much more than one. Culyba et al has shown that Lys102
forms interactions with the HJ, and is essential for resolvase activity. In fact, we identified four
amino acids in the N-terminal end of α4 helix (Tyr97, Arg100, Lys101 and Lys102) that are good
candidates. Among these four amino acids, Tyr97, Arg100 and Lys101 are facing the inner side
of resolvase, which is also the interface between the α4 helix and the HJ arm. All of these amino
acids have a high frequency to interact with nucleic acids. We plan to mutate each of them to Ala,
study their effects on the binding affinity to HJs, and measure their enzymatic activity. We expect
that all of them should have lower affinity to HJs compared to wild type resolvase. Some of them
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may retain enzymatic activity, but the activity may drop substantially. Another region is the huge
loop region between α4 and α5. This region is docked into the minor groove of cleavable arms of
the HJ. I plan to delete the central part, but still maintain a length to make sure that the loop still
connects α4 and α5 without disrupting the resolvase fold. I expect that the deletion will weaken
the affinity of CPV-resolvase to HJs, but may not completely abolish the resolvase activity.

Figure 4-4. Planned experiment on α4 and linker region between α4 and α5. A) shows the structural model resolvase to
half HJ DNA. The regions docked to DNA minor groove are colored in red. B) shows the detailed structure of N-terminal
of α4, which possibly interacts with Junction DNA. C) shows truncated loop region connecting α4 and α5. Figure B and
Figure C are shown in the same orientation as Figure A.

3). Study the structural basis of poxvirus possessing higher metal affinity than other
RNaseH members. Poxviruses carry out their whole life cycle in the host cell cytoplasm. This
raises the question of how resolvase structure adapts to low Mg2+ concentrations in the
cytoplasm. Poxvirus resolvase has one extra aspartic acid (Asp130) in the active site. This
residue interacts with the cofactor Mg2+ through a water molecule. Here I designed following
experiment, and will determine whether Asp130 is required for poxvirus viability. Vaccinia virus
will be used instead of canarypox virus, since vaccinia virus has been extensively studied and
there is a well-established protocol to culture and work with the virus (138). Since Asp130 is well
conserved through all the poxvirus family, using any poxvirus strain should provide the same
result.
I will use vaccinia virus to infect mammalian cell strain (Baby hamster kidney cells (BHK21); ATCC#: CCL-10) to test poxvirus resolvase activity. Endogenous resolvase will be
eliminated by RNA interference. Then VV infected cells will be transfected respectively with wildtype A22R and D140N/A22R expression plasmid (D140 in vaccinia virus resolvase occupies the
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same position of Asp130 in canarypox virus resolvase). Structure models are shown in Figure 45. The expected results are that supplying wild-type A22R will rescue VV particle production,
while D140N/A22R will not. D140N/A22R enzymatic activity will be also be studied in vitro using
synthetic HJs as substrate. This experiment aims to probe that D140 is required for VV viability
but not for poxvirus enzymatic activity. Since eukaryote argonautes have one histidine in the last
active site α helix, and this structure provides high metal affinity, we will also test the two other
A22R mutants based on replacing aspartic acid with histidine. We will transfect cells with D140HD141A, and D140A-D141H A22R respectively after depleting endogenous A22R expression,
shown in Figure 4-5. We expect both constructs will yield viable VV particles.

Figure 4-5. Planned experiment to study the effect of D140 on VV viability. A) shows the structure model of A22R
resolvase active site. B) shows the structure model of D140N resolvase. C) and D) show the D140H-D140A, D140AD141H resolvase respectively. Red dashed box shows the A site, and green dashed box shows the B site.

Determine the three dimensional structure of resolvase•HJ complex
The overall structure of poxvirus resolvase is similar to bacterial RuvC, but with several
distinct differences which are involved in the substrate recognition. Determing the three
dimensional structure of a resolvase•HJ complex will greatly enrich our understanding of poxvirus
resolvase and provide a structural platform to develop antiviral drugs.
1). Determine the crystal structure of a resolvase•HJ complex. The crystal structure of
the resolvase•HJ complex would be most informative to understand the mechanism of resolvase
recognizing and cleaving HJ DNA. The crystal structure of resolvase will be used to guide HJ
design to crystallize the resolvase•HJ complex. The initial resolvase•HJ complex crystals
described earlier in this thesis were obtained by using HJ DNA with 15-bp arms. However, the
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quality of these crystals is not high enough to solve the structure. Based on the CPV
resolvase•HJ model, CPV resolvase binds HJ DNA in an asymmetrical manner. Resolvase binds
to the cleavable arms by about 10bp, and binds to uncleaved arms contacting about 5~6 bp.
Thus, trimming the uncleaved arms to smaller sizes may help the complex grow high quality
crystals. I will screen resolvase•HJ complexes with different HJ arm sizes, and aim to obtain
single and larger crystals to solve the structure. D59A resolvase will be used to form a complex
with HJ DNA to prevent substrate cleavage. We expect that the overall structure of CPV
resolvase•HJ will be similar to the complex of T.thermophilus RuvC•HJ and thus to our model
which is shown again below in Figure 4-6A.

Figure 4-6. The structural model CPV resolvase•HJ complex in the absence /presence of divalent ion. Figure A shows
the model in the absence of divalent ion. HJ arms have different sizes. The cleavable arms has 10bp, while extended
arms has 6bp. Figure B shows the model in the presence of divalent ion. All four arms have 10bp.

2). Study the conformational change between the binding and cleaving states of CPV
resolvase•HJ complex. It has been long realized that E.coli RuvC binding and cleavage of
substrate are distinct steps (130). There are considerable conformational changes associated
within this process. In our structural model of the resolvase•HJ complex, the two active site are
separated by a distance of 36 Å. However, the distance between the target phosphodiesters is
24 Å. This suggests that structural model is more likely an initially bonding state, but not cleaving
state. The four-way junction substrate could extend the phosphate-phosphate distance by
flattening the HJ conformer. We expect that HJ will adopt more flat planar structure when forming
a complex with resolvase in the presence of divalent ions, shown in Figure 4-6B. This
conformation would be more properly configured for cleavage: thus we call this the cleaving state.
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Resolvase uses a two-metal-ion mechanism to carry out its enzymatic activity. Addition
of divalent ions may promote the conformation change. Another evidence which supports CPV
resolvase undergoing a large conformational change upon divalent ion binding comes from the
enthalpy change. I estimated up to 10 H-bond or ordered water molecules are broken or
squeezed out when CVP resolvase•HJ transition from the binding state to cleavage state (Table
4-I). Ca2+ binds to the resolvase active site to coordinate with HJ substrate, but inhibits cleavage
(88). Thus, Ca2+ will be added to resolvase•HJ complexes to promote formation of a flat
conformation. The conformation will be determined by X-ray crystallography and small angle Xray scattering (SAXS) method.
Table 4-I. Estimation broken H-bonds during CPV-Res•HJ transition from binding to cleavage state

Events
Mn2+ : CPV-Res•HJ
Mn2+ to CPV-Res•HJ (A site)
Mn2+ to CPV-Res•HJ (B site)
2+
Mn total contribution
Mn2+ : CPV-Res
Mn2+ : CPV-Res (A site)
Mn2+ : CPV-Res (B site)*
2+
Mn : HJ (as CPV-Res•HJ)
Mn2+ : HJ (A site)*
Mn2+ : HJ (B site)*
Conformation change upon
Mn2+ bind CPV-Res•HJ
Energy to break one CPV-Res•HJ
or ordered Water H-bond
Energy to break intramolecular
or ordered Water H-bond
Energy to form H-bond with solvent
H-bonds broken upon Mn2+ binding

Number of bonds

At least 14
At least 8
2x2
At least 2 x 2
At least 6
At least 1 x 2
At least 2 x 2
1
1
2
~ 10

∆H (kcal/mol)
~ 10.87
2.76 ± 0.02
8.11 ± 0.38
Est: -21.49
Est: -12.28
-6.14 ± 0.22
Est: -6.14
Est: -9.21
Est: -3.07
Est: -6.14
~ 10.87-(-21.49)
= 32.36
~3
~ 7 (139)
~ -2 (140)

* Bond energy is calculated as same value as Mn2+ binding to A site. According the two-metal-ion theory (12), metal at A
site will form at least two bonds with resolvase and at least one bond with HJ; metal at B site will form at least two bonds
with resolvase and at least two bonds with HJ.

Study the mechanism of resolvase inhibitor and develop more efficient inhibitors
Culyba et al used fowlpox virus resolvase and screened the several small compound
libraries, identifying several promising compounds which could potentially be used as resolvase
inhibitors (21). In this part of my future plan, I focus on studying the mechanism of resolvase
inhibition, and developing more efficient inhibitors based on the current inhibitor structure.
Based on our ITC experiment, inhibitor (showed in Figure 4-7B) does not show
measureable binding affinity to resolvase alone, suggesting it does not simply bind to active site
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pocket. However, the inhibitor shows binding affinity to the CPV-resolvase•HJ complex,
suggesting that the inhibitor might bind to both the CPV resolvase and HJ substrate. We found
that there is about a 10Å distance between the resolvase β4-α2 loop and the HJ. The inhibitor
core moiety has been docked to this interface (Figure 4-7A), where it could potentially block the
conformational change of HJ required to assemble the active site. If the inhibitor behaves exactly
as we expect, it should inhibit CPV resolvase in an uncompetitive manner. Therefore, CPV
resolvase will have smaller value of Km and Vmax. (They are the properties of uncompetitive
inhibition)

Figure 4-7. Structural model of resolvase inhibitor mechanism and inhibitor structures. A) shows structural model of CPV
resolvase•HJ•inhibitor tertiary complex. B) shows the resolvase inhibitor structure, DPTPN. Inhibitor core is shown in
dashed circle. C): R1 and R2 moieties are variable groups in resolvase inhibitors. D) shows the minimum compound we
will try. Figure E and F show two compounds with R1 moiety being changed to hydroxyl and acetate groups.

We will carry out experiments as described by Culyba et al (21) and our published results
to study the mechanism and kinetics of DPTPN to inhibit CPV resolvase. When DPTPN binds
into the interface between CPV resolvase and HJ, it will be sandwiched between resolvase Tyr63
and HJ bases. Therefore, it might increase the binding affinity between resolvase and HJ DNA.
EMSA experiments will be applied to study the affinity between resolvase and HJ complex. We
will measure the affinity change of resolvase and HJ in the presence and absence of inhibitors.
Another important area is developing more effective inhibitors against poxvirus resolvase.
The interface between the β4-α2 loop of CPV resolvase and the HJ DNA has limited space: it
could fit a core structure of DPTPN, but not the whole molecule. The R1 and R2 moieties are
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predicted will to cause steric clashes for DPTPN to bind in that area. Thus, we will remove the
R1 and R2 group (Figure 4-7C) to and test the binding affinity. I predict that the core structure
(Figure 4-7D) of DPTPN will have a stronger affinity than the intact structure. I further note that
the R1 and R2 groups are extremely hydrophobic, contributing to poor solubility of the inhibitor.
Thus, it will be very difficult to deliver such an inhibitor to the infected tissues.
In our structural model, the inhibitor binds to the interface between CPV-resolvase and
HJ. This is an open position, not an enclosed hydrophobic cavity. The major core structure of
the inhibitor is two aromatic rings. The R groups could be modified by adding hydrophilic groups
to increase its solubility, possibly resulting in efficient delivery to the resolvase. I plan to change
the R1 moiety to hydroxyl and acetate groups (shown in Figure 4-7E, F). These modifications
should improve inhibitor solubility and increase its inhibitory effects.
In total, future directions aim to systematically study poxvirus resolvase using
biochemical and structural approaches. These experiments will greatly enrich our understanding
of the mechanism poxvirus resolvase uses to recognize and cleave of HJ DNA. These studies
will provide a platform to design and screen inhibitors against poxvirus infection which will be
extremely useful in preventing the use of poxviruses in bio-terrorism.
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CHAPTER 5: Metal&EDTA method to purify metal dependent proteins
Abstract
Poxvirus resolvases are a group of enzymes which specifically recognize and cleave
four-way Holliday Junction DNA. They use Mg2+ or Mn2+ ion as cofactor to carry out their
enzymatic activity. In this chapter, we developed one simple and efficient method to purify
canarypox virus (CPV) resolvase. The whole process needs two steps and only one SPsepharose chromatography column. The first step is running linear salt gradient with buffer
containing 5 mM of Mn2+, and the resolvase was eluted at about 0.6 M NaCl. The second step is
running linear salt gradient with buffer containing 0.5 mM EDTA, and the resolvase was eluted at
about 0.3 M NaCl. The final resolvase could reach 99% purity. Surface property analysis
indicates that CPV resolvase active sites comprise of negative charged residues, and are
surrounded by positive residues. When two active sites are neutralized by Mg2+ or Mn2+, CPV
resolvase will bind SP-sepharose resin more tightly than it does in the presence of EDTA. This
method (Metal&EDTA) could be effectively used to purify E.coli RuvC and RNaseH. Since most
of the DNA and RNA polymerases, DNA and RNA nucleases, DNA and RNA ligases, and some
metalloproteinase share the similar surface properties, and use Mg2+ or Mn2+ or other divalent
ions as cofactor to carry out their biological functions, the use of Metal&EDTA method may be
extended to purify these enzymes.
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Introduction
Poxviruses are a large group of viruses which infects a very broad range of eukaryotic
hosts, including mammals, birds, reptiles and insects (1). Poxviruses use a novel mechanism to
replicate their genomes that involves formation of genome concatemers (141). The poxvirus
resolvases play an essential role in cleaving these concatemers and are therefore promising
targets for antiviral drugs (6,7,21). They function as a dimer, and have molecular weight around
35 kDa (9). The poxvirus resolvases use Mg2+ or Mn2+ as co-factor to carry out enzymatic activity
(88). We cloned the CPV resolvase gene to pET21a vector and over-expressed it in BL21(DE3)
cell. Through three chromatography separations, we purified the CPV resolvase to high purity.
Resolvase crystals were obtained by micro-dialysis method and we were able to solve the threedimension structure (129), shown in figure 5-1. In CPV resolvase structure, one Mg2+ was
observed at the active site. The Mg2+ ion forms direct interactions with Asp8 and Asp131, and
indirect interactions with Asp130 and Asp134 through a water molecule. CPV resolvase has the
similar folding pattern to E.coli RuvC (24) and belongs to RNaseH super family (29).

Figure 5-1. Crystal structure of CPV resolvase. A) shows the overall structure of CPV resolvase in cartoon. B) shows the
CPV resolvase active site. Critical amino acids are shown as sticks; Mg2+ is shown as blue spheres; water molecules are
shown as red spheres. Hydrogen bonds and salt bonds are shown as dashed lines. Figure B is not shown in the same
orientation as figure A. PDB access code: 5E6F.

During our study of CPV resolvase, we found that resolvase crystals could be only
obtained from wild form. Any tags fusing with N- or C-terminal will lead the resolvase resistant to
crystallize. The original protocol needs three chromatography columns (SP-sepharose, MonoS,
and Superdex-200) to get high purity resolvase. When varying purification conditions, we
developed a simple and efficient method to purify highly pure and wild form CPV resolvase. The
whole process was greatly simplified to two steps and only one chromatography column (SP68

sepharose). Since poxvirus resolvase share the similar surface property with other divalent ion
dependent nucleic acid enzymes, the same protocol may be extended to purify these enzymes.
We further realize that metalloproteinases, which comprise the largest protease family, also
possess the similar the surface property as CPV resolvase and are divalent ion dependent, thus
the use of divalent ion and EDTA method, may be extended to purify metalloproteinase as well.

Results
Regular method to purify CPV resolvase
To carry out biochemical and structural study of poxvirus resolvase, we cloned canarypox
virus resolvase (CPV) gene to pET21a vector, and over expressed CPV resolvase in BL21(DE3)
cell. CPV resolvase functions as a dimer. It has a molecular weight about 35 KDa and pI of 8.5.
We worked out one protocol to purify CPV resolvase by combination of two ion-exchange and
one gel-filtration chromatography. This protocol will give us the CPV resolvase about 99% of
purity. The results are in shown in figure 3-2.
The first step to purify CPV resolvase is running SP-sepharose chromatography. We
found that CPV resolvase could be effectively bonded to the column and eluted at about 0.3 M
NaCl during linear NaCl gradient elution. At this stage, the CPV resolvase is about 70 percent
purity. The results are shown in figure 3-2A and 3-2B. Next, we collected CPV resolvase peak
fractions and diluted by adding one volume of buffer A1 to decrease the NaCl concentration.
Then the diluted CPV resolvase peak fraction was loaded to MonoS chromatography column for
further separation. The CPV resolvase peak was eluted at about 0.35 M NaCl. Most of impurity
bands are removed, but several minor bands with molecular weight between 25~100 kDa could
be detected on the SDS-PAGE gel. The purity reach 95% purity and these results are shown in
figure 3-2C and 3-2D. Finally, CPV resolvase peak was pooled, concentrated and loaded to
Superdex-200 for final purification. After gel-filtration, only one minor band with molecular weight
between 25 and 30 kDa could be detected, and the CPV resolvase is over 99% purity, shown in
figure 3-2E and 3-2F. The resolvase peak fractions from Superdex-200 elution were collected
and concentrated by 10 kDa MWCO Centricon tube to 30~50 mg/ml and flashed frozen in liquid
nitrogen and keep at -80°. We also tested the Hydroxyapatite (HAP) separation effect following
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SP-sepharose, the result showed that HAP could not separate CPV resolvase band from other
proteins (Appendix B).

Figure 5-2. Regular protocol to purify CPV resolvase. A) and B) show the results of SP-sepharose chromatography. A)
shows the salt elution profile. B) shows the SDS-PAGE results of different fractions. Lane1: Ladder marker; Lane 2:
lysate; Lane 3: pellet; Lane4: supernatant; Lane 5: flow through; Lane 6: 48ml; Lane 7: 52ml; Lane 8: 56ml; Lane 9: 60ml;
Lane 10: 64ml; Lane 11: 68ml; Lane12: 72ml; Lane 13: 76ml; Lane 14: 80ml; Lane 15: 84ml. C) and D) show the results
of MonoS chromatography. C) shows the salt elution profile. D) shows the SDS-PAGE results of different fractions.
Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution; Lane 3: 25ml; Lane 4: 26ml;
Lane 5: 27ml; Lane 6: 28ml; Lane 7: 29ml; Lane 8: 30ml; Lane 9: 31ml; Lane 10: 32ml; Lane 11: 33ml; Lane 12: 34ml;
Lane 13: 35ml; Lane 14: 36ml. E) and F) show the results of gel-filtration chromatography. E) shows the gel-filtration
elution profile. F) shows the SDS-PAGE results of different fractions. Lane1: Ladder marker; Lane 2: CPV resolvase
peaks pooled from MonoS elution; Lane 3: 15ml; Lane 4: 16ml; Lane 5: 17ml; Lane 6: 18ml; Lane 7: 19ml; Lane 8: 20ml.
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Purify CPV resolvase with Mg2+ and EDTA
We tried other methods to improve CPV resolvase purification efficiency. We realized
that in the SDS-PAGE of regular method to purify CPV resolvase, considerable amount of CPV
resolvase are in the pellet when spin down the lysate. If we add Mg2+ to the culture media and
purification buffer to stabilize CPV resolvase, CPV resolvase may increase its stability, thus we
could improve final yield. Therefore for 5 mM Mg2+ was added to culture media and lysis buffer.
5 mM MgCl2 was also added to the chromatography buffer A1 and B1 to make buffer A2 and B2.
We run SP-sepharose chromatography by same linear salt gradient as in regular method. The
SDS-PAGE indicates that there is still large amount of CPV resolvase in the pellet suggesting
adding MgCl2 to the culture media and purification buffers doesn’t improve CPV resolvase
stability. However, to our surprise, we found that CPV resolvase peak elution volume is delayed
by about 13 ml, corresponding of NaCl concentration of 0.4 M. And the CPV resolvase peak
fractions are much purer than CPV resolvase in figure 5-2B. Considerable amount of impurity
was removed from CPV resolvase peak, especially the protein molecular weight between
30~100kDa. These results are shown in figure 5-3A and 5-3B.
The CPV resolvase peak shifted its elution volume. It renders us to think that the elution
volume may shift back to original position if we add EDTA to chelate Mg2+. The elution volume
difference may remove some impurity bands in CPV resolvase peak fractions if we run SPsepharose chromatography again. Therefore, 0.5 mM EDTA was added to buffer A1 and B1 to
make buffer A3 and B3. We collected CPV resolvase peak fractions and diluted by adding two
volume of buffer A1 to decrease the NaCl concentration. A similar salt gradient was run through
SP-sepharose chromatography column with buffer A3 and B3. The results are exactly as we
expected, and CPV resolvase peak shifts back to the original elute volume, as shown in figure 53C. The SDS-PAGE (Figure 5-3D) result shows that most the impurity bands were removed from
CPV resolvase. The impurities are concentrated in the later fractions and well separated from
major peak fractions.
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Figure 5-3. Purification of CPV resolvase with Mg2+ and EDTA. A) and B) show the results of SP-sepharose
chromatography of CPV resolvase with 5mM MgCl2. A) shows the salt gradient elution profile. B) shows the SDS-PAGE
results of different fractions. Lane1: Ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5: flow
through; Lane 6: 60ml; Lane 7: 64ml; Lane 8: 68ml; Lane 9: 72ml; Lane 10: 76ml; Lane 11: 80ml; Lane 12: 84ml; Lane 13:
88ml; Lane 14: 92ml; Lane 14: 96ml. C) and D) show the results of SP-sepharose chromatography purification of CPV
resolvase with EDTA. C) shows the salt gradient elution profile. Figure D) shows the SDS-PAGE results of different
fractions. Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution; Lane 3: 52ml; Lane 4:
56ml; Lane 5: 60ml; Lane 6: 64ml; Lane 7: 68ml; Lane 8: 72ml; Lane 9: 76ml; Lane 10: 80ml.

Purify CPV resolvase with Mn2+ and EDTA
The purification of CPV resolvase by Mg2+ and EDTA gave us better results than regular
method. However, there are still some impurity bands in the CPV resolvase fractions. Mn2+ has
similar chemical properties as Mg2+, and most of nucleic acid enzymes could replace by Mn2+ with
Mg2+. Furthermore, fowlpox virus resolvase shows high activity when Mn2+ replaces Mg2+ as
cofactor (88). Therefore, we tested purification of CPV resolvase by adding Mn2+ to
chromatography buffer. 5 mM of MnCl2 was added to the chromatography buffer A1 and B1 to
make buffer A4 and buffer B4. A salt gradient SP-sepharose chromatography was run using
buffer A4 and B4. We are excited to find that Mn2+ further delays the elute volume of CPV
resolvase than Mg2+. The elute volume shift from 66 to 102 ml, and the NaCl concentration
corresponds 0.6 M. After first step of purification, the resolvase is about 80% purity. These
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results are shown in figure 5-4A and 5-4B.

Figure 5-4. Purification of CPV resolvase with Mn2+ and EDTA. A) and B) show the results of SP-sepharose
chromatography of CPV resolvase with 5 mM MnCl2. A shows the salt gradient elution profile. Figure B show the SDSPAGE results of different fractions. Lane1: Ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5:
flow through; Lane 6: 84ml; Lane 7: 88ml; Lane 8: 92ml; Lane 9: 96ml; Lane 10: 100ml; Lane 11: 104ml; Lane 12: 108ml;
Lane 13: 112ml; Lane 14: 116ml; Lane 14: 120ml; Lane 15: 124ml. C) and D) show the results of SP-sepharose
chromatography purification of CPV resolvase. C shows the salt gradient elution profile. Figure D shows the SDS-PAGE
results of different fractions. Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution;
Lane 3: 56ml; Lane 4: 60ml; Lane 5: 64ml; Lane 6: 68ml; Lane 7: 72ml; Lane 8: 76ml; Lane 9: 80ml; Lane 10: 84ml.

Then we collected the CPV resolvase peak and add 2 equal volume of buffer A3 to
decrease the NaCl concentration. A salt gradient was run using buffer A3 and B3. SDS-PAGE
show very nice results. The CPV resolvase peak could be fully separated from other impurity
bands. There is only one impurity band located at the later peak factions. The earlier and
majority peaks are almost 100% pure. These results are shown in figure 5-4C and 5-4D.
ITC experiment on titration of CPV resolvase with Mn2+ or Mg2+
Mn2+ greatly delays the CPV resolvase retention volume. It is necessary to know where
and how many Mn2+ ions bind to CPV resolvase. In our former paper, we identified one Mg2+ at
each active site. We also found that Mg2+ and Mn2+ do not bind resolvase aside from active site
(129). The Mg2+ was assigned based on the electron density size and surrounding environment.
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However, Mg2+ and water molecules don’t have differences when judged by the size of electron
density. The exact stoichiometry of CPV resolvase and metal ion should be determined by ITC
experiment.
The titration of CPV resolvase to Mg2+ was performed, but the Kd value could not be
exactly determined because of the low affinity. Thus, we fixed N at 2, and let the software to
determine the Kd value. We estimated that the Kd value of CPV resolvase to Mg2+ is around 100
mM. As an alternative, we titrated wild CPV resolvase with Mn2+, and the results are shown in
figure 5-5. Mn2+ has a stoichiometry of 2.42:1 to CPV resolvase dimer. It suggests one CPV
resolvase dimer bind two Mn2+ ions, which mean one active site binds one Mn2+. Kd value is
1.185 mM, suggesting Mn2+ will saturate CPV resolvase during our purification (5 mM). This
experiment is carried out by lowering CPV resolvase concentration to 17.5 mg/ml (0.5 mM) and
increasing Mn2+ to 50 mM to make sure that ITC results could be close to basal level at the end of
titration.

Figure 5-5. Titration of CPV resolvase with Mg2+ and Mn2+. A) shows the result of CPV resolvase titrated with Mg2+. B)
shows the result of CPV resolvase titrated with Mn2+.

Purify Tri-Mut CPV resolvase with Mn2+ and EDTA
Divalent ion (Mg2+ or Mn2+) and EDTA could increase the purification efficiency. We
speculate that binding of Mn2+ or Mg2+ to the CPV resolvase active site, neutralizes the negatively
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charged residues and thus increases the CPV resolvase binding affinity to SP-sepharose resin. If
negatively charged residues are mutated to alanine, same surface electrostatic property could be
achieved as binding of divalent ions. In crystal structure of CPV resolvase, one Mg2+ ion is
observed in the active site. The Mg2+ ion directly interacts with Asp8 and Asp131, and indirectly
interacts with Asp130, Asp134 mediated by one water molecule (Figure 5-1B). Therefore,
mutation of Asp130, Asp131, and Asp134 should abolish the metal binding ability of CPV
resolvase. In the light of this idea, we made D130A-D131A-D134A CPV resolvase construct, and
tested its binding affinity to SP-sepharose in the presence of Mn2+ and EDTA. These results are
shown in figure 5-6.
TriMut CPV resolvase could be overexpressed in BL21 (DE3) cell, but it has a poor
solubility, as it shown in figure 5-6D. Only a small fraction of CPV resolvase is soluble. Same
protocol was run as purifying wild CPV resolvase with Mn2+ and EDTA. Comparing the figure 56C and 5-6D with 5-2A, it is clear that the TriMut peaks are eluted later than wild type in the
presence of 5 mM Mn2+. However, when Mn2+ was removed by EDTA, the TriMut elution volume
is rough as the same position as eluted with Mn2+. This experiment suggests that TriMut CPV
resolvase binds SP-sepharose more tightly than wild form and Mn2+ doesn’t contribute to the
binding affinity. SDS-PAGE also shows that most impurity bands couldn’t be separated from
CPV resolvase band; this is consistent with the figure 5-6A and 5-6B.
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Figure 5-6. Structure model of CPV resolvase active sites and purification of TriMut CPV resolvase with Mn2+ and EDTA.
A) shows the structure model of CPV resolvase active site in the presence of 5mM of Mn2+. B) shows the structure model
of Tri-Mut CPV resolvase at the active site. C) and D) show the results of SP-sepharose chromatography of CPV
resolvase with 5mM MnCl2. C) shows the salt gradient elution profile. D)show the SDS-PAGE results of different
fractions. Lane1: Ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5: flow through; Lane 6: 80ml;
Lane 7: 84ml; Lane 8: 88ml; Lane 9: 92ml; Lane 10: 96ml; Lane 11: 100ml; Lane 12: 104ml; Lane 13: 108ml; Lane 14:
112ml; Lane 15: 116ml. E) and F) show the results of SP-sepharose chromatography purification of CPV resolvase. E)
shows the salt gradient elution profile. F) show the SDS-PAGE results of different fractions. Lane1: Ladder marker; Lane
2: CPV resolvase peaks pooled from SP-sepharose elution; Lane 3: 80ml; Lane 4: 84ml; Lane 5: 88ml; Lane 6: 92ml;
Lane 7: 96ml; Lane 8: 100ml; Lane 9: 14ml; Lane 10: 108ml; Lane 11: 112ml; Lane 12: 116ml.

Purified CPV resolvase has no nuclease contamination
One concern of using Mn2+ and EDTA method is whether contamination is in the final
purified product. Supercoiled plasmids or linear DNA fragment was mixed with CPV resolvase
and incubated at 37 degree for 2 hours. Electrophoresis results show both of supercoiled
plasmids and linear DNA do not have migration difference before and after incubation. The
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electrophoresis results demonstrate that there is no contamination of other nucleic enzyme in
purified poxvirus CPV resolvase. These results are shown in figure 5-7.

Figure 5-7. Agarose gel electrophoresis to detect CPV resolvase contamination. Plasmid lane was prepared by mixing
plasmid with only CPV resolvase cleavage buffer. Plasmid/Res lane was prepared by mixing plasmid with CPV resolvase.
PCR lane was prepared by mixing linear DNA with only CPV resolvase cleavage buffer.PCR/Res lane was prepared by
mixing plasmid with CPV resolvase.

Purify E.coli RuvC by Mn&EDTA method.
The Mn&EDTA method could be successfully used to purify CPV resolvase. Most of the
nucleic acid enzymes are divalent ions dependant, and they share the similar surface property as
CPV resolvase. We tested our idea on the E.coli RuvC. Like CPV resolvase, RuvC is junction
resolvase, which plays essential role in DNA recombination in bacteria (53). As a prototype of
junction resolvase, E.coli RuvC has been extensive studied (142). RuvC has RNaseH folding
pattern, and belong to RNaseH-integrase superfamily (24). It needs high concentration of
glycerol and salt to be stable (53,143). Therefore, we used same buffer to purify RuvC as CPV
resolvase. The results are shown as Figure 5-8.
We first run the salt gradient of SP-sepharose chromatography in the presence of 5 mM
MnCl2. The result is shown in figure 5-8C and 5-8D. We run a linear salt gradient from 0.1 M to
1.0 M NaCl. RuvC could effectively bonds to SP-sepharose resin, and RuvC peak was eluted at
79 ml, corresponding of 0.5 M NaCl. The RuvC purity could reach 70 percent. Then RuvC peak
fractions were collected and diluted with one volume of Buffer A3, and loaded to SP-sepharose
column for next step purification. A second linear salt gradient was run from 0.1 M to 1.0 M NaCl
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in the presence of 0.5 mM EDTA, and RuvC peak was eluted at 65 ml, corresponding of 0.35 M
NaCl. Most of the impurity bands eluted with RuvC in the first step were eluted much later than
RuvC. Only two minor impurity bands were observed with molecular weight around 58 kDa and
25 kDa. The overall RuvC peak purity reaches 98% purity, as shown in figure 5-8E and 5-8F.

Figure 5-8. E.coli RuvC structure and purify E.coli RuvC with Mn2+ and EDTA. A) shows overall structure of RuvC (PDB:
1HJR) and B) shows the active site of RuvC. Critical amino acids are shown as sticks. C) and D) show the results of SPsepharose chromatography of RuvC with 5 mM MnCl2. C) shows the salt gradient elution profile. D) shows the SDSPAGE results of different fractions. Lane1: Ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5:
flow through; Lane 6: 58ml; Lane 7: 63ml; Lane 8: 66ml; Lane 9: 70ml; Lane 10: 72ml; Lane 11: 76ml; Lane 12: 80ml;
Lane 13: 84ml; Lane 14: 88ml; Lane 14: 92ml; Lane 15: 96ml. E) and F) show the results of SP-sepharose
chromatography purification of RuvC. E) shows the salt gradient elution profile. F) shows the SDS-PAGE results of
different fractions. Lane1: Ladder marker; Lane 2: RuvC peaks pooled from SP-sepharoseMn2+ elution; Lane 3: 52ml;
Lane 4: 56ml; Lane 5: 60ml; Lane 6: 64ml; Lane 7: 70ml; Lane 8: 74ml; Lane 9: 78ml; Lane 10: 82ml; Lane 11: 86ml;
Lane 12: 90ml; Lane 13: 94ml; Lane 14: 96ml; Lane 14: 100ml; Lane 15: 104ml.

We compared all available protocols to purify bacteria RuvC. As the prototype and
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critical member in DNA recombination, E.coli RuvC had been extensively studied in the 1990’s.
Authors used very complicated protocol to purify RuvC. These protocols are listed in figure 5-9A
and 5-9B. Both protocols have four steps to get highly pure RuvC (53,143). It is not hard to image
there should be huge amount work to prepare buffers, to run chromatography columns sequentially to

obtain pure RuvC. These protocols will also take long time. It will take several days to finish all
steps. As a comparison, Mn&EDTA method provides simple and efficient method to purify E.coli
RuvC, as shown in figure 5-9C.

Figure 5-9. Protocols used to purify Bacteria RuvC. A) and B) show the protocols used to purify E.coli RuvC in 1990’s
(53,143). C) shows the protocol used in this study. D) and E) show the protocols used to purify T.Th RuvC (62,63).

More recently, RuvC from Thermus.Thermophilus has attracted researchers’ attention
because of its unique features of stability under high temperature. Authors used different
protocols to purify T.Th RuvC. One group took fully the advantage that T.Th RuvC is stable in
high temperature. They incubated cell lysate at 70 degree for 30min to precipitate most of
bacteria protein. And then one more step of Heparin-Sepharose will give highly pure T.Th RuvC
(62), shown in figure 5-9D. The other group fused a Histag at the N-terminal of RuvC. They then
purified it by affinity method with Ni-NTA column. However, adding a Histag cause a problem for
crystallization, and authors removed the Histag by protease cleavage. Finally, Authors run a high
resolution MonoS chromatography column to get pure RuvC (63), shown in figure 5-9E.
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Comparing all these protocols to purify bacteria RuvC, we could draw the conclusion that
Mn&EDTA method provides most simple and efficient way to purify RuvC.
Mn&EDTA method to purify E.coli RNaseH
We further tested purification of E.coli RNaseH with Mn&EDTA method. E.coli RNaseH
is the first enzyme possessing RNaseH folding pattern with the crystal structure determined.
RNaseH cleaves RNA strand in the DNA/RNA duplex during DNA replication. One Mg2+ ion was
observed in the active site of RNase HI when crystals were grown in buffer containing 100 mM
Mg2+ (144), while two Mn2+ were observed when crystals were grown in buffer containing 1mM
Mn2+ (145). We expect that E.coli RNase HI could be purified by Mn2+&EDTA method.
We first tested to purify RNaseH by Mn2+ then followed by EDTA. However, we found
that bounded Mn2+ in the first step couldn’t be easily removed during second step purification.
Therefore, we used a reversed protocol: using EDTA containing buffer to purify RNaseH first then
followed by Mn2+ containing buffer. The expression level of RNaseH in E.coli is so huge, that
RNaseH fraction will saturate SP-sepharose column for about 30ml from one liter cell culture
(Data is not shown). In this experiment, only one fifth of RNaseH was used to test the purification.
RNaseH could be overexpressed in BL21(DE3) cell strain. Almost all RNaseH is in the
supernatant after centrifugation. We first run the 0.05 ~ 1.0 M NaCl gradient of SP-sepharose
chromatography in the presence of 0.5 mM EDTA. The result is shown in figure 5-10A and 5-10B.
RNaseH could effectively bonds to SP-sepharose resin, and RNaseH peak was eluted at 55 ml,
corresponding of 0.2 M NaCl. The RNaseH purity reaches 80 percent. Then RNaseH peak
fractions were collected and diluted with one volume of Buffer A3, and loaded to SP-sepharose
column for next step purification. A second linear salt gradient was run from 0.05 M to 1.0 M
NaCl in the presence of 5 mM Mn2+, and RNaseH peak was eluted at 68 ml, corresponding of 0.3
M NaCl. Most of the impurity bands eluted with RNaseH in the first step were eluted much later
than RNaseH. The overall RNaseH peak purity reaches 98% purity, and several minor impurity
bands could be observed. These results are shown in figure 5-10C and 5-10D.
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Figure 5-10. Purification of RNaseH with EDTA and Mn2+ by SP-sepharose. A) and B) show the results of SP-sepharose
chromatography of RNaseH with 0.5 mM EDTA. A) shows the salt gradient elution profile. B) show the SDS-PAGE
results of different fractions. Lane1: ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5: flow
through; Lane 6: 46ml; Lane 7: 48ml; Lane 8: 50ml; Lane 9: 52ml; Lane 10: 54ml; Lane 11: 56ml; Lane 12: 58ml; Lane 13:
60ml; Lane 14: 62ml; Lane 14: 64ml; Lane 15: 66ml. C) and D) show the results of SP-sepharose chromatography
purification of RNaseH with 5mM MnCl2. C) shows the salt gradient elution profile. D) shows the SDS-PAGE results of
different fractions. Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution; Lane 3: 58ml;
Lane 4: 60ml; Lane 5: 62ml; Lane 6: 64ml; Lane 7: 66ml; Lane 8: 68ml; Lane 9: 70ml; Lane 10: 72ml; Lane 11: 74ml;
Lane 12: 76ml; Lane 13: 78ml..

We further purified RNaseH with MonoS chromatography column by Mn2+&EDTA method.
RNaseH peak fraction from first step purification by SP-sepharose was loaded on MonoS column
equilibrated with 5% buffer B5. After washing, we run the 0.05 ~ 1.0 M NaCl gradient by six
chromatography column volume (48ml) in the presence of 0.5 mM EDTA. RNaseH peak was
eluted at 22.5 ml, corresponding of 0.2 M NaCl. Most impurities bands are separated from
RNaseH except one with molecular weight around 50 kDa. These results are shown in figure 39A and 3-9B. Then, the RNaseH fractions were collected, diluted by equal volume of buffer A6
and loaded to MonoS column for further purification. A 0.05 ~ 1.0 M NaCl gradient by six
chromatography column volume (48ml) was run in the presence of 5 mM MnCl2. RNaseH peak
was shift to 26.0 ml, corresponding of 0.25 M NaCl. The last impurity band was well separated
from RNaseH, and RNaseH almost reach 100% pure. These results are shown in Figure 3-9C
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and 3-9D.

Figure 5-11. Purification of RNaseH with EDTA and Mn2+ by MonoS. A) and B) show the results of MonoS
chromatography of RNaseH with 0.5 mM EDTA. A) shows the salt gradient elution profile. B) shows the SDS-PAGE
results of different fractions. Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution;
Lane 3: 20ml; Lane 4: 21ml; Lane 5: 22ml; Lane 6: 23ml; Lane 7: 25ml; Lane 8: 35ml. C) and D) show the results of
MonoS chromatography purification of RNaseH with 5mM MnCl2. C) shows the salt gradient elution profile. D) shows the
SDS-PAGE results of different fractions. Lane1: Ladder marker; Lane 2: RNaseH peaks pooled from MonoS elution with
EDTA; Lane 3: 24ml; Lane 4: 25ml; Lane 5: 26ml; Lane 6: 27ml; Lane 7: 28ml; Lane 8: 29ml.

Mn&EDTA method to purify T7 ligase
We also tested purification of T7 ligase by Mn&EDTA method. DNA ligases catalyze the
formation of phosphodiester bonds at single-strand breaks between adjacent 3’-hydroxyl and 5’phosphate termini in double-stranded DNA (146). Bacteriophage T7 encodes a DNA ligase,
which can utilize ATP and Mg2+ as a cofactor to carry out the reaction (147,148). T7 ligase could
be overexpressed in BL21 (DE3) cell, and majority protein is in the supernatant. However, when
we directly loaded supernatant to SP-sepharose column, we found that the elution volume is so
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early that T7 ligase couldn’t be separately from most cellular protein, thus only using SPsepharose could not obtain highly pure T7 ligase. T7 ligase binds SP-sepharose column at about
0.15 M NaCl. Therefore, we used Heparin-Sepharose as pre-separation to remove the most of
impurity. These results are shown in figure 5-12A and 5-12B. We run a linear salt gradient from
0.1 M to 1.0 M NaCl. T7 ligase binds to Heparin-Sepharose tightly. To elute it from the column,
the salt concentration need reach 0.6 M NaCl. Most of impurity is removed after Heparin
chromatography. T7 ligase peaks were collected, and we did next step experiment with SPsepharose chromatography.
We then diluted T7 ligase peaks with five volume of buffer A6, and load it to SPsepharose column. A linear salt gradient was run from 0.05 to 1.0 M NaCl in the presence of 5
mM MnCl2. The majority peak was eluted at 61 ml and a minor peak around 45ml. However, the
SDS-PAGE result indicates both peaks are T7 ligase peak. In all fractions, there is only a single
band. All impurities have been washed away in the flow through. These results are shown in
figure 5-12C and 5-12D. Since binding of Mn2+ delay the elution volume, the first minor likely is
the denatured T7 ligase, which loses bonding affinity to Mn2+.
We also tested the purifying T7 ligase by SP-sepharose in the presence of EDTA. T7
ligase peaks collected from Heparin elution was diluted and loaded to SP-sepharose column. A
linear salt gradient was run from 0.05 to 1.0 M NaCl in the presence of 0.5 mM EDTA. There is
one peak showed in the elution at 51 ml. Again, the SDS-PAGE result shows there is only a
single band. All impurities have been washed away in the flow through. These results are shown
in figure 5-12E and 5-12F. Although only using SP-sepharose couldn’t obtain pure T7 ligase, the
elution volume shift from 61 to 51 ml, suggesting binding of Mn2+ did change ligase surface
property.
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Figure 5-12. Purification ofT7 ligase with Heparin and Mn2+&EDTA. A) and B) shows the results of Heparin-Sepharose
chromatography of T7 ligase. A) shows the salt gradient elution profile. B) shows the SDS-PAGE results of different
fractions. Lane1: Ladder marker; Lane 2: lysate; Lane 3: pellet; Lane 4: supernatant; Lane 5: flow through; Lane 6: 88ml;
Lane 7: 92ml; Lane 8: 96ml; Lane 9: 100ml; Lane 10: 104ml; Lane 11: 108ml; Lane 12: 112ml; Lane 13: 116ml; Lane 14:
120ml; Lane 14: 124ml; Lane 15: 128ml. C) and D) show the results of SP-sepharose chromatography of T7 ligase with 5
mM MnCl2. (C) shows the salt gradient elution profile. D) shows the SDS-PAGE results of different fractions. Lane1:
Ladder marker; Lane 2: T7 ligase pooled from Heparin elution; Lane 3: 44ml; Lane 4: 46ml; Lane 5: 48ml; Lane 6: 50ml;
Lane 7: 52ml; Lane 8: 54ml; Lane 9: 56ml; Lane 10: 58ml; Lane 11: 60ml; Lane 12: 62ml; Lane 13: 64ml; Lane 14: 66ml;
Lane 14: 7068ml; Lane 15: 70ml. E) and F) show the results of SP-sepharose chromatography of T7 ligase with 0.5 mM
EDTA. E) shows the salt gradient elution profile. F) shows the SDS-PAGE results of different fractions. Lane1: Ladder
marker; Lane 2: T7 ligase pooled from Heparin elution; Lane 3: 2538ml; Lane 4: 40ml; Lane 5: 42ml; Lane 6: 44ml; Lane 7:
46ml; Lane 8: 48ml; Lane 9: 50ml; Lane 10: 52ml; Lane 11: 54ml; Lane 12: 56ml; Lane 13: 58ml; Lane 14: 60ml; Lane 14:
62ml; Lane 15: 64ml.

Discussion and future directions
Nucleic acid enzymes play critical roles in genetic engineering. Hundreds of DNA and
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RNA enzymes have been commercialized by biotech companies. However, most of these
enzymes need several chromatography steps to get high purity. It takes huge amount of work to
purify these enzymes especially for small labs. Developing a universal protocol to purify nucleic
acid enzyme will greatly decrease the amount of work and benefit nucleic acid study.
In this chapter, we developed one simple, efficient method to purify CPV resolvase.
Comparing to regular method, Mn2+ and EDTA method has several advantages. 1). Simple and
efficient. The whole purification process is greatly simplified to two steps and only one
chromatography column. Comparing regular method, it will save enormous amount of time and
efforts to make different buffers, to run multiple chromatography columns. Most importantly, the
final CPV resolvase has a high purity at least 98%. 2). High yield. The elution ion strength and
retention time are so different in two purification steps that almost all the CPV resolvase eluted
from first chromatography are recovered in the second chromatography, as shown in figure 5-4A.
Only CPV resolvase could be eluted at two different ion strengths. All the impurities are washed
away either in first chromatography or in the second chromatography. 3). Wide form. CPV
resolvase is purified as wide form, thus will not have the side effect with an affinity tag, and could
directly be used to crystallization trial. 4). Low cost. SP-sepharose is a cheap resin, which could
often be disposable. Comparing to resin with high resolution, such as MonoS chromatography
column, the cost using Metal&EDTA method is much lower.

Figure 5-13. CPV resolvase elute volume change with divalent ion or EDTA. A) shows the elute volume change in the
presence of Mn2+ or EDTA. B) shows the elute volume change in the presence of Mg2+ or EDTA.

We can’t exclude tiny amount of DNA/RNA endo- or exo-nucleases still exist in the final
purified CPV resolvase. Even there is some contamination; their amount must be several orders
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less than CPV resolvase. Based on our contamination assay, contamination nucleases could be
inactivated or ignored.
In figure 5-13A, the CPV resolvase peak eluted form buffer containing Mn2+ is fully
separated from CPV resolvase peak eluted from buffer containing EDTA. However, in figure 513B, the CPV resolvase peak eluted from buffer containing Mg2+ overlaps with CPV resolvase
peak eluted from buffer containing EDTA, suggesting the resolvase active site is not fully
occupied Mg2+. It is consistent with the low bonding affinity of Mg2+. It may need over hundred
milli-molar of Mg2+ to get the same effect as Mn2+, making Mg2+ impropriate for CPV resolvase
separation.
It is very interesting that adding 5 mM Mg2+ or Mn2+ only contribute very little to the ion
strength in the elution buffer. Comparing to the elute volume shift; the divalent ion contribution
could be ignored. If adding Mn2+ doesn’t play other role, and only contributes ion strength in the
buffer, CPV resolvase should be eluted a little bit earlier than without Mn2+. This lead to the
question how could small amount of divalent ion could generate so huge effect. Since the SPsepharose is positively charged ion-exchange resin. It binds to positive charged area of
macromolecule. We postulate that binding divalent metal ion changed CPV resolvase surface
property. As CPV resolvase using Mn2+ or Mg2+ as cofactor to carry out enzymatic activity, we
conjectured that divalent ions may bind to the active site, thus neutralize the negatively charge
amino in the active site. Our ITC experiment on CPV resolvase and Mn2+ suggested that divalent
ion bind to CPV resolvase with a stoichiometry 2:1 (one CPV resolvase dimer binds two divalent
ion or one active site binds one divalent ion). We generated the CPV resolvase electrostatic
potential map and compared the difference with Mn2+ and without Mn2+, and the results are
shown in figure 5-14.
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Figure 5-14. Electrostatic potential map of CPV resolvase. Negatively charged areas are colored red while positively
charged areas are colored blue. A) shows the surface bearing the active sites. B) shows the same orientation as (A), but
with Mg2+ or Mg2+ bonded. The map is calculated from D8A-D131A, which is equal to Mg2+ or Mn2+ neutralize Asp8 and
Asp131 negative charges. C) and D) show other side of CPV resolvase.

In the CPV resolvase electrostatic potential map, charges are not evenly distributed. One
surface bearing the active sites is positive charge dominated, except the active site, while the
other side is negatively charged dominated. When the active site bind Mg2+ or Mn2+, they
neutralize two negatively charge residues, making the negatively charged regions almost gone.
As a result, CPV resolvase binds SP-sepharose resin more tightly in the presence of divalent ion
than in the absence of divalent ion, it could be only eluted by high concentration of salt.
Interestingly, similar results were observed in the B.Halodruans RNase H. When critical amino
acid D132 is mutated to asparagine, RNase H increases its binding affinity to RNA/DNA duplex
(12). It is likely caused by charge change at the active site. D132N has less negatively charged
surface, therefore could bind substrate more tightly than wild type.
Some nucleic acid enzymes bind Mn2+ so tightly that it couldn’t be easily removed by just
washing with EDTA containing buffer, such as RNaseH and T7 ligase. This problem could be
overcome by either buffer exchange with Millipore Centricon tube or reversing the elution
sequence to EDTA followed by Mn2+ elution.
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The potential application of Metal&EDTA method
The binding of divalent ion, changed electrostatic potential of metal dependant nucleic
acid enzymes, but we are still very surprised to find that the ion strength to elute enzyme are so
different , that most of impurity could be effectively remove from first or second step. If the
method could only be applied to purify CPV resolvase, it doesn’t mean much for protein
purification. However, if this technique could be used to purify a large group of enzymes, it would
be major contribution to the protein purification field. Here I listed possible application of this
method. Since some enzymes use divalent ions other than Mg2+ or Mn2+, this method should be
named to divalent ion and EDTA method (abbreviation: Metal&EDTA). Could Metal&EDTA
method be used to purify other nucleic acid enzymes? We selected typical enzymes and made
their electrostatic potential map, including large fragment of E.coli DNA polymerase I (34),
restriction enzyme BamHI (37) and T7 DNA ligase(42), as shown in figure 10. We found that all
of them have the similar properties. The charged residues are not evenly distributed with one
surface is positive charged residue dominated, and other side is negatively charged residue
dominated (not shown). One universal feature is that the active site is negatively charged
surrounded by large area of positive residues. When divalent ion binds to the active site, it will
neutralize the negative charged residues, making the positively charged amino acid area wider.
Most of the DNA and RNA polymerases, DNA and RNA nucleases, DNA and RNA
ligases are Mg2+ or Mn2+ dependent. These enzymes have the similar surface properties as CPV
resolvase. Therefore, the Mn2+ and EDTA method may be extended to purify these enzymes.
1). Purify enzymes from RNaseH-Integrase family. As just discussed, most RNaseH
family members show high affinity to divalent ions, and have been crystals in the presence of
Mg2+ or Mn2+ (149,150). Although E.coli RNaseH crystals were obtained in 100 mM MgCl2, or
1mM MnCl2 and some of them are soaked in 45 mM MnCl2, the real concentration to saturate
active site of RNaseH family member may be not so high. The high concentration of Mg2+ or
Mn2+ are more likely to make sure the enzymes have a 100% of occupancy to obtain nice crystals.
As we see that CPV resolvase has the affinity of 108 ± 26.7 mM to Mg2+, but 5 mM of MgCl2 still
give a pretty nice result. In fact, the metal affinity of some of RNaseH family to Mg2+ or Mn2+ has
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been determined by ITC. RNaseHII from Methanoccus Jannaschii has the affinity of 13 μM and
141 μM to Mn2+ and Mg2+ respectively (108). Junction resolvase Cce1 from Saccharomyces
cerevisiae mitochondria has the affinity of 0.85 μM to Mg2+ (106). These results strongly support
Metal&EDTA method will give nice results when used to purify RNaseH-Integrase family
members.
2). Other Mg2+ dependent nucleases. Some other members don’t have RNaseHintegrase folding pattern, but also using two-metal-ion mechanism to carry out cleavage of nucleic
acid substrate, and they also show high affinity to divalent metal ions. They members include
junction resolvase, such as T4 endo VII nuclease (87,151), T7 endo I nuclease (86,152), and
eukaryote junction resolvase EME1 (112). Especially T7 endo I nuclease has a affinity of
0.58mM to Mn2+, which has been determined by ITC (107). Double stranded RNA nuclease
Dicer, which play an essential role in RNA interference is another candidate. Human dicer has
been crystallized in buffer containing 20 mM MgCl2, and two Mg ions were identified in each
active site (92). All restriction enzyme are good candidates for Metal&EDTA method, however,
there is very limited data on the metal affinity of restriction enzymes.
3). Nucleic acid polymerases and ligases. These enzymes are divalent ion dependent,
but they have some differences from nucleases. Metal ions in the nuclease play the role to
activate a water molecule, which in turn performs nucleophilic attack on the phosphate, thus
breaks the di-ester bond between two neighbor nucleotides (14). In polymerase and ligase, two
divalent ions functions stabilizing the intermediate. The nucleophile is 3’-hydroxy group from
nucleotides (153). Thus, the Metal&EDTA method may not get good results when directly used
to purify polymerase and ligases, as we see in the purification of T7 ligase. It may need prepurification before apply Metal&EDTA method.
4). Aside from divalent ion dependent nucleic acid enzymes, we realize that some
divalent ion dependent proteases also possess similar surface property as CPV resolvase.
Figure 5-15 shows the electrostatic potential map of bovine pancreatic carboxypeptidase (BPC)
with and without Zn2+ bonded. Unlike nucleic acid enzymes, which use two metal ions at their
active sites, metalloproteinases only need one divalent ion at their active sites(95). Three critical
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amino acids form active site. One of them is glutamate, and the other two amino acids are
histidines. These three amino acids form one salt bond and two dipolar bonds Zn2+. One water
molecule also binds to Zn2+, and being activated by Zn2+, performs nucleophilic attach against
carbon atom at protein backbone. Most metalloproteinases use Zn2+ as their cofactor, but some
metalloproteinases prefer to use other divalent ions, such as Mn2+, Cu2+, Co2+ based on the
subtle difference at the active site (96). Metalloproteinases have extremely high affinity to their
cofactor, which often reach nano-molar level (97).
The electrostatic potential map of bovine pancreatic carboxypeptidase is not evenly
distributed. One side bearing the active site is positive charge dominated, while the other side is
negative charged dominated, as shown in figure 5-15D and 5-15E. The surface property of BPC
is similar to CPV resolvase, especially at the active site side: negative charged area is
surrounded positively charged area. When divalent ion binds, it neutralizes the negative charged
area, shown in figure 5-15C. We expect that Metal&EDTA method will get nice results to purify
bovine pancreatic carboxypeptidase.
Some of metalloproteinases may be not as typical as BPC. If their surfaces are not
evenly distributed, Hydroxyapatite (HAP) will be a powerful resin to purify protein. HAP has been
widely used to purified various protein (154). The functional groups of Hydroxyapatite are Ca2+
and phosphate, thus it provides an excellent resin to purify protein whatever the overall charge is.
We expect that metal bonded and metal free protease will make a difference for HAP column.
One advantage for metalloproteinase purification is they have extremely high affinity to divalent
metal ions (the affinity usually is below micro-molar level), and adding μM of divalent will not
cause any negatively effect on enzymes or resin. Therefore, it is worthy to test purifying
metalloproteinase with HAP chromatography by Metal&EDTA method.
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Figure 5-15. Crystal structure and electrostatic potential map bovine pancreatic carboxypeptidase. Negatively charged
areas are colored red while positively charged areas are colored blue. A) shows the overall crystal structure at 1.2 Å
resolution (PDB: 1M4L). B) shows the active site composition. Salt bonds or dipolar bonds are shown as dashed lines.
C) shows the surface bearing the active site with Zn2+ bonded. The electrostatic potential map is calculated based on the
E72K mutation, which is equal to with Zn2+ bonded. D) shows the same orientation as C), but with Zn2+ removed. E) and
F) show other side of bovine pancreatic carboxypeptidase.
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Future directions
Metal&EDTA method provides a simple and efficient way to purify divalent ion dependent
enzymes. It has great advantages comparing to regular method to purify divalent ion dependent
enzymes. However, not all divalent ion dependent enzymes could use Metal&EDTA method and
get good results, as we see T7 ligase could not get good separation if we only use Metal&EDTA
method. An extra pre-purification is required for Metal&EDTA method to obtain pure T7 ligase.
So far, we only tested E.coli RuvC, RNaseH and phage T7 ligase. RuvC and RNaseH shares
high structural similarity with CPV resolvase, therefore, it is not surprising that Metal&EDTA
method could be successfully used to purify RuvC and RNaseH. Phage T7 ligase is very
different from CPV resolvase structurally and functionally. Although it uses Mg2+ as cofactor, the
Mg2+ play different role in T7 ligase to CPV resolvase. In CPV resolvase, Mg2+ is used to activate
water molecule, which in turn functions as nucleophile to perform nucleophilic attach. In T7 ligase,
Mg2+ is used to stabilize the transition state, and 3’-hydroxy group of nucleic acid terminal. This
rule applies other ligases, DNA polymerases and RNA transcriptases. However, Metal&EDTA
method did make a difference when purify T7 ligase, as the elution volume shifts 10 ml when
Metal&EDTA method, suggesting Metal&EDTA could help divalent ion dependent enzyme
purification.
In this chapter, we only tested Metal&EDTA method with SP-sepharose chromatography
column. We did not test the Mg2+ or Mn2+ effect on the Heparin-Sepharose and MonoS
chromatography column. Different chromatography column may have different bind affinities to a
specific divalent ion dependent enzyme. As we see in the purification of Phage T7 ligase,
Heparin-Sepharose binds T7 ligase more tightly than SP-sepharose. Therefore, negatively
charged resins, such as Heparin-Sepharose, MonoS, SP-sepharose, Phosphate-cellulose and
Hydroxyapatite should be tested to find one which gives best result.
In discussion section, I listed possible application of Metal&EDTA method. Most likely,
RNaseH family members will get nice results when using Metal&EDTA method. For
Metalloproteinase family members, it will need to do further experiment to test this idea. Bovine
pancreatic carboxypeptidase shows similar electrostatic potential map as CPV resolvase. It is
92

expected that using Metal&EDTA to purify BPC give nice result. However, some other
metalloproteinases surface charges are more evenly distributed (example human
carboxypeptidase; data not shown). It is questionable to get nice results to purify other
metalloproteinases. Therefore, it will need extra pre-purification such as, ammonium sulfate
precipitation or other chromatography purification. Hydroxyapatite chromatography could bind protein
with acid or basic isoelectric point. For restriction enzymes, they could be further divided to subgroups

based on their active site composition(155). Their bind affinities to chromatography column may
be different. It is necessary to test each subgroup whether they could be directly purified by one
chromatography column like CPV resolvase or need combination of two chromatography columns
like phage T7 ligase.
In summary, it is necessary to develop a protocol to purify each type of divalent
dependent enzymes using Metal&EDTA method.
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Chapter 6: Serine recombinase introduction
Large serine recombinases (LSRs) carry out site-specific recombination between short
DNA sequences in prokaryotes that fulfill a variety of biological functions (156,157). Most
identified LSRs are bacteriophage integrases, but some catalyze the movement of antibiotic
resistance genes by transposition (158,159) and other mobile elements (160), or carry out
programmed DNA rearrangements (161). The LSRs are named for their relationship with the
well-studied serine recombinases, many of which function to resolve transposition intermediates
or regulate gene expression by inversion of regulatory sequences (162). Most
resolvase/invertase enzymes have a catalytic domain of ~150 residues at their amino terminus,
followed by a small, helix-turn-helix (HTH) DNA-binding domain (Figure 6-1B). The LSRs share a
similar amino-terminal catalytic domain, but have much larger carboxyl-terminal regions that
range in size from ~300 residues for the bacteriophage R4 and A118 integrases to ~550 residues
for the TnpX transposase (Figure 6-1A). Here, we will refer to the resolvases and invertases as
small serine recombinases. Although the C-terminal region of the LSRs is comprised of multiple
structural domains, we refer to this as the ‘‘C-terminal domain’’, or CTD, for consistency with the
literature.

Figure 6-1. Large versus small serine recombinases. A) LSR domain organization. Some LSR enzymes have additional
cysteine-rich domains at their carboxyl-terminal ends that are not shown here. B) Small serine recombinase domain
organization showing the similarity between the LSR enzymes and the well-studied resolvase/invertases. Note that some
serine recombinase superfamily members have domain arrangements different from those shown here (162).
Abbreviations – cat: catalytic domain; RD: recombinase domain; ZD: zinc ribbon domain; CC: coiled coil motif; HTH: helixturn-helix DNA-binding domain. The helix (αE) that connects the catalytic domain to the RD or HTH domains is indicated.
This figure is adapted from reference (163).

The LSRs that function as bacteriophage integrases are often referred to as serine
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integrases, emphasizing that they are serine recombinase family members and therefore carry
out recombination by a series of transesterification reactions that use a conserved serine
nucleophile. The tyrosine recombinases, which include the well-studied integrase from
bacteriophage λ and the Cre recombinase from bacteriophage P1, have structures that are
unrelated to the serine recombinases and use a different overall mechanism that involves
phosphoryl transfer with a tyrosine nucleophile (162). The serine integrases utilize short, specific
DNA sequences, or ‘‘attachment sites’’, in the virus (attP) and in the host (attB). The LSRs that
are not phage integrases use similar attachment sites to carry out what are essentially the same
integration and/or excision reactions (157).
The serine integrases have several important properties that distinguish them from the
integrases related to phage λ. The integration reaction can be carried out in vitro, with no
requirement for accessory proteins, auxiliary DNA sequences or specific substrate topologies. In
addition, the attP and attB sites required are 40–50 bp in length, allowing for relatively simple
manipulation of substrates. Because of these properties, the attP x attB integration reaction can
be performed with high specificity and directionality in inter- and intra- molecular contexts, and in
a variety of eukaryotic cells (164-169). The simplicity and highly directional nature of these
systems has led to the use of serine integrases as powerful genome engineering tools (156,170).
The bacteriophage φC31 integrase has also shown promise for use in gene therapy applications
(171). Serine integrases have also been used to design modules for data storage and
construction of logic gates in biological systems (172,173).

LSR structure
The LSRs are composed of three primary structural domains: an amino-terminal catalytic
domain similar to that found in the small serine recombinases, a DNA-binding ‘‘recombinase
domain’’, and a DNA-binding zinc ribbon domain (Figure 6-2). Each of the three domains is
rather complex and the connectors between domains play important functional roles. The crystal
structures of catalytic domain and CTD domain have been determined separately, in which the
CTD was determined as the complex with attP left half site (attPL). Here, we describe the LSR
structure using TP901 catalytic domain (PDB code 3BVP) and Listeria innocua (LI) integrase
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CTD/attPL (from bacteriophage A118, Figure 6-2A) complex (PDB code 4KIS) as examples.

Figure 6-2. Typical LSR structure and attP sequence. A) A118 attP left half site, where the serine integrase binds is
labeled. B) The LSR catalytic domain. The structure of the TP901 integrase catalytic domain dimer is shown (PDB code
3BVP). Conserved catalytic residues are indicated as spheres at Cα and mark the location of the active site pocket.
Ala117 corresponds to the position of Val129 in φC31 integrase. Selected secondary structural elements are labeled. C)
Structure of the zinc ribbon domain core, with the extended αK and αL helices that make up the coiled-coil motif not
shown. Secondary structure elements and the RD–ZD linker are indicated. The zinc ion is represented by a sphere and
the zinc-coordinating cysteine residues are drawn as stick models. The attP half site numbering follows that is shown in
Figure A. In contrast to the recombinase domain, the zinc ribbon domain extends across nine base-pairs of the major
groove, where it interacts with the ‘‘ZD motif’’. D) The LSR recombinase domain, represented by the LI integrase
CTD/attP complex structure (PDB code 4KIS). Secondary structure elements and the RD–ZD linker are indicated. The
attP half-site numbering corresponds to that used in Figure A. Note that only the HTH motif from the recombinase domain
interacts in the major groove. All other RD–attP interactions involve the minor groove. Figures B, C and D are adapted
from reference (163).

The catalytic domain The sequence similarity between the LSR and small serine
recombinase catalytic domains suggested that these domains would be structurally similar. The
catalytic domain consists of a five-stranded β sheet surrounded by five α helices. The crystal
structure of the TP901 integrase catalytic domain confirmed that this was the case and revealed a
number of small differences that exist between the two families (Figure 6-2B). Most of these are
simple insertions between structural elements that increase the average LSR catalytic domain
size by 10–15 residues. The serine nucleophile and three arginine residues that surround the
scissile phosphate during catalysis (174) are strictly conserved (shown in figure 6-2B).
The αE helix The αE helix connects catalytic domain and recombination domain. It has
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been crystallized in both structures of catalytic domain and CTD. The αE helix plays a crucial
role in the recombination pathway, mediating inter-subunit interactions involved in both LSR
dimer formation and LSR tetramer formation. This helix also plays an important role in the
progression from synapsis of attachment sites to DNA cleavage, subunit rotation and DNA
ligation to generate products (175).
Recombination domain The middle domain in the LSRs has been termed the
‘‘recombinase domain’’ based on LSR family member homology. While there is no significant
sequence similarity between the LSR RD and the HTH DNA-binding domain found in the small
serine recombinases, it was expected that this domain would have a related function. Indeed, the
crystal structure of the LI integrase CTD-DNA complex revealed that the LSR recombinase
domain does contain a structurally similar HTH motif (Figure 6-2D), .The LSR HTH subdomain
(αF-αG-αH) is preceded by a pair of β-strands (β6–β7) and followed by a second pair of strands
(β8–β9) and a fourth α-helix (αI). Mutagenesis studies in the TnpX transposase (176) and LI
integrase (114) have provided strong biochemical support for a role of this region in DNA binding.
Zinc ribbon domain The zinc ribbon domain contains four highly conserved cysteine
residues and it was inferred from early sequence analyses that a zinc-binding module was
present in the LSRs. The LI integrase structure revealed that residues 269–320 form a zinc
ribbon (Figure 6-2C), which is typically defined as two b-hairpins with zinc-coordinating residues
located near the base of the hairpins (177). The four cysteine residues that coordinate zinc in the
LSRs are almost completely conserved, but there do appear to be some exceptions with a
histidine replacing cysteine. The zinc ribbon domain has two important functions: DNA-binding
and mediating interactions between integrase subunits. This domain binds DNA by wrapping the
β11–β12 hairpin and the β12–β12 segment around the major groove (Figure 6-2C), accounting
for nine base-pairs of continuous contact at the outer ends of the attP site. Deletion of the entire
domain results in a dramatic reduction of DNA-binding affinity to attP and attB sites for the Bxb1
and LI integrases (114,178). It has been suggested that inter-subunit interactions are mediated
by the coiled-coil (CC) motifs (179), but the nature of these interactions is not yet clear. In LI
integrase, the coiled-coil motif can be excised from the zinc ribbon domain with no effect on
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integrase binding to attP and attB. However, the resulting ∆ coiled-coil (∆CC) integrase loses the
ability to carry out intermolecular recombination and to discriminate between sites during
intramolecular recombination in vivo (114).

LSR catalytic mechanism
During the integration reaction, the serine integrase binds to attP and attB as a dimer,
mediates association of the sites to form a tetrameric synaptic complex, and catalyzes strand
exchange to generate an integrated prophage and new attachment sites, attL and attR. The
reverse reaction, where the prophage is excised by site-specific recombination between attL and
attR sequences, does not occur in the absence of a phage-encoded recombination directionality
factor (RDF). The LSRs use the same mechanism to exchange strands as do the small serine
recombinases (157,180). This reaction is shown schematically in Figure 6-3, incorporating
features recently proposed based on structural models (114).

Figure 6-3. The integration reaction catalyzed by large serine recombinases. Integrase dimers bound to attP and attB
associate to form a synaptic complex stabilized by interactions between catalytic domain dimers and by interactions
involving the CC motifs. Coordinated cleavage of all four DNA strands by the catalytic domains results in 5’phosphoserine linkages between the DNA and the protein subunits plus 3’-overhanging dinucleotides containing the site’s
crossover sequence. Rotation of subunit pairs about a horizontal axis results in formation of a strand-exchange
configuration where ligation to form recombinant attL and attR products will occur efficiently if the unpaired dinucleotides
are complementary. The unique ZD arrangements on the resulting attL and attR sites promote an intramolecular
interaction between CC motifs that inhibits the reverse excision reaction. This figure is adapted from reference (163).

Despite the similarity in mechanism of strand exchange, the small serine recombinases
function under very different topological contexts and do not share the large C-terminal region
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that is responsible for coordination of unique LSR activities. LSR site-selectivity and directionality
are regulated at the synapsis step of the recombination pathway (178,181) in a manner that
involves the CTDs. In this model, coiled-coil motif controls the integration directionality. When
LSR dimer forms complex with attP and attB, the coiled-coil motif prefer to form intermolecular
interaction, thus promote formation of attP and attB synapsis and integration. When LSR dimer
forms complex with attL and attR, the coiled-coil motif prefers to form intramolecular interaction,
thus inhibits formation of attL and attR synapsis and incision.
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CHAPTER 7: The attP site in listeria bacteriophage integration
This chapter incorporates all members’ work of the Van Duyne lab. Karen Rutherford purified
∆CC-CTD protein, prepared attPL, obtained ∆CC-CTD•attPL crystal and collected diffraction data.
Robert Sharp performed one of triplicate intermolecular recombination assay. Kushol Gupta
performed the sedimentation equilibrium experiment and measured the oligomeric constant of LI
integrase and ∆CC-Integrase. Gregory Van Duyne involved in all experiments in this study.

Abstract
Large serine recombinases (LSRs) catalyze the movement of DNA elements into and out
of bacterial chromosomes using site-specific recombination between short DNA att sites. LSR
differs from serine recombinase (SR) by possessing a large C-terminal domain (CTD). Crystal
structure of CTD•attPL revealed that CTD contacts attPL from one side and forms numerous
specific and non-specific interactions with attPL nucleotides. In this chapter, we employed
different approaches, including X-ray crystallography, DNA competition binding assay,
intermolecular recombination assay and electrophoretic mobility shift assay, systematically
studied the interaction between attP and Listeria innocua (LI) serine integrase. Our results
demonstrated that most nucleotides which form non-specific interactions could be mutated
without affect binding affinity to LI integrase and recombination efficiency. Nucleotides which
form specific interaction showed decreased binding affinity to LI integrase and recombination
efficiency. The LI integrase or CTD has different affinities to attP site or half sites. In general,
attP has higher affinity to LI integrase/CTD than half attP sites and attPL has higher affinity to LI
integrase/CTD than attPR. These features likely adapts to LSR biological functions.
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Introduction
Listeria bacteriophage integration to and incision from Listeria DNA genome is a very
complicated process. The major players in the process are rather simple, for it only has two
protein components (serine integrase and recombination directionality factor, and the later is only
required during incision process), and four DNA fragments (attP, attB, attL and attR. Two of them
function simultaneously). Listeria integrase belong to large serine recombinase family, and it is a
multi domain enzyme. The different domains interact with the att DNA at different positions. The
LSR continuously switches its conformation, thus change its affinity to different fragment to fulfill
different function in the bacteriophage life cycle.
Dimerization of the small serine recombinases has been well established with firm
biochemical and structural bases (162,175). As expected, the Bxb1, φC31 and A118 integrases
are also apparent dimers in solution based on size exclusion chromatography. However, the
issue of dimerization is more complicated for the LSRs since the coiled-coil region of the zinc
ribbon domain is also thought to mediate integrase-integrase interactions (179). Most LSR
attachment sites are 40–50 bp in length, with attP generally 48-50 bp and attB 38-40 bp.

Figure 7-1. Large serine recombinase-attP site complexes. A), schematic models of the LI integrase•attP complex. B)
shows the attP sequence of bacteriophage A118. Nucleotides identical in the two half-sites are in bold and the central
dinucleotide is colored red. Base pairs in rectangle box shows attP left half site (attPL); other base pairs shows attP right
site (attPR). The regions contacted by the RD, the ZD and the RD–ZD linker are indicated. C), the structural model was
generated by combining two integrase CTD•attPL complexes (114), using the γδ-resolvase/DNA complex (182) as a
guide. The catalytic domains shown are also from the γδ-resolvase/DNA complex. Figures A and C are adapted from
reference (163). Figure B is adapted from reference (114).

The multi-domain and flexible nature of serine integrase makes crystallization very
difficult. The conserved catalytic domain structure was first determined in 2008 (183). Until very
recently, CTD crystal structure was reported as complex with attP left site (114). Schematic and
structural representations of a LSR binding to its attP site are shown in Figure 7-1A. Figure 7-1B
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shows the attP site of bacteriophage A118. The structure model of LSR•attP (Figure 7-1C) is
based on the structure of the LI integrase CTD bound to an attP half-site. Given the similarity
between integrases at the domain level, this mode of binding is likely to be shared by most LSRs.
The integrase domains are spread out across the attP half-site, where each structural component
contacts a distinct surface on the site. Together with αE, the recombinase domain contacts base
pairs 0-12, the RD-ZD linker contacts base-pairs 13-15, and the ZD contacts base-pairs 16–24,
where it recognizes a nine base-pair ‘‘ZD motif’’. Overall, 25 base pairs of the A118 attP half-site
are covered by the integrase. Surprisingly, the vast majority of integrase-DNA contacts involving
αE, the RD, and the RD-ZD linker are to the sugar-phosphate backbone and to bases in the
minor groove. The only major groove interactions are via αH from the HTH motif. In addition, the
majority of the contacts made by the zinc ribbon domain involve the major groove, where the β11β12 hairpin and the β12-β12 loop span nine base-pairs at the end of the site.
Although considerable progresses have been made in LSR study, most available
knowledge focuses on biochemical study. The limited structural information is the major barrier to
understand the LSR mechanism in detail. The available structure of LI CTD•attPL provided
critical information that it could nicely explain the LSR mechanism by switching intermolecular
and intramolecular interaction of coiled-coil motif. In this model, ZD domain goes into major
groove of attPL site, thus likely forms interaction with bases and determines the attP sequences
specificity. However, the low resolution restricted our understanding of the detailed interaction
network between ZD motif and attPL. Therefore, it is necessary to obtain a higher resolution
structure of CTD•attPL structure to visualize the interaction. Meanwhile, performing biochemical
assay using attP point mutations will help understand the detail CTD interacts with attP site.
Another researching area on LSR is the attachment site binding energetics. Scientists
speculated there are affinity differences between LSR or CTD and attP, attB, attL and attR sites,
and they contribute to integration and incision. Surprisingly, the LSR shows similar range of
affinity to att sites. In addition, CTD alone shows similar range of infinity to att sites as LSR
(178,184). These results are quite confusing. To further study the binding energetic of LSR/CTD
to att sites and guide crystallization of LSR/CTD complex with att sites, it is necessary to study
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binding affinity of LSR or CTD to attP or attP half sites. In this chapter, we employed different
approaches, including X-ray crystallography, DNA competition binding assay, intermolecular
recombination assay and electrophoretic mobility shift assay to study the interaction attP and
serine integrase.

Material and Method
Crystallization of ∆CC-CTD•attPL and solving the structure
∆CC-CTD protein and attPL are prepared by Karen Rutherford. AttPL was annealed by
two DNA oligos to make 5’ overhang with G and C to facilitate crystallization. (
5’-GTTTAGTTCCTCGTTTTCTCTCGTT-3’, 5’-CAACGAGAGAAAACGAGGAACTAAA-3’). ∆CCCTD•attPL complex was prepared in buffer (10mM Tris-HCl, pH 8.0, 150mM NaCl, 1mM TCEP)
by molar ration 1:1.5 (30μM:45μM). The ∆CC-CTD•attPL crystals was obtained in 0.1M Tris-HCl
pH 7.5, 0.2M (NH4)2SO4, 25% PEG3350 by hanging drop evaporation method. Crystals are
cryo-protected in reservoir solution with 20 v/v glycerol. The diffraction was collected at APS
Beamline 23-IDD. Crystallization and data collection are performed by Karen Rutherford, a
former postdoc in the lab. Initial phasing information was solved by molecular replacement with
CTD•attPL as searching model. CCP4i package was used to refinement the crystal structure and
Coot software package was used to perform structure adjustment.
Intermolecular recombination assay
AttP mutants are amplified by PCR with plasmid (pGV2345, a plasmid harboring wild attP
sequence) as templates and further purified, quantified. Supercoiled attB plasmid pGV1741 are
freshly purified, quantified and aliquoted to keep at -20°C. Both attP mutants and attB plasmid are
dissolved in buffer (10 mM Tris, pH 8.5, 0.5 mM EDTA). LI Integrase was prepared at 2.5μM in
buffer containing 20 mM Tris pH 8, 150 mM NaCl, 50 μg/ml BSA, 10% glycerol, 2 mM DTT.
Reactions were carried out in the PCR tube by mixing of 4μl of 5X reaction buffer (100
mM Tris pH 8, 750 mM KCl, 5 mM spermidine HCl, 10 mM DTT, 25 mM MgCl2, 125 μg/ml BSA,
25% glycerol), 7.5μl sterile water, 2.5 μl supercoiled plasmid (500ng/μl), 2 μl integrase and 4μl of
attP mutant (25ng/μl). The mixtures were incubated at 32°C for 20min. 10ul of reaction products
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were loaded to agarose gel (0.8% in 1X TAE buffer with 0.5ug/ml ethidium bromide) and run in
buffer (1X TAE with 0.5ug/ml ethidium bromide) at 50V for 2 hours and 30minutes. These
experiments are carried out as triplicate or more. The electrophoresis results are photographed
by Kodak image workstation 4000, and quantified by QUANTIUM5.0
Integrase DNA-binding competition assay
Linear attP was cut from attP-harboring plasmid, gel purified, quantified and radio labeled
with 32P. Linear attP mutants: attP mutants are amplified by PCR with plasmid (pGV2345, a
plasmid harboring wild attP sequence) as templates. PCR products were purified, quantified.
Both attP and attP mutants are dissolved in 1X TE buffer. PAGE gel was prepared at 6%, using
37.5:1 acrylamide mixture in 1X TE buffer (25mM Tris, 192mM glycine).
2μl attP mutants (25nM), 8μl attP* (1nM in 1X binding buffer containing 2 mM Tris pH 7.4,
150 mM KCl, 2 mM DTT, 25 μg/ml BSA, 25 μg/ml salmon DNA, 105% glycerol, 0.02%
bromophenol blue), 10μl Integrase at 32 nM in 1X bind buffer were added to PCR tube, mix
briefly, spin down, and incubate in the 32°C heat block for 30 min. Load 10 μl per lane and run
the gel in 1X TE buffer at 200V for 2.5 hours, 10°C. Dry the gel for 1 hour at 70°C deg. Expose
overnight for phosphorimager analysis. Scan the gel and save the image for analysis. These
experiments are carried out as triplicate or more.
Electrophoresis mobility shift assay to study attP affinity to LSR/CTD
Linear attP was cut from attP-harboring plasmid, gel purified, quantified. Linear attPL or
attPR was synthesized as DNA oligo, and annealed with complimentary oligos. All linear
attP/attPL/attPR oligos are quantified, radio labeled with 32P. DNA (attP, attPL, attPR) dissolving
buffer: 10 mM Tris, pH 8.5, 0.5 mM EDTA
LI Integrase was prepared at 400nM in 1X binding buffer, and sequentially diluted by
factor of 2 to 200, 100, 50, 25, 12.5, 6.3, 3.1, 1.6, 0.8, 0.4, 0.2, 0.1nM. CTD was prepared at
6400nM in 1X binding buffer, and sequentially diluted by factor of 2 to 3200, 1600, 800, 400, 200,
100, 50, 25, 12.5, 6.3, 3.1, 1.6nM.
All other steps are same as Integrase DNA-binding competition assay.
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Results
∆CC-CTD•attPL structure
The first experiment we performed is obtaining the high resolution crystal structure of
CTD•attPL. Our lab has solved the crystal structure of CTD•attPL at 3.2Å using CTD of Listeria
innocua prophage and left half site of attP (attPL) of bacteriophage A118 (114). There are four
CTD•attPL molecules in one asymmetric unit and coiled-coiled (CC) motifs adopt different
conformations. We speculate that if the CC motif is truncated from CTD, the CTD will become
structurally homogenous and may help to obtain high quality crystals. In the light of this idea, we
make truncated version of ∆CC-CTD (residue 342-416 are truncated), and co-crystallized with
attPL. These crystals are obtained in distinct condition to CTD•attPL, belong to different space
group and diffract to 2.8Å. Each asymmetric unit has only one ∆CC-CTD•attPL molecule.
We solved the structure with molecular replacement with full length CTD•attPL as
searching model. Table I shows the statistics of data collection and refinement of ∆CCCTD•attPL. The overall structure of ∆CC-CTD•attPL is similar to CTD/attPL, with an overall rmsd
of 1.087Å. When aligned as Cα, it has an rmsd of 1.016Å, suggesting that the coiled-coil motif
doesn’t change the overall CTD structure.
∆CC-CTD is located at one side of attPL, and spreads on whole attPL, as shown in
Figure 7-2A. Briefly, αE helix contacts with minor groove of 0-3 base pair. Recombination
domain crosses cover major groove of 4-12 base pair. Linker region between recombination
domain and Zinc finger binding domain contacts with minor groove of 13-15 base pair. The zinc
finger binding domain makes extensive contacts with major groove of 16-24 base pair, in which
zinc finger motif interacts with 16-20 base pairs and β11-β12 motif run through major groove of
19-24, making extensive contacts with nucleo bases to determine the sequence specificity.
The contacts between ∆CC-CTD and attPL could be divided to two categories. One
category is non-specific contacts between ∆CC-CTD and attPL phosphate and sugar backbones,
which constitute the majority interactions. The other category is sequence specific contacts
between ∆CC-CTD and attPL nucleo bases, which constitute the minority interactions. The
detailed contacts between CTD and attPL have been described (114). There is no considerable
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difference between CTD•attPL an ∆CC-CTD•attPL, I will not repeat description here.
Table 7-I. Summary of data collection and refinement statistics
Crystal
∆CC-CTD•attPL
Space Group
P212121
Unit Cell
a=48.3Å, b=57.1Å, c=167.9Å
α=β=γ=90°
Wavelength (Å)
0.97919
Resolution (Å)
57.11-2.85
Completeness (%)
98.5(98.8)
Rmerge
0.057(0.99414)
Mean I/σ
14.9(2.3)
Redundancy
3.0(3.1)
Unique Reflections
10662
Molecular replacement
Model
4KIS
Resolution (Å)
3.2
Refinement
Rfree*
0.282
Rwork
0.202
Number of atoms
Protein
1921
DNA
1020
Zn2+
2
Solvent
12
RMSD
Bond length (Å)
0.012
Bond Angles (°)
1.764
Ramachandran plot (%)
Favored
94.4
Allowed
5.6
Rmerge=Σ|Ih - <Ih>|Σ Ih, where <Ih> is the average intensity over symmetry
equivalent measurements; R-factor, Σ|Fobs – Fcalc|/ ΣFobs, where summation is data
used in refinement. Numbers in parentheses represent values in the highest
resolution shell. *Rfree was calculated with 5% of the data.

We carefully examined specific contacts between ∆CC-CTD and attPL. Three regions
are observed to form specific contacts, shown in figure 7-2. The first region is located at the
major groove of 5-10 base pairs. αH helix goes into the major groove (Figure 7-2B). ND2 and
OD1 atoms of Asn208 side chain interact with both nucleosides of base pair 9. Interestingly, the
recombination motif adopts a shape of bridge, hanging over major groove of 5-10 base pairs, with
only αH helix goes into the major groove. The second specific contact is located at the linker
region between recombination domain and zinc binding domain (Figure 7-2D). Both atoms of
nitrogen (ND2) and oxygen (OD1) of Asn259 side chain interact with nucleo base pair at 15th
position. The last specific contact is located at the zinc binding domain (Figure 7-2C). β11 strand
goes in to the major groove of base pair 18-24. Oxygen atom of Asp287 side chain and main
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chain oxygen atoms of Asp287, Thr288 and Val289 form hydrogen bond net with base pair 20-23.

Figure 7-2. Crystal structure of ∆CC-CTD•attPL and specific contacts between ∆CC-CTD and attPL. A) shows the
overall structure of ∆CC-CTD•attPL complex. Figures B, C and D show detailed specific contacts between ∆CC-CTD and
attPL at different regions. In all Figure B, D and D, hydrogen bonds are shown as dashed lines. Non specific contacts are
not showed.

LI Integrase competition assay
To study the contribution of each nucleo base pair of attP to form complex with LI
integrase, we designed binding competition assay. In this assay, wild attP was radio labeled.
AttP mutants were used to bind LI integrase competing with wild attP. If the base pair mutation
weakens the interaction with LI integrase, more fraction of wild attP will bind LI integrase. The
fraction of radio labeled wild attP could be detected by EMSA. Quantifying the ratio between
radio labeled attP alone band and attP•integrase complex band will show the contribution of
specific base pair. We designed 79 attP mutants and studied their effects on forming complex
with LI integrase. Table 7-II shows the sequences of 79 mutants.
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Table 7-II. List of attP mutants used in this study
Number
name
Sequences
0
lip
5’-TTGTTTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAAAAAT
5’-TTGTTTAGTATCTCGTTATCTCTCGTaGGtGGGAGAAGAAACGGGATACCAAAAAT
1
lip1A
5’-TTGTTTAGTATCTCGTTATCTCTCGTgGGcGGGAGAAGAAACGGGATACCAAAAAT
2
lip1G
5’-TTGTTTAGTATCTCGTTATCTCTCGTcGGgGGGAGAAGAAACGGGATACCAAAAAT
3
lip1C
5’-TTGTTTAGTATCTCGTTATCTCTCGaTGGAtGGAGAAGAAACGGGATACCAAAAAT
4
lip2A
5’-TTGTTTAGTATCTCGTTATCTCTCGtTGGAaGGAGAAGAAACGGGATACCAAAAAT
5
lip2T
5’-TTGTTTAGTATCTCGTTATCTCTCGgTGGAcGGAGAAGAAACGGGATACCAAAAAT
6
lip2G
5’-TTGTTTAGTATCTCGTTATCTCTCGcTGGAgGGAGAAGAAACGGGATACCAAAAAT
7
lip2C
5’-TTGTTTAGTATCTCGTTATCTCTCaTTGGAGtGAGAAGAAACGGGATACCAAAAAT
8
lip3A
5’-TTGTTTAGTATCTCGTTATCTCTCtTTGGAGaGAGAAGAAACGGGATACCAAAAAT
9
lip3T
5’-TTGTTTAGTATCTCGTTATCTCTCgTTGGAGcGAGAAGAAACGGGATACCAAAAAT
10
lip3G
5’-TTGTTTAGTATCTCGTTATCTCTCcTTGGAGgGAGAAGAAACGGGATACCAAAAAT
11
lip3C
5’-TTGTTTAGTATCTCGTTATCTCTaGTTGGAGGtAGAAGAAACGGGATACCAAAAAT
12
lip4A
5’-TTGTTTAGTATCTCGTTATCTCTtGTTGGAGGaAGAAGAAACGGGATACCAAAAAT
13
lip4T
5’-TTGTTTAGTATCTCGTTATCTCTgGTTGGAGGcAGAAGAAACGGGATACCAAAAAT
14
lip4G
5’-TTGTTTAGTATCTCGTTATCTCaCGTTGGAGGGtGAAGAAACGGGATACCAAAAAT
15
lip5A
5’-TTGTTTAGTATCTCGTTATCTCgCGTTGGAGGGcGAAGAAACGGGATACCAAAAAT
16
lip5G
5’-TTGTTTAGTATCTCGTTATCTCcCGTTGGAGGGgGAAGAAACGGGATACCAAAAAT
17
lip5C
5’-TTGTTTAGTATCTCGTTATCTaTCGTTGGAGGGAtAAGAAACGGGATACCAAAAAT
18
lip6A
5’-TTGTTTAGTATCTCGTTATCTtTCGTTGGAGGGAaAAGAAACGGGATACCAAAAAT
19
lip6T
5’-TTGTTTAGTATCTCGTTATCTgTCGTTGGAGGGAcAAGAAACGGGATACCAAAAAT
20
lip6G
5’-TTGTTTAGTATCTCGTTATCaCTCGTTGGAGGGAGtAGAAACGGGATACCAAAAAT
21
lip7A
5’-TTGTTTAGTATCTCGTTATCgCTCGTTGGAGGGAGcAGAAACGGGATACCAAAAAT
22
lip7G
5’-TTGTTTAGTATCTCGTTATCcCTCGTTGGAGGGAGgAGAAACGGGATACCAAAAAT
23
lip7C
5’-TTGTTTAGTATCTCGTTATaTCTCGTTGGAGGGAGAtGAAACGGGATACCAAAAAT
24
lip8A
5’-TTGTTTAGTATCTCGTTATtTCTCGTTGGAGGGAGAaGAAACGGGATACCAAAAAT
25
lip8T
5’-TTGTTTAGTATCTCGTTATgTCTCGTTGGAGGGAGAcGAAACGGGATACCAAAAAT
26
lip8G
5’-TTGTTTAGTATCTCGTTATcTCTCGTTGGAGGGAGAgGAAACGGGATACCAAAAAT
27
lip8C
5’-TTGTTTAGTATCTCGTTAaCTCTCGTTGGAGGGAGAAtAAACGGGATACCAAAAAT
28
lip9A
5’-TTGTTTAGTATCTCGTTAtCTCTCGTTGGAGGGAGAAaAAACGGGATACCAAAAAT
29
lip9T
5’-TTGTTTAGTATCTCGTTAgCTCTCGTTGGAGGGAGAAcAAACGGGATACCAAAAAT
30
lip9G
5’-TTGTTTAGTATCTCGTTAcCTCTCGTTGGAGGGAGAAgAAACGGGATACCAAAAAT
31
lip9C
5’-TTGTTTAGTATCTCGTTaTCTCTCGTTGGAGGGAGAAGtAACGGGATACCAAAAAT
32
lip10A
5’-TTGTTTAGTATCTCGTTtTCTCTCGTTGGAGGGAGAAGaAACGGGATACCAAAAAT
33
lip10T
5’-TTGTTTAGTATCTCGTTgTCTCTCGTTGGAGGGAGAAGcAACGGGATACCAAAAAT
34
lip10G
5’-TTGTTTAGTATCTCGTTcTCTCTCGTTGGAGGGAGAAGgAACGGGATACCAAAAAT
35
lip10C
5’-TTGTTTAGTATCTCGTaATCTCTCGTTGGAGGGAGAAGAtACGGGATACCAAAAAT
36
lip11A
5’-TTGTTTAGTATCTCGTgATCTCTCGTTGGAGGGAGAAGAcACGGGATACCAAAAAT
37
lip11G
5’-TTGTTTAGTATCTCGTcATCTCTCGTTGGAGGGAGAAGAgACGGGATACCAAAAAT
38
lip11C
5’-TTGTTTAGTATCTCGaTATCTCTCGTTGGAGGGAGAAGAAtCGGGATACCAAAAAT
39
lip12A
5’-TTGTTTAGTATCTCGgTATCTCTCGTTGGAGGGAGAAGAAcCGGGATACCAAAAAT
40
lip12G
5’-TTGTTTAGTATCTCGcTATCTCTCGTTGGAGGGAGAAGAAgCGGGATACCAAAAAT
41
lip12C
5’-TTGTTTAGTATCTCaTTATCTCTCGTTGGAGGGAGAAGAAAtGGGATACCAAAAAT
42
lip13A
5’-TTGTTTAGTATCTCtTTATCTCTCGTTGGAGGGAGAAGAAAaGGGATACCAAAAAT
43
lip13T
5’-TTGTTTAGTATCTCcTTATCTCTCGTTGGAGGGAGAAGAAAgGGGATACCAAAAAT
44
lip13C
5’-TTGTTTAGTATCTaGTTATCTCTCGTTGGAGGGAGAAGAAACtGGATACCAAAAAT
45
lip14A
5’-TTGTTTAGTATCTtGTTATCTCTCGTTGGAGGGAGAAGAAACaGGATACCAAAAAT
46
lip14T
5’-TTGTTTAGTATCTgGTTATCTCTCGTTGGAGGGAGAAGAAACcGGATACCAAAAAT
47
lip14G
5’-TTGTTTAGTATCaCGTTATCTCTCGTTGGAGGGAGAAGAAACGtGATACCAAAAAT
48
lip15A
5’-TTGTTTAGTATCtCGTTATCTCTCGTTGGAGGGAGAAGAAACGaGATACCAAAAAT
49
lip15T
5’-TTGTTTAGTATCgCGTTATCTCTCGTTGGAGGGAGAAGAAACGcGATACCAAAAAT
50
lip15G
5’-TTGTTTAGTATCcCGTTATCTCTCGTTGGAGGGAGAAGAAACGgGATACCAAAAAT
51
lip15C
5’-TTGTTTAGTATaTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGtATACCAAAAAT
52
lip16A
5’-TTGTTTAGTATtTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGaATACCAAAAAT
53
lip16T
5’-TTGTTTAGTATgTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGcATACCAAAAAT
54
lip16G
5’-TTGTTTAGTAaCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGtTACCAAAAAT
55
lip17A
5’-TTGTTTAGTAgCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGcTACCAAAAAT
56
lip17G
5’-TTGTTTAGTAcCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGgTACCAAAAAT
57
lip17C
5’-TTGTTTAGTtTCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGAaACCAAAAAT
58
lip18T
5’-TTGTTTAGTgTCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGAcACCAAAAAT
59
lip18G
5’-TTGTTTAGTcTCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGAgACCAAAAAT
60
lip18C
5’-TTGTTTAGaATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATtCCAAAAAT
61
lip19A
5’-TTGTTTAGgATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATcCCAAAAAT
62
lip19G
5’-TTGTTTAGcATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATgCCAAAAAT
63
lip19C
5’-TTGTTTAaTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATAtCAAAAAT
64
lip20A
5’-TTGTTTAtTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATAaCAAAAAT
65
lip20T
5’-TTGTTTAcTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATAgCAAAAAT
66
lip20C
5’-TTGTTTaGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACtAAAAAT
67
lip21A
5’-TTGTTTtGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACaAAAAAT
68
lip21T
5’-TTGTTTgGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACcAAAAAT
69
lip21G
5’-TTGTTTcGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACgAAAAAT
70
lip21C
5’-TTGTTaAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCtAAAAT
71
lip22A
5’-TTGTTgAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCcAAAAT
72
lip22G
5’-TTGTTcAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCgAAAAT
73
lip22C
5’-TTGTaTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAtAAAT
74
lip23A
5’-TTGTgTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAcAAAT
75
lip23G
5’-TTGTcTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAgAAAT
76
lip23C
5’-TTGaTTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAAtAAT
77
lip24A
5’-TTGgTTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAAcAAT
78
lip24G
5’-TTGcTTAGTATCTCGTTATCTCTCGTTGGAGGGAGAAGAAACGGGATACCAAgAAT
79
lip24C
Nucleotides which have been mutated are shown in lowercase and bold with grey background.
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The attP mutant competition assay results are shown in Figure 7-3. These mutants cover
all base pairs 1-24. Most attP base pairs have palindrome structures; therefore we test other
three type nucleoside. For those positions are not palindrome structures, we make them to
palindrome structure and test each of four types of base pairs.

Figure 7-3. attP mutation effect on LI integrase binding. Figure A-E shows the EMSA results of competition. Figure A
from left to right: attP control; attP mutant 1-19. Figure B: attP control; attP mutant 20-38. Figure C: attP mutant 39, attP
control; attP mutant 40-57. D: attP mutant 58-59, attP control; attP mutant 60-76. E: attP mutant 77-79, wild attP. Figure
F shows the quantified results.

The DNA binding competition assays indicated that most attP mutants had similar binding
affinity as wild attP. Base pair mutations at positions 20 and 23 greatly affect binding efficiency,
for any mutation will weak attP binding to LI integrase, showed Figure in 7-3F. Some mutants,
such as at positions 2, 9, 14, 15 and 19, have negative effects when mutated to specific base pair.
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These results are showed in Figure 7-3F. I will discuss these results in the discussion section.
Intermolecular recombination assay
The second experiment we did was measuring the recombination efficiency of attP
mutants when each base pair was mutated. In this experiment, mutant attPs were used to
recombine with attB. After recombination, it will linearize circular plasmids harboring the attB
sequences. By comparing the intensity ratio between linear and circular plasmid band, we could
infer the attP mutation on recombination effects. These results are shown Figure 7-4.

Figure 7-4. attP mutation effect on recombination. Figure A-D shows the EMSA results of competition. Figure A from left
to right: attP mutant 1-24. Figure B from left to right: attP mutant 25-48. Figure C from left to right: attP mutant 49-64. D
from left to right: attP mutant 65-79, wild attP control; Figure E shows the quantified results.

The intermolecular recombination results showed that most attP mutants have similar
recombination efficiency as wild attP, as shown in Figure 7-4E. Only several mutants located at
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position 2, 9, 15 and 20 has low recombination efficiency than wild attP. Especially mutant at
position 20, all mutants showed low recombination efficiency. I will discuss this in the discussion
section.
AttP affinity to LI integrase and CTD
The last experiment we did was the measuring the affinities between attP and LI
integrase. These assays included: LI integrase to attP, attPL and attPR; CTD to attP, attPL and
attPR. The results are shown in Figure 7-5.

Figure 7-5. The affinity of attP sites to LI integrase and CTD. Figures A, B and C show LI integrase affinities to attP,
attPL and attPR. Figures D, E and F show CTD affinities to attP, attPL and attPR. In all figures, the first lanes are radiolabeled attP, attPL or attPR alone. In Figures A, B and C, integrase concentrations from left to right are: 400, 200, 100, 50,
25, 12.5, 6.3, 3.1, 1.6, 0.8, 0.4, 0.2, 0.1nM. In Figures D, E and F, CTD concentrations from left to right are: 6400, 3200,
1600, 800, 400, 200, 100, 50, 25, 12.5, 6.3, 3.1, 1.6nM. Arrows in Figure B and C point to bands corresponding Integrase
monomer and attPL (attPR) complex. Arrows in Figure D, E and F point to bands corresponding CTD dimer and attP
(attPL or attPR) complex.

From these figures, we could estimate that the Kd values of LI integrase or CTD to attP,
attPL or attPR. These values are summarized in following Table 7-III. The affinities of LI
integrase to attP, attPL and attPR are different. It is expected that attP has the highest affinity of
6nM. Interestingly, the affinities of LI integrase to attPL and attPR are different, even though
attPL and attPR have same size and similar sequence. CTD has different patterns to bind attP,
attPL and attPR. Surprisingly, attP and attPL bind CTD with almost same affinity. CTD only has
very weak affinity to attPR.
Table 7-III: Summary of attP sites to LI integrase affinity
attPR
attP
attPL
LI Integrase
6nM
50nM
~400nM
CTD
100nM
150nM
4800nM
In Figure 7-5B and 7-5C, we found that there are weak bands below the In•attPL or
In•attPR bands (Shown as arrows). These bands likely correspond to LI integrase
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monomer•attPL or attPR. In Figure 7-5D, there are weak band (shown as arrow) above the major
band: these bands likely correspond to one attP binding CTD dimer molecules. In Figures 7-5E
and 7-5F, the weak bands (shows as arrows) likely correspond to one attPL or attPR binding CTD
dimer molecules.

Discussion
In this chapter, we determined the crystal structure of ∆CC-CTD•attPL complex. ∆CCCTD•attPL has similar structure to CTD•attPL except truncation of coiled-coil motif. The nonspecific contacts comprise the majority interactions between ∆CC-CTD and attPL. The specific
contacts only constitute a small fraction of interactions between ∆CC-CTD and attPL.
In the attP competition and intermolecular recombination assays, most attP mutants have
no distinctive effect on LI integrase binding and recombination. This could be explained by the
fact that these mutants only form non-specific interactions with LI integrase. They only contact LI
integrase by backbone sugar and phosphate moieties. Nucleoside mutation does not change the
non-specific interaction with LI integrase.
However, we noticed that some attP mutants have weaker binding affinity than wild attP,
and these attP mutants are located at positions 2, 9, 14, 15, 19, 20 and 23. In addition, some attP
mutants have lower recombination efficiency than wild attP, and these attP mutants are located at
positions 2, 9, 15, 20. These results indicate that LI integrase and attP binding affinity closely
relates with attP recombination efficiency. When binding affinity drops, attP likely has decreased
recombination efficiency. AttP mutants which possesses low binding affinity and low
recombination efficiency are not randomly distributed. In fact, nucleosides at these positions
interact with LI integrase and forms specific interaction. Mutations at these positions will abolish
the specific interaction between LI integrase and attP, therefore they will have weak binding
affinity which leads to low recombination efficiency.
Interestingly, none of attP mutant completely abolishes the attP binding and
recombination. It suggests that all specific and non-specific interaction between attP and LI
integrase play important roles in the process of attP binding and recombination. Multiple attP
mutations may be required to cause a severe effect on its binding to Integrase and recombination.
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The affinity of att sites to full-length SR or CTD is a hot research area in serine
recombination study. Among the LSR systems where attachment site binding has been studied
quantitatively, there is a general consensus that integrase dimers bind within a similar range of
affinities to attP, attB, attL and attR sites (163). Scientists pay less attention to the LSR affinity to
half att sites than full att sites. We, for the first time, carried out experiments and symmetrically
studied the LSR affinity to half attP sites.
There is a long puzzling question in LSR study. The affinities of LSR to att sites and CTD
to att sites are in the same range. As pointed out by Ghosh et al (178), the similar net DNAbinding affinities observed for the full-length integrase and single CTD constructs imply that a
significant energetic cost is associated with an integrase dimer binding to its attachment sites.
Indeed, if the CTD interaction energies were additive, the net affinity expected for an integrase
dimer binding to att-site DNA would amount to a Kd of about 10-14 M. One interpretation is that
the free integrase dimers adopt stable configurations that need to be disrupted in order to bind an
attachment site and that the cost of doing so is approximately that of a single CTD-half site
interaction (163).
We noted one weak band below the integrase•attPL (or attPR) strong band. The
following discussion refers to attPL. The weak band clearly exists and it could not be ignored.
There are two explanations of the weak and strong bands. One explanation is: the top band is
dimer integrase and two attPL; the low band is dimer integrase and one attPL. The alternative
explanation is: the top band is dimer integrase and one attPL; the low band is monomer integrase
and one attPL. We believe the second explanation is the truth. Two arguments support this
conclusion. One arguments is that there is much more integrase than attPL in the experiment.
Two attPL molecules will choose to bind two integrase dimers (one attPL binds one integrase
dimer) rather than bind one integrase dimer. The other argument is that if the top band is two
attPL and one integrase dimer, it should have similar mobility rate to dimer integrase•attP.
Compared to Figure 7-5A, the top band migration is faster than dimer integrase•attP, thus it
support the top band is dimer integrase•attPL complex. In the same way, the top band in Figure
7-5C correspond to dimer integrase•attPR.
113

Now, it leads to another question: could integrase dissociate to monomer at the
concentration level of 400nM. This observation is contradictory to the conclusion that SR and
LSR are stable dimers (163). According to our unpublished data (performed by Kushol Gupta
and me), Listeria integrase is a stable dimer with Kd < 1nM, but also is a weak tetramer with Kd of
45.5 μM. The ∆CC-Integrase behavior is very different. It is a stable dimer with Kd of 20nM. This
result indicates coiled-coiled motif contributes to integrase oligomeric formation: the
intramolecular interaction of coiled-coil make dimer much more stable and also contribute form
weak tetramer. According to the LSR mechanism proposed by Rutherford et al (114), coiled-coil
motif could not form intramolecular interaction. Therefore, it is reasonable to assume that the Kd
value of integrase dimerization in intergrase•attPL is around 20nM. Integrase monomer could
easily fall off from dimer integrase•attPL complex, thus monomer integrase•attPL will show as
weak band in Figure 7-5B.
The fact that the affinities of LSR to att sites and CTD to att sites are in the same range is
better explained by an alternative way. LSR has a Kd of dimerization around 10-8 M when forms
complex with attP. EMSA assay could not measure the affinity when LSR concentration closes to
10-8 M. However, if one intermolecular disulfide bond is introduced at αE helix, make the LSR as
dimer much more stable when the concentration less than 10-8 M, the much high Kd could
obtained. The proper Kd value of monomer-dimer are likely adopts LSR function. Higher Kd of
dimerization may help bonding LSR to att sites, but make the rotation much difficult after
cleavage. Lower Kd of dimerization will cause more serious problem, since it will abolish the
binding of LSR to att sites.
There are weak bands above the strong shift bands in Figures 7-5D, E and F. Based on
the same fact that CTD amount is much more than attP (attPL or attPR), the weak should
correspond to two CTD and one attP (attPL or attPR). Comparing the weak band in figure 7-5D
and E, CTD•attP is much stronger than CTD•attPL. These results could be explained by CTD
dimerization promote attP. In the process of CTD dimer binding to attP, one CTD monomer binds
to attP half site first. After first CTD monomer binding, the second CTD monomer binding to
leftover attP half site is boosted by two factors: first CTD monomer brings the second CTD
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monomer to vicinity and the latter has tendency to bind attP. In contrast, the second CTD
monomer is not boosted by binding to attPL in the process forming CTD dimer and attP complex.
CTD has a much stronger affinity to attPL than to attPR (150nM vs 4800nm). This
observation is consistent with our crystallization study. CTD•attPL crystals could be obtained
while CTD•attPR could not. In our crystallization condition, the final CTD•attPL concentration is
17.5μM. At this condition, over 99% of CTD and attPL exist as complex. At same concentration,
about 30% of CTD and attPR do not form complex. To get CTD•attPL, it is necessary to try high
concentration of CTD•attPR complex or introduction artificial crosslink between CTD and attPR.
In summary, this study provides detailed information to understand the interaction
between attP site and Integrase. The affinity differences between integrase, CTD and attP, attP
half sites are likely adapted to LSR biological functions. Similar experiments should be performed
to study LSR interaction with attB, attL and attR sites and carry out crystallization trials.
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APPENDIX A: Chapter 2&3
Material and Methods
Chemicals: acetate acid, acrylamide, agarose, ammonium persulfate, bisacrylamide, boric acid,
EB (Ethidium Bromide), EDTA (Ethylenediaminetetraacetic acid), glycerol, HCl, protease inhibitor
mixture, IPTG(Isopropyl β-D-1-thiogalactopyranoside), magnesium chloride, manganese
chlorides, NaN3, PMSF(phenylmethanesulfonylfluoride), sodium chloride, se-methionine, sodium
potassium tartrate, sucrose, TEMED (tetramethylethylenediamine), SDS (sodium dodecyl sulfate),
Tris (tris(hydroxymethyl)aminomethane).
Vector: pET21a
Expression plasmids: Wild type resolvase, D130A, D132A, E59A, E59A-D130N, D130AD131A-D134A, D130A-D131A-D134A, ∆7 (97-103 deletion).
Media: LB (Lysogeny broth), EZ Rich methionine-free medium (Teknova)
Cell strain: DH5α, BL21(DE3).
Chromatography Column: SP-sepharose, Mono-S, Superdex-200.
Buffers:
1). Buffers used to purify CPV resolvase:
20 mM Tris, pH 7.4, 15% glycerol, 0.01%NaN3;
20 mM Tris, pH 7.4, 15% glycerol, 0.01%NaN3, 0.2 M NaCl;
20 mM Tris, pH 7.4, 15% glycerol, 0.01%NaN3, 1.0 M NaCl;
2). Buffer used to dissolve DNA oligos:
10 mM Tris, pH 8.5, 0.5 mM EDTA;
3). Buffer used to anneal DNA duplex or HJ:
20 mM Tris, pH8.0, 100 mM NaCl;
4). Buffers used to run DNA electrophoresis:
1x TAE buffer: 40 mM Tris-acetate and 1 mM EDTA, pH 8.3;
0.5x TBE buffer: 45 mM Tris borate, 1 mM EDTA, pH 8.3;
5). Buffer used to run SDS-PAGE:
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4x Resolving buffer: 1.5 M Tris-HCl, pH 8.8, 0.4% SDS;
4x Stacking buffer: 0.5 M Tris-HCl, pH6.8, 0.4% SDS;
1x Running buffer: 25 mM Tris, 192 mM Glycine, 0.1% SDS;
5x Loading buffer: 250 mM Tris, pH 6.8, 10% v/v SDS, 0.05% w/v Bromophenol blue, 44%
v/v glycerol;
Staining buffer: 10% w/v Ammonium Sulfate, 0.12% w/v Commassie blue, 10% v/v
Phosphoric acid, 20% v/v Methanol.
Resolvase expression and purification
The resolvase gene of canarypox virus was codon-optimized and synthesized by IDT
(Appendix B). The gene was inserted into pET21a vector between NdeI and BamHI restriction
sites. The plasmid was transformed into BL21(DE3) cell and grown on LB plate with ampicillin. A
single colony was inoculated into 30 ml of LB with 100 μg/ml of ampicillin and grown overnight at
37° and 250 rpm. The next morning, 10 ml of overnight culture was inoculated into 1 L LB media
with ampicillin. When OD600 reached 0.6, IPTG (Isopropyl β-D-1-thiogalactopyranoside) was
added into the media at final concentration of 0.1 mM. The temperature was adjusted to 18°
degree and cells continued to grow overnight.
The cell pellet was spun down at 8,000 rpm for 10 minutes and was resuspended in lysis
buffer containing 20 mM Tris-HCl (pH 7.4), 15% glycerol (v/v), 0.2 M NaCl, 0.01% NaN3. The
cells were lysed in two passes with an Avestin EmulsiFlex-C3 homogenizer, and the lysate was
spun at 16,000rpm at 4° for 20 minutes. The supernatant was filtered with Whatman paper and
loaded onto a SP-sepharose column (24 ml bed volume) equilibrated with lysis buffer. The lysis
buffer was continued to run until the baseline was flat. A linear gradient was run from 0.2 M to
1.0 M NaCl in 20 mM Tris-HCl (pH 7.4), 15% glycerol (v/v), 0.01% NaN3 buffer by 5 column
volumes (120 ml). The resolvase peak was eluted roughly at the ionic strength of 0.3 M NaCl. At
this stage, the resolvase was about 80% purity.
The resolvase peak (24 ml) was pooled and diluted with an equal volume (24 ml) of
buffer containing 20 mM Tris-HCl (pH7.4), 15% glycerol, 0.01% NaN3. Then, 16 ml of resolvase
peak fraction was loaded onto a MonoS column (8 ml bed volume) for further purification. The
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same gradient was run from 0.2 M to 1.0 M NaCl in 20 mM Tris-HCl (pH 7.4), 15% glycerol (v/v),
0.01% NaN3 buffer in 6 column volumes (48 ml). The resolvase peak fractions were pooled
again, resulting in about 95% purity. Resolvase was purified in a total of three injections on
MonoS and concentration with 10 kDa MWCO Centricon devices (Millipore) to 2 ml. Four injection
of 0.5 ml were loaded onto a Superdex-200 10/230 column (24 ml bed volume) for final
purification. The running buffer for gel-filtration chromatography contained 20 mM Tris-HCl (pH
7.4), 15% glycerol, 1 M NaCl and 0.01% NaN3. After gel-filtration, the resolvase purity reached
nearly 100%. The resolvase peak fractions were collected and concentrated by using 10 kDa
MWCO Centricon devices to 30~50 mg/ml and frozen in liquid nitrogen, and keep at -80° for
future use.
Resolvase mutant constructs were generated using the Quickchange site-directed
mutagenesis procedure, and mutant resolvases were expressed and purified as wild type
resolvase. Selenomethionine-substituted protein was overexpressed using the methionine
auxotroph B834(DE3) grown in EZ Rich methionine-free medium (Teknova) supplemented with
100 mg/L of D/L-selenomethionine. Selenomethionine resolvase was expressed and purified
using the same protocols as native resolvase.
Crystallization and diffraction data
CPV resolvase crystals were obtained by microdialysis, where 10 μl of 10 mg/ml protein
in 20 mM Tris-HCl (pH 7.4), 15% glycerol, 1 M NaCl and 0.01% NaN3 was dialyzed against 1.5 ml
of 50 mM Tris-HCl (pH 8.5), 180 mM MgCl2, 150 mM sodium-potassium tartrate, 0.35-0.50 M
NaCl at 22°C using 10 μl dialysis buttons (Hampton Research) and 8 kDa MWCO dialysis
membrane. Crystals generally appeared after one week and continued to grow for another week
to typical dimensions of 0.1 x 0.1 x 0.5 mm. The crystals were cryo-protected by gradually
increasing the sucrose concentration from 0-50% by dialysis.
The crystals are tetragonal, P43212, with one resolvase dimer in the asymmetric unit and
diffract to 2.6 Å. Native resolvase diffraction data were collected at the NECAT beam line 24-IDE and processed with XDS package (185). The native resolvase diffraction data exhibited
anisotropy with diffraction limits of 2.3 Å along c* but 2.7 Å along a* and b*. The data were
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ellipsoidally truncated, anisotropically scaled, and an isotropic B of -20.61 Å was applied using
the UCLA Diffraction Anisotropy Server (186). Diffraction data for SeMet resolvase were
measured at the Advanced Photon Source (APS) beam line 23-ID-D, and processed with
HKL2000 (187). SeMet peak dataset was collected at 0.97947Å with 1° oscillation. Translation of
SeMet resolvase crystal along longest dimension was employed to decrease diffraction decay.
Structure determination
SHELXD (188) was used to locate both internal Se sites at 5 Å from the anomalous
difference data, but the resulting SAD-phased map could not be readily interpreted (R=0.55).
HHpred was used to search for homologous proteins (189) and produced three potential models
in the RuvC family for molecular replacement: PDB codes 4EP4, 1HJR, and 1KCF. Phased
molecular replacement was performed using MOLREP (190) to place each model into the SADphased map with scores of 0.131, 0.109, and 0.134, respectively. The last model (1KCF; 21%
identical to CPV resolvase) was combined with the Se-Met phases using Phaser (191). This
resulted in a the model with Rwork=0.43 and Rfree=0.49. Several rounds of phase combination
between the Se-SAD data and native dataset dropped the Rwork below 0.40. The resulting
model was used to refine against the native data and the data extend to 2.6 Å. Another several
rounds of model building with COOT (192) and refinement with CNS (193) improved the structure
to Rwork=0.223 and Rfree=0.264. Residues 114-127 of both subunits are disordered, but were
fit into weak density to provide approximate locations for modeling studies.
Resolvase kinetic experiments
Bulged DNA substrates are efficiently cleaved by resolvase and the products dissociate
rapidly form the enzyme. In this study, we used synthetic bulged DNA as substrates to perform
kinetic measurements. The bulged DNA sequence and all the reaction protocols were exactly
same as described by Culyba (21). DNA oligos were purchased form IDT and FPLC purified.
Unlabeled DNA oligos were mixed at equal molar ratio at 100uM in 10 mM Tris-HCl, 0.1 M NaCl,
boiled for 5 min and slowly cooled down to room temperature. Fluorescein labeled substrate was
mixed at a 2:1 molar ratio of unlabeled to 6-Carboxfluorescein labeled DNA oligo.
Reactions for kinetic analysis were carried out in 100 μl buffer, containing 25 mM Tris119

HCl (pH 8.0), 100 mM NaCl, 5 mM MgCl2 (or 0.5 mM MnCl2), at 37° for 30 minutes. The final
resolvase concentration was 10 nM; fluorescein labeled bulged DNA concentration was fixed at 2
nM and unlabeled DNA substrate concentration was varied from 0 to 1920 nM. Fluorescein
polarization signal was recorded every 60 seconds by a Beacon 2000 fluorescence polarization
system (Invitrogen). The percentage of cleavage was calculated by the formula: (FP level - Basal
FP level)/(Initial FP - Basal FP) *100%. Each experiment was done in triplicate to calculate a
standard deviation. Initial velocities were calculated from non-linear regression fits of the kinetic
data using an exponential decay model in the Prism software package. Km and Vmax were
calculated using the Michaelis-Menten model in Prism.
To measure the Km values of metal ions, experiments were carried out and analyzed as
described above, with the following modifications. Bulged DNA concentrations were fixed at their
Km value for Mg2+ and Mn2+ respectively. Mg2+ concentration was varied from 0.25 mM to 13 mM,
while Mn2+ concentration was varied from 0.012 mM to1.3 mM.
Holliday junction cleavage assays
The HJ substrate was prepared by mixing four DNA oligos at equal molar ratio (100uM)
(Appendix A, one of them is 6-fluoresencin labeled) in 10 mM Tris-HCl (pH8.0), 100 mM NaCl.
The mixture was boiled for 5 minutes and then slowly cooled down to room temperature in a
water bath.
The cleavage buffer contained 20 mM Tris-HCl (pH8.0), 100 mM NaCl, 1% glycerol.
CPV resolvase and HJ substrate concentrations were 100 nM and 10 nM respectively. Final
metal ion concentrations of Mg2+, or Mn2+ or combinations of Mg2+ and Mn2+ are specified in
relevant figures. 20μl reactions were incubated at 37°C for 30 min and then stopped by adding
5x stop solution (100 mM EDTA, 5% SDS, 30% glycerol and 0.1% bromophenol blue). The
reaction products were separated on 10% polyacrylamide gels by electrophoresis in 0.5x TBE
buffer. The fluorescein label was visualized with a Typhoon instrument (GE healthcare).
Isothermal titration calorimetry
For CPV resolvase binding experiments, resolvase was in buffer containing 20 mM Tris
(pH7.4), 1 M NaCl, 15% glycerol and concentration of 45mg/ml (1.3 mM). The titration metal ion
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(Mg2+ or Mn2+) was 30 mM in same buffer (prepared by mixing 0.203g MgCl2*6H2O or 0.198g
MnCl2*4H2O, 20 μl 1M Tris, pH 7.4, 0.2 ml 5M NaCl, 0.3ml 50% glycerol (v:v), adding distilled
water to 1ml ). The ITC experiment was carried out by injecting metal ion into resolvase solution
and measure the heat change. In total, there were 20 injections and each injection was 2 μl.
There were 3 minutes intervals between injections. Control experiments was performed by
titration of Mg2+ (Mn2+) to buffer (used to dissolve CPV resolvase), and the enthalpy change was
subtracted in calculation Mg2+ (Mn2+)•CPV resolvase enthalpy change.
For metal binding to resolvase•HJ experiments, the HJ was prepared by mixing equal
molar ratios of four oligos in buffer containing 10 mM Tris, pH7.4, 100 mM NaCl. The mixture
was boiled for 5 minutes and slowly cooled down to room temperature. Resolvase mutants and
DNA HJ was mixed at a 1: 1 molar ration, and dialysis against buffer (10 mM Tris-HCl, pH7.4,
100 mM NaCl) to remove the glycerol and high concentration of NaCl. The resolvase•HJ
complex concentration was adjusted to 0.1 mM. MgCl2 and MnCl2 are also dissolved at 2 mM in
same buffer. The experiments were carried out using the same protocol as for titration of
resolvase with divalent ion. All titrations were repeated three or more times and data was
processed with the ITC-200 origins package. The stoichiometry and binding constants of Mn2+ to
apo resolvase and resolvase•HJ complex were automatically determined, while the stoichiometry
of Mg2+ was fixed at 2 and binding constants to apo resolvase, and mutant resolvase•HJ were
automatically determined.
Construction of CPV resolvase•HJ model
The T.thermophilus RuvC•HJ complex (PDB code 4LD0) was first modified as follows.
The terminal base-pairs and/or hairpin nucleotides were removed on each junction arm and the
arms were extended to 10-bp in length by overlap superposition of idealized B-DNA duplex
segments. The HJ core where RuvC binds was not changed. A CPV resolvase•HJ model was
then constructed by superposition of the resolvase dimer onto the RuvC dimer using the Cα
positions of conserved catalytic residues. The side chain dihedral angles of several amino acids
at the protein-DNA interface were adjusted to avoid steric clashes. The only steric overlap
between the resolvase main chain and the HJ DNA involved the disordered loop connecting α4
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and α5, which was not experimentally well-defined but may become ordered upon substrate
binding. We did not attempt to model a DNA-binding conformation for this loop.
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Data files
CPV resolvase gene and protein sequence
Codon optimized DNA sequence of canarypox virus resolvase:
ATG•ACC•ATC•ATC•TGC•TCT•GTA•GAC•ATT•GGC•ATC•AAA•AAC•CCG•GCA•TAC•ACC•
ATC•TTT•CGT•TAC•GAA•GAT•TCT•AAA•GTC•TCC•CTG•ATC•GCA•ATC•GAG•AAA•TCC•
GAC•TGG•TCT•GAC•AAC•TGG•GAA•TAC•AAC•GTG•ACT•AAA•GAT•CTG•ACT•AAA•TAT•
AAC•CCG•GAC•ATC•ATC•GTG•CTG•GAA•AAA•CAG•GGT•TAC•CGT•TCT•CCG•AAT•GCT•
AAA•ATC•ATT•TAC•TTC•ATC•AAA•GGT•TTC•TTC•TAT•AAT•ACC•AAC•ACT•TCC•GTG•
ATC•GTT•CGT•AAT•CCG•ACT•TTC•CAA•GGC•GGT•TCC•TAC•TCT•GAC•CGT•AAA•AAA•
CAG•TCT•GTT•ATC•ACC•TTC•ATG•GAC•AAA•CTG•AGC•CGT•TAC•TCT•GAT•CAC•ATC•
GAC•GAC•ATT•CTG•TCT•AGC•TTC•ACT•AAA•CTG•GAC•GAC•ATC•GCG•GAC•TCT•TTC•
AAC•CTG•GGT•ATC•GCG•TAC•ATC•GAA•TCC•ACG•TTC•AAA•AAA•AAC•GTT•AAA•TAA
Primary sequence of canarypox virus resolvase:
MTIICSVDIGIKNPAYTIFRYEDSKVSLIAIEKSDWSDNWEYNVTKDLTKYNPDIIVLEKQGYRSPNA
KIIYFIKGFFYNTNTSVIVRNPTFQGGSYSDRKKQSVITFMDKLSRYSDHIDDILSSFTKLDDIADSF
NLGIAYIESTFKKNVK
Codon changed sequence
ATG•ACC•ATC•ATC•TGC•TCT•GTA•GAC•ATT•GGC•ATC•AAA•AAC•CCG•GCA•TAC•ACC•
ATC•TTT•CGT•TAC•GAA•GAT•TCT•AAA•GTC•TCC•CTG•ATC•GCA•ATC•GAG•AAA•TCC•
GAC•TGG•TCT•GAC•AAC•TGG•GAA•TAC•AAC•GTG•ACT•AAA•GAT•CTG•ACT•AAA•TAT•
AAC•CCG•GAC•ATC•ATC•GTG•CTG•GAA•AAA•CAG•GGT•TAC•CGT•TCT•CCG•AAT•GCT•
AAA•ATC•ATT•TAC•TTC•ATC•AAA•GGT•TTC•TTC•TAT•AAT•ACC•AAC•ACT•TCC•GTG•
ATC•GTT•CGT•AAT•CCG•ACT•TTC•CAA•GGC•GGT•TCC•TAC•TCT•GAC•CGT•AAA•AAA•
CAG•TCT•GTT•ATC•ACC•TTC•ATG•GAC•AAA•CTG•AGC•CGT•TAC•TCT•GAT•CAC•ATC•
GAC•GAC•ATT•CTG•TCT•AGC•TTC•ACT•AAA•CTG•GAC•GAC•ATC•GCG•GAC•TCT•TTC•
AAC•CTG•GGT•ATC•GCG•TAC•ATC•GAA•TCC•ACG•TTC•AAG•AAG•AAC•GTT•AAA•TAA
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CPV resolvase properties
10
20
30
40
50
60
MTIICSVDIG IKNPAYTIFR YEDSKVSLIA IEKSDWSDNW EYNVTKDLTK YNPDIIVLEK
70
80
90
100
110
120
QGYRSPNAKI IYFIKGFFYN TNTSVIVRNP TFQGGSYSDR KKQSVITFMD KLSRYSDHID
130
140
150
DILSSFTKLD DIADSFNLGI AYIESTFKKN VK
Number of amino acids: 152
Molecular weight: 17560.9
Theoretical pI: 7.72
Amino acid composition:
Ala (A)
5
3.3%
Arg (R)
5
3.3%
Asn (N) 10
6.6%
Asp (D) 14
9.2%
Cys (C)
1
0.7%
Gln (Q)
3
2.0%
Glu (E)
5
3.3%

Gly
His
Ile
Leu
Lys
Met
Phe

(G)
(H)
(I)
(L)
(K)
(M)
(F)

6
1
19
7
15
2
9

3.9%
0.7%
12.5%
4.6%
9.9%
1.3%
5.9%

Pro
Ser
Thr
Trp
Tyr
Val

(P)
(S)
(T)
(W)
(Y)
(V)

4
16
10
2
10
8

2.6%
10.5%
6.6%
1.3%
6.6%
5.3%

S

3

Total number of negatively charged residues (Asp + Glu): 19
Total number of positively charged residues (Arg + Lys): 20
Atomic composition:
Carbon
C
799
Hydrogen H
1231

Nitrogen
Oxygen

N
O

199
240

Sulfur

Formula: C799H1231N199O240S3
Total number of atoms: 2472
Extinction coefficients:
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
Ext. coefficient
25900
Abs 0.1% (=1 g/l)
1.475, assuming all pairs of Cys residues form cystines
Ext. coefficient
25900
Abs 0.1% (=1 g/l)
1.475, assuming all Cys residues are reduced
Estimated half-life:
The N-terminal of the sequence considered is M (Met).
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 28.49
This classifies the protein as stable.
Aliphatic index: 85.26
Grand average of hydropathicity (GRAVY): -0.351
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List of residues involved in interface interaction of CPV resolvase
Residue Number Chain
TRP
GLU
TYR
THR
ARG
SER
PRO
LYS
TYR
PHE
LYS
GLY
PHE
TYR
ASN
TRP
GLU
TYR
THR
TYR
ARG
LYS
TYR
PHE
LYS
GLY
PHE
TYR
ASN

40
41
42
45
64
65
66
69
72
73
75
76
77
79
80
40
41
42
45
63
64
69
72
73
75
76
77
79
80

A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
B
B
B
B
B
B
B
B
B
B
B
B
B
B

Complex
ASA* (Å2)
36.2
43.43
139.33
13.98
117.51
20.46
65.97
51.61
51.25
0.07
42.24
0.0
45.12
52.93
122.3
33.54
37.54
129.04
9.66
93.32
150.05
50.98
31.18
0.35
51.34
0.22
44.77
66.66
131.71

Free ASA
(Å2)
51.21
82.07
154.53
26.89
202.97
27.17
106.73
95.76
141.75
58.77
77.64
53.48
92.88
160.48
135.48
49.07
88.47
145.20
26.26
176.35
201.98
93.24
118.16
51.96
80.82
51.32
93.11
174.33
140.51

*ASA: accessible surface area
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Buried (ASA)
Interface (Å2)
15.01
38.64
15.2
12.91
85.46
6.71
40.76
44.15
90.5
58.7
35.4
53.48
47.76
107.55
13.18
15.53
50.93
16.16
16.6
83.03
51.93
42.26
86.98
51.61
29.48
51.1
48.34
107.67
8.8

Buried ASA
%
29.31
47.08
9.84
48.01
42.10
24.70
38.19
46.10
63.84
99.88
45.60
100.00
51.42
67.02
9.73
31.65
57.57
11.13
63.21
47.08
25.71
45.32
73.61
99.33
36.48
99.57
51.92
61.76
6.26

Summary of CPV-resolvase dimerization interface interaction
Buried area upon the complex formation (Å2) 1325.9
Buried area upon the complex formation (%) 8.92
Interface area (Å2) 662.95
Interface area MolA (%) 8.55
Interface area MolB (%) 9.31
POLAR Buried area upon the complex formation (Å2) 989.1
POLAR Buried area upon the complex formation (%) 74.60
POLAR Interface area (Å2) 494.55
NO POLAR Buried area upon the complex formation (Å2) 336.7
NO POLAR Buried area upon the complex formation (%) 25.39
NO POLAR Interface area (Å2) 168.35
Residues at the interface_Total: 29
Residues at the interface_MolA: 15
Residues at the interface_MolB: 14
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List of residues involved in interface interaction of E.coli RuvC
Residue

Number

Chain
ID
LEU
40
A
PRO
41
A
LEU
44
A
LYS
45
A
TYR
48
A
VAL
68
A
PHE
69
A
ALA
71
A
LYS
72
A
ALA
74
A
ALA
77
A
LEU
78
A
LEU
80
A
GLY
81
A
GLN
82
A
ARG
84
A
GLY
85
A
VAL
86
A
ILE
88
A
VAL
89
A
VAL
92
A
ASN
93
A
VAL
98
A
GLU
100
A
LEU
40
B
PRO
41
B
LEU
44
B
LYS
45
B
TYR
48
B
VAL
68
B
ALA
71
B
LYS
72
B
ALA
74
B
ASP
75
B
ALA
77
B
LEU
78
B
LEU
80
B
GLY
81
B
GLN
82
B
ARG
84
B
GLY
85
B
VAL
86
B
ILE
88
B
VAL
89
B
VAL
92
B
ASN
93
B
VAL
98
B
GLU
100
B
ASA: accessible surface area

Complex ASA
Å2
29.39
30.4
5.08
74.76
21.44
42.06
137.47
42.53
175.29
21.02
3.49
13.67
51.09
0.0
11.97
9.42
0.0
0.0
0.0
0.0
29.11
50.54
22.43
48.53
28.84
16.27
3.0
59.27
27.06
61.83
23.27
131.53
16.45
59.62
3.4
10.5
44.59
0.0
4.25
8.96
0.0
0.0
0.85
0.03
32.77
59.81
27.51
55.89

Free ASA
Å2
68.15
95.67
45.93
125.05
65.78
67.80
159.71
53.28
190.76
83.23
46.83
119.17
55.87
41.00
64.01
43.86
35.05
24.41
38.70
56.75
86.13
91.46
42.51
78.46
66.29
95.59
46.67
116.19
65.13
77.52
45.40
139.36
88.18
85.81
35.72
110.73
49.09
36.36
51.13
42.25
35.35
22.01
40.91
62.88
76.48
100.50
51.25
78.41
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Buried (ASA)
Interface Å2
38.76
65.27
40.85
50.29
44.34
25.74
22.24
10.75
15.47
62.21
43.34
105.5
4.78
41.0
52.04
34.44
35.05
24.41
38.7
56.75
57.02
40.92
20.08
29.93
37.45
79.32
43.67
56.92
38.07
15.69
22.13
7.83
71.73
26.19
32.32
100.23
4.5
36.36
46.88
33.29
35.35
22.01
40.06
62.85
43.71
40.69
23.74
22.52

Buried ASA
%
56.87
68.22
88.94
40.22
67.41
37.96
13.93
20.18
8.11
74.74
92.55
88.53
8.56
100.00
81.30
78.52
100.00
100.00
100.00
100.00
66.20
44.74
47.24
38.15
56.49
82.98
93.57
48.99
58.45
20.24
48.74
5.62
81.34
30.52
90.48
90.52
9.17
100.00
91.69
78.79
100.00
100.00
97.92
99.95
57.15
40.49
46.32
28.72

Summary of E.coli RuvC dimerization interface interaction
Buried area upon the complex formation (Å2) 1905.7
Buried area upon the complex formation (%) 10.71
Interface area (Å) 952.85
Interface area MolA (%) 10.59
Interface area MolB (%) 10.83
POLAR Buried area upon the complex formation (Å) 1476.9
POLAR Buried area upon the complex formation (%) 77.50
POLAR Interface area (Å) 738.45
NO POLAR Buried area upon the complex formation (Å) 428.8
NO POLAR Buried area upon the complex formation (%) 22.50
NO POLAR Interface area (Å) 214.4
Residues at the interface_Total: 48
Residues at the interface_MolA: 24
Residues at the interface_MolB: 24
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Primary sequence alignment of poxvirus resolvases
Penguinpox
Pigeonpox
Fowlpox
Canarypox
Vaccinia
Camelpox
Cowpox
Monkeypox
Taterapox
Crocodilepox
Smallpox
Yokapox
Goatpox
Sheeppox
Tanapox
Deerpox
Swinepox
Squirrelpox

:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:

*
20
*
40
*
60
*
------------------MRKSIMIICSVDIGIKNPAYTIFNYDK---------DNSTIKLIAIEKSDWS-----------------------MIICSVDIGIKNPAYTIFNYDK---------DNSTIKLIAIEKSDWS-----------------------MIICSVDIGIKNPAYAIFNYDN---------TSNTIKLIAIEKSDWT----------------------MTIICSVDIGIKNPAYTIFRYE-----------DSKVSLIAIEKSDWSMETLTSSSQSLMSSPMSKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWS-----------MSSPMSKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWSMETLTSSSQSLMPLPMSKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWS---------------MSKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWSMETLTSSSQSLMSSPISKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWS-----------------------MIIAAIDPGTRNPAVAWIEVVPGAGDGVGTAAAARVRLRALRRCDWSG
METLTSSSQSLISSPMSKKDYSSEIICAFDIGAKNPARTVLEVK----------DNS-VRVLDISKLDWSMETSVNLSQSLTHSQMLKRDSNSEIICAFDIGAKNPARTILEVR----------GQE-VRIIDISKLDWS----------MSNNHC-LKHIKKEVICAFDIGAKNPARTVLEIE----------SNN-IKIIDISKLDWS----------MSNNHC-LKNIKKEVICAFDIGAKNPARTILEIE----------SNN-IKIIDISKLDWS----------------------MEIVCAFDLGKKNPARTIFEID----------GNG-IKLIDISKLDWS----------MSKNYYNAPTEQKEVICAFDIGAKNPARTIIEVY----------NNNSIKILDISKLDWS----------MSNNHY-----RKEIICAFDIGAKNPARTILEIE----------NNI-IRIIDISKLDWS-------MPKRRARRPATRDGCRRVVSAFDIGAKNPARTVLEVS----------GDS-VRVLDVSKLDWS-

:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:

43
38
38
37
59
48
59
44
59
48
59
59
48
48
37
50
44
52

Penguinpox
Pigeonpox
Fowlpox
Canarypox
Vaccinia
Camelpox
Cowpox
Monkeypox
Taterapox
Crocodilepox
Smallpox
Yokapox
Goatpox
Sheeppox
Tanapox
Deerpox
Swinepox
Squirrelpox

:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:

80
*
100
*
120
*
140
KNWERSVAKDLTSYN----PDVVILEKQGFKSPNSKIIYFIKGFFYNTN--TKVIVRNPTFKGGSYRNRKK
KNWERSVAKDLTSYN----PDVIILEKQGFKSPNSKIIYFIKGFFYNTN--TKVIVRNPTFKGGSYRNRKK
KNWERSVARDLTRYN----PDVVILEKQGFKSPNSKIIYFIKGFFYNSN--TKVIVRNPTFKGGSYRNRKK
DNWEYNVTKDLTKYN----PDIIVLEKQGYRSPNAKIIYFIKGFFYNTN--TSVIVRNPTFQGGSYSDRKK
SDWERRIAKDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-AAKVICVSPVMSGNSYRDRKK
SDWERRIAKDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-AAKVICVSPVMSGNSYRDRKK
SDWERRIAKDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-ATKVICVSPVMSGNSYRDRKK
SDWERRIAQDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-AAKVICVSPVMSGNSYRDRKK
SDWERRIAKDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-AAKVICVSPVMSGNSYRDRKK
RDWQRRVAADLLDPARAPRPDLVVVEKQGRGSRLARIVYFVQGLVWPRA-----AVRNPSFRGGRYADRKA
SDWERRIAKDLSQYE----YTTVLLERQPRRSPYVKFIYFIKGFLYHTS-AAKVICVSPVMSGNSYRDRKK
SDWEKRIAKDLSQYE----YNTVLLERQPRRSPYVKFIYFIKGFLYHNSSNIKVICVSPVMSGNSYRDRKK
CKWEEQVAKDLFQHN----YNYVLLEQQSKRSPYIKFIHFIKGLLYNSD--TKVISVSPVMVGCSYKDRKK
CKWEEQVAKDLFQHN----YNYVLLERQSKRSPYIKFIHFIKGLLYNSD--TKVISVSPVMVGYSYKDRKK
TNWEKKVADDISKYN----YTSVLLERQPKRSPYVKFIYFIKGFLYNTF--TKVICVSPVMNGKSYKDRKK
TDWEKRIARDISQYD----YKFVLLERQPRRSPYVKFIYFIKGFLYHSH--TKVICVSPVMTGNSYKDRKR
TDWEKKVARDISQYD----YTSVLLERQPRRSPYVKIIYFIKGYLYNTR--SKVICVSPVMTGDSYRERKR
ADWESRVARDVAAFD----ADTVLLETQPRGSPHARFVYFIRGVLHGNR---RVLCVAPAMRGNSYRWRKR

:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:

108
103
103
102
125
114
125
110
125
114
125
126
113
113
102
115
109
116

Penguinpox
Pigeonpox
Fowlpox
Canarypox
Vaccinia
Camelpox
Cowpox
Monkeypox
Taterapox
Crocodilepox
Smallpox
Yokapox
Goatpox
Sheeppox
Tanapox
Deerpox
Swinepox
Squirrelpox

:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:

*
160
*
180
*
200
*
QSVDTFIQKISEYSEYKNDILNKYTKLDDIADSFNLGLSYMESLLKKCKISKD---------------QSIDTFIQKISEYSEYKNDILNKYTKLDDIADSFNLGLSYMESLIKKCKISKD---------------QSIDVFIQKISEYTDYKNDILNKYTKLDDIADSFNLGLSYMESLLKKCKISKD---------------QSVITFMDKLSRYSDHIDDILSSFTKLDDIADSFNLGIAYIESTFKKNVK------------------RSVEAFLDWMDTFG--LRNSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTPYN-RCKSRNYIKKM---RSVEAFLDWMDTFG--LRDSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTPYN-RCKSRNYIKKMY--RSVEAFLDWMDTFG--LRDSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTPYN-RCKSRNYIKKM---RSVEAFLDWMDTFG--LRDSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTPYN-RCKYRNYIKKM---RSVEAFLDWMDTFG--LRDSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTPYN-RCKSRNYIKKM---RSVRLFRRRAALLG---VPATALTGKLDDLADSLNLALAAAAELKFDSV-------------------RSVEAFFDWMDIFG--LRDSVPDRRKLDDVADSFNLAMRYVLDKWNTNYTHYN-RCKSRNYIKKM---RSVEAFLDWMNAFG--MRDYVPDRRKLDDVADSFNLAMRYVLDKWNTNYIPYN-KYRCKNYIKNM---KSTESFLNWMKVFG--LVNSIPKGKKIDDVADSFNIALRFVLDKWDINYIPYK-KNKKIVKKPFKNNNG
KSTESFLNWMKVFG--LVNSIPKGKKIDDVADSFNIALRFVLDKWDINYIPYK-KIKK----------RSIEVFLNWMTVFG--LKKNIPK-RKLDDVADSFNLAMRYILNKWKISYKPYI-KNKKN---------RSIETFLNWMSIFG--LIDFIPIRRKLDDVADSFNLAMRYVLDKWNINHAPYV-KHKSIKKCKIDDNSI
RSVETFLNWMNVFG--IMDFIPDRRKLDDVADSFNIAMRYILDKLNIKYYSYINRYKKM---------VSVRRFLSWMDMFG--LRDSVPDRRKLDDVADSFNIAMRFVLTRL------------------------

161
156
156
152
187
177
187
172
187
160
187
188
179
168
157
181
166
159

Characters in black rectangle are the five conserved amino acids in the active pocket.
Virus name Genebank access code
Virus name Genebank access code
Crocodilepox: YP_784335
Penguinpox: NP_039150
Smallpox: NP_042170
Pigeonpox: YP_00946184
Yokapox: YP_004821479
Fowlpox: NP_039150
Goatpox: AGZ95429
Canarypox: NP_955284
Sheeppox: NP_659686
Vaccinia: CAM58313
Tanapox: YP_001497109
Camelpox: AAG37631
Deerpox: YP_227498
Cowpox: AGY98876
Swinepox: NP_570271
Monkeypox: AAY97133
Squirrelpox: YP_008658536
Taterapox: YP_717451
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:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:
:

Oligonucleotides used for the assay substrates
Substrate Oligonucleotides
5’-AGCTTCTGTGCAGCAGCTGCTCTCAACTGCAGTCTAGACT-3’
Sub A
5’-AGTCTAGACTGCAGTTGAGAGCTTGCTAGGACGGATCCCT-3’
5’-AGGGATCCGTCCTAGCAAGCTTTTTGTTTTGATTGCGAGG-3’
5’-CCTCGCAATCAAAACAAAAAGCAGCTGCTGCACAGAAGCT-3’-F
5’-AGCTTCTGTGCAGCAGCTGCTCTCAACTGCAGTCTAGACT-3’
Sub B
5’-AGTCTAGACTGCAGTTGAGAGCTTGCTAGGACGGATCCCT-3’
5’-AGGGATCCGTCCTAGCAAGCTTTTTGTTTTGATTGCGAGG-3’
5’-CCTCGCAATCAAAACAAAAAGCAGCTGCTGCACAGAAGCT-3’
5’-TCCGTCCTAGCAAGCCGCTGCTACCGGAAG-3’
Sub C
5’-CTTCCGGTAGCAGCGAGAGCGGTGGTTGAA-3’
5’-TTCAACCACCGCTCTTCTCAACTGCAGTCT-3’
5’-AGACTGCAGTTGAGAGCTTGCTAGGACGGA-3’
5’-TCCTACCACCAGATACACGCCACAGTTTTTTTTTTGATTA-3’-F
Sub D
5’-TAATCTTTTTTTTTTCTGTGGCGTGTATCTGGTGGTAGGA-3’
5’-TCCTACCACCAGATACACGCCACAGTTTTTTTTTTGATTA-3’
Sub E
5’-TAATCTTTTTTTTTTCTGTGGCGTGTATCTGGTGGTAGGA-3’
5’-CCTCGCAATCAAAACAAAAAGCAGCTGCTGCACAGAAGCT-3’-F
Sub F
5’-AGCTTCTGTGCAGCAGCTGCTTTTTGTTTTGATTGCGAGG-3’
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use
Enzymatic
study
Enzymatic
study
ITC study

Bulged
substrate
bulged
substrate
Duplex DNA

Enzymatic activity of wild resolvase and mutants

Enzymatic activities of wild resolves and mutant were determined by measuring fluorescence
polarization change. The experiment is described in the resolvase kinetic study.
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Appendix B: CHAPTER 5
Material and Methods
Primers
Primers used to clone D130A-D131A-D134A CPV resolvase
1). 5’-CTAGCTTCACTAAACTGGCAGCAATCGCGGCATCTTTCAACCTGGGTATCG-3’
2). 5’-CGATACCCAGGTTGAAAGATGCCGCGATTGCTGCCAGTTTAGTGAAGCTAG-3’
Primers used to clone E.coli RuvC
1). 5’-TATACCATGGCTATTCTCGGCATTGATCCGGGTTCGC-3’
2). 5’-ATTCGGATCCTTAACGCAGTCGCCCTCTCGCCAGGTTCAG-3’
3). 5’-CACCTTGCTGAAACTGCCCGCTAATCCAC-3’
4). 5’-GTGGATTAGCGGGCAGTTTCAGCAAGGTG-3’
Primers used to clone E.coli RNaseH
1). 5’- GTCAGTCATATGCTTAAACAGGTAGAAATTTTCACCG-3’
2). 5’- GTCAGTAAGCTTAAACTTCAACTTGGTAGCCTGTATC-3’
Vector: pET21a, pET33b,
Plasmids: Wild CPV resolvase in pET21a, D130A-D131A-D134A CPV resolvase in pET21a,
RuvC in pET33b, RNaseH in pET21a
Media: LB (Lysogeny broth)
Cell strain: DH5α, BL21(DE3).
Chromatography columns: SP-sepharose, Mono-S, Superdex-200, Heparin-Sepharose,
Hydroxyapatite.
Buffers:
1). Buffers used to purify CPV resolvase and E.coli RuvC:
Lysis buffer: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 0.2 M NaCl;
Buffer A1: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3;
Buffer B1: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 1.0 M NaCl;
Buffer A2: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 5 mM MgCl2;
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Buffer B2: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 1.0 M NaCl, 5 mM MgCl2;
Buffer A3: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 0.5 mM EDTA;
Buffer B3: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 1.0 M NaCl, 0.5 mM EDTA;
Buffer A4: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 5 mM MnCl2;
Buffer B4: 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3, 1.0 M NaCl, 5 mM MnCl2;
2). Buffers used to purify E.coli RNaseH:
Lysis buffer: 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3, 0.05 M NaCl;
Buffer A5: 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3, 0.5 mM EDTA;
Buffer B5: 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3, 1.0 M NaCl, 0.5 mM EDTA;
Buffer A6: 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3, 5 mM MnCl2;
Buffer B6: 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3, 1.0 M NaCl, 5 mM MnCl2;
3). Buffers used to purify phage T7 ligase:
Lysis buffer: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 0.2M NaCl;
Buffer A7: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3;
Buffer B7: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 1.0 M NaCl;
Buffer A8: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 5 mM MnCl2;
Buffer B8: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 1.0 M NaCl, 5 mM MnCl2;
Buffer A9: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 0.5 mM EDTA;
Buffer B9: 20 mM Tris-HCl, pH 7.4, 0.01% NaN3, 1.0 M NaCl, 0.5 mM EDTA;
4). Buffer used to dissolve DNA oligos:
10 mM Tris-HCl, pH 8.5, 0.5 mM EDTA.
5). Buffer used to anneal DNA duplex:
20 mM Tris-HCl, pH 8.0, 100 mM NaCl.
6). Buffers used to run DNA electrophoresis:
1x TAE buffer: 40 mM Tris-acetate and 1 mM EDTA, pH 8.3.
0.5x TBE buffer: 45 mM Tris borate, 1 mM EDTA, pH 8.3.
7). Buffers used to run SDS-PAGE:
4x resolving buffer: 1.5 M Tris-HCl, pH 8.8, 0.4% SDS
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4x stacking buffer: 0.5 M Tris-HCl, pH6.8, 0.4% SDS
1x running buffer: 25 mM Tris, 192 mM Glycine, 0.1% SDS
5x loading buffer: 250 mM Tris, pH 6.8, 10% v/v SDS, 0.05% w/v Bromophenol blue, 44%
v/v Glycerol.
8). Staining buffer: 10% w/v Ammonium sulfate, 0.12% w/v Commassie blue,
9). Distain buffer: 10% v/v Phosphoric acid, 20% v/v Methanol.
CPV resolvase cell culture and expression
The CPV resolvase gene was codon optimized and synthesized by IDT (Integrated DNA
Technologies) and inserted into pET21a vector (Novagen) between NdeI and BamHI restriction
sites. CPV resolvase was expressed in strain BL21 (DE3) by LB (Lysogeny broth) media at 18°C
upon induction with 0.1 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) when the cells reached
an optical density of 0.6 at 600 nm. After 16 hours, the bacteria cells were collected by
centrifugation and resuspended in lysis buffer (20 mM Tris-HCl, pH 7.4, 15% Glycerol (v:v), 0.2 M
NaCl, 0.01% NaN3). The resuspended cell pellets are either flashed frozen in liquid nitrogen for
long term storage or directly go to the next stage for purification. Resolvase mutant construct
(D130A-D131A-D134A, Tri-Mut) was generated by Quick-change site-directed mutagenesis kit
(Strategene). Same cell culture and purification protocols were applied to Tri-Mut CPV resolvase.
Regular method to purify CPV resolvase
One liter resuspended cell pellet was lysed at high pressure using an Avestin EmulsiFlexC3, clarified by centrifugation, and filtered before loading to 24 ml SP-sepharose chromatography
column (GE Healthcare) equilibrated with lysis buffer. After washing, a linear salt gradient was
run from 0.2 M to 1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3 buffer by 5
volume of SP column (120 ml). The salt gradient buffer was mixed from buffer A1 (20 mM TrisHCl, pH 7.4, 15% Glycerol, 0.01% NaN3) and buffer B1 (20 mM Tris-HCl, pH 7.4, 15% Glycerol,
0.01% NaN3, 1 M NaCl). The resolvase peak (24 ml) was pooled and diluted with equal volume
of buffer A1. Then 16 ml of resolvase peak fraction was loaded onto 8 ml MonoS column (GE
Healthcare) for further purification. A salt linear gradient chromatography was run from 0.25 M to
0.55 M NaCl in 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3 buffer in 6 volume of MonoS
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chromatography column (48 ml). Then resolvase peak fractions were pooled from MonoS
elution and concentrated by 10 kDa MWCO Centricon tube (Millipore) to 2 ml and 0.5 ml was
loaded to 23 ml Superdex-200 10/230 column (GE Healthcare) for final purification. The running
buffer for gel-filtration chromatography contains is Buffer B1. The resolvase peak fractions from
Superdex-200 elution were collected and concentrated by 10 kDa MWCO Centricon tube to
30~50 mg/ml and flashed frozen in liquid nitrogen and keep at -80°. Multiple runs and injections
(for MonoS and gel-filtration) are required to purify one liter CPV resolvase cell pellet. CPV
resolvase purity was quantified by Quantum.
Metal&EDTA method to purify CPV resolvase
Filtered supernatant from one liter cell culture was loaded to 24 ml SP-sepharose column
(GE Healthcare) equilibrated with lysis buffer. After washing, a linear salt gradient
chromatography was run from 0.2 M to 1.0 M NaCl in 20 mM Tris-HCl (pH 7.4), 15% Glycerol, 5
mM MgCl2, 0.01% NaN3 buffer by 5 volume of SP-sepharose column (120 ml). The salt gradient
buffer was mixed from buffer A2 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 5mM MgCl2, 0.01%
NaN3) and buffer B2 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 5mM MgCl2, 0.01% NaN3, 1M
NaCl). Resolvase peak fractions were pooled and diluted with two volume of buffer A3 (20 mM
Tris-HCl, pH 7.4, 15% Glycerol, 0.5 mM EDTA, 0.01% NaN3) and loaded again to SP-sepharose
chromatography column for next step purification. A linear salt gradient chromatography was run
from 0.2 M to 1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3 and 0.5 mM
EDTA buffer by 5 volume of SP column (120ml). The salt gradient buffer was mixed from buffer
A3 and buffer B3 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 0.5mM EDTA, 0.01% NaN3, 1.0 M
NaCl). Resolvase peaks were collected, concentrated to 30~50 mg/ml and flashed frozen in
liquid nitrogen and kept at -80°.
The protocol using Mn2+ and EDTA to purify CPV resolvase was same as Mg2+ and
EDTA except the first chromatography using buffer A4 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 5
mM MnCl2, 0.01% NaN3) and buffer B4 (20 mM Tris-HCl, pH 7.4, 15% Glycerol, 5 mM MnCl2,
0.01% NaN3, 1M NaCl). A linear salt gradient chromatography was run from 0.2 M to 1.0 M NaCl
by mixing Buffer A4 and B4.
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ITC experiment to determine the metal affinity to CPV resolvase
CPV resolvase was dissolved in buffer containing 20 mM Tris-HCl (pH 7.4), 1 M NaCl, 15%
Glycerol at concentration of 17.5 mg/ml (dimer concentration: 0.5 mM). The titration Mn2+ or Mg2+
was 50 mM in same buffer. The ITC experiment was carried out by injecting metal ion into CPV
resolvase solution and measure the heat change. All experiments are performed at 25°C.
Totally, there are 27 injections and each injection is 1.5 μl (except first inject 1.0 μl). There is 3
minutes interval between two injections. Final data was processed with the ITC-200 ORIGINS
package. Stoichiometry of CPV resolvase to Mg2+ is fixed at 1:2.
These experiments are also performed with high concentration of CPV resolvase (1.34
mM, 47 mg/ml) and low concentration of Mg2+ or Mn2+ (30 mM).
Contamination assay
Super-coiled pET21a plasmid harboring the CPV resolvase gene was used as circular
DNA. Linear DNA is prepared by purification of PCR (Polymerase chain reaction) product of CPV
resolvase gene. Super-coiled plasmid or linear DNA (final concentration: 50 μg/ml) was mixed
with CPV resolvase at mass ratio 1:1 in buffer containing 25 mM Tris-HCl, pH 8.0, 5 mM MgCl2
and 1% Glycerol. We incubated the reaction mixture for 2 hours at 37°C. The incubation product
was added equal volume of buffer containing 10% Glycerol, 2% SDS and 0.04% bromophenol
blue. 10 μl of product was loaded to 1% agarose for electrophoresis analysis.
Metal&EDTA method to purify E.coli RuvC
The E.coli RuvC gene was amplified by PCR from BL21(DE3) cell strain and inserted into
pET33b vector (Novagen) between NdeI and BamHI restriction sites. RuvC was over-expressed
in strain BL21 (DE3) by LB (Lysogeny broth) media at 20°C upon induction with 0.1 mM IPTG
when the cells reached an optical density of 0.6 at 600nm. After 16 hours, the bacteria cells were
collected by centrifugation and resuspended in lysis buffer (20 mM Tris-HCl, pH 7.4, 15%
Glycerol (v:v), 0.15 M NaCl, 0.01% NaN3). The resuspended cell pellets are either flashed frozen
in liquid nitrogen for long term storage or directly go to the next stage for purification.
Two liter resuspended cell pellet was lysed at high pressure using an Avestin EmulsiFlex-C3,
clarified by centrifugation, and filtered before loading to 24 ml SP-sepharose chromatography
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column (GE Healthcare) equilibrated with lysis buffer. After washing, a linear salt gradient
chromatography was run from 0.15 M to 1.0 M NaCl in 20 mM Tris-HCl (pH 7.4), 15% Glycerol, 5
mM MnCl2, 0.01% NaN3 buffer by 5 volume of SP-sepharose column (120 ml). The salt gradient
buffer was mixed from buffer A2 and buffer B2. RuvC peak fractions were pooled and diluted
with two volume of buffer A3 and loaded again to SP-sepharose chromatography column for next
step purification. A linear salt gradient chromatography was run from 0.15 M to 1.0 M NaCl in 20
mM Tris-HCl, pH 7.4, 15% Glycerol, 0.01% NaN3 and 0.5 mM EDTA buffer by 5 volume of SP
column (120ml). The salt gradient buffer was mixed from buffer A3 and buffer B3. In both steps
of chromatography, RuvC purity was monitored by SDS-PAGE. RuvC peaks were collected,
concentrated and flashed frozen in liquid nitrogen and kept at -80°.
Metal&EDTA method to purify E.coli RNaseH
The E.coli RNaseH gene was amplified by PCR from genomic DNA of DH5α strain and
inserted into pET21a vector (Novagen) between NdeI and HindIII restriction sites. RNaseH was
over-expressed in strain BL21(DE3) by LB (Lysogeny broth) media at 15°C upon induction with
0.1 mM IPTG when the cells reached an optical density of 0.6 at 600nm. After 16 hours, the
bacteria cells were collected by centrifugation and resuspended in lysis buffer (20 mM Tris-HCl,
pH 7.4, 15% Glycerol (v:v), 0.05 M NaCl, 0.01% NaN3). The resuspended cell pellets are either
flashed frozen in liquid nitrogen for long term storage or directly go to the next stage for
purification.
One liter resuspended cell pellet was lysed at high pressure using an Avestin EmulsiFlexC3, clarified by centrifugation, and filtered. One fifth of supernatant was loaded to 24 ml SPsepharose chromatography column (GE Healthcare) equilibrated with lysis buffer. After washing,
a linear salt gradient chromatography was run from 0.05 M to 1.0 M NaCl in 20 mM Tris-HCl (pH
7.4), 10% Glycerol, 0.5 mM EDTA, 0.01% NaN3 buffer by 5 volume of SP-sepharose column
(120 ml). The salt gradient buffer was mixed from buffer A5 and buffer B5. RNaseH peak
fractions were pooled and diluted with two equal volume of buffer A3 and loaded again to SPsepharose chromatography column for next step purification. A linear salt gradient
chromatography was run from 0.05 M to 1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 10% Glycerol,
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0.01% NaN3 and 5 mM MnCl2 buffer by 5 volume of SP column (120ml). The salt gradient buffer
was mixed from buffer A6 and buffer B6.
RNaseH peak fractions from first step are further purified by MonoS chromatography
column (8ml, GE Healthcare). MonoS column was equilibrated with 5% buffer B5, and RNaseH
peak fractions collected from SP-sepharose was loaded to MonoS column. After washing, a
linear salt gradient chromatography was run from 0.05 M to 1.0 M NaCl in 20 mM Tris-HCl (pH
7.4), 10% Glycerol, 0.5 mM EDTA, 0.01% NaN3 buffer by 6 volume of MonoS column (48 ml).
The salt gradient buffer was mixed from buffer A5 and buffer B5.RNaseH peak fractions were
pooled and diluted with two volume of buffer A6 and loaded again to MonoS chromatography
column for next step purification. A linear salt gradient chromatography was run from 0.05 M to
1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 10% Glycerol, 0.01% NaN3 and 5 mM MnCl2 buffer by 5
volume of MonoS column (120ml). The salt gradient buffer was mixed from buffer A6 and buffer
B6.In both steps of chromatography, RNaseH purity was monitored by SDS-PAGE.
Metal&EDTA method to purify Phage T7 ligase
Plasmid (pET28b) harboring Phage T7 ligase gene is kept by our lab. RuvC was overexpressed in strain BL21(DE3) by LB media at 37°C upon induction with 0.1 mM IPTG when the
cells reached an optical density of 0.6 at 600nm. It continued for another three hours, and the
bacteria cells were collected by centrifugation and resuspended in lysis buffer (20 mM Tris-HCl,
pH 7.4, 0.2 M NaCl, 0.01% NaN3). The resuspended cell pellets directly go to the next stage for
purification or by adding 15% glycerol at final concentration and flashed frozen in liquid nitrogen
for long term storage.
One liter resuspended cell pellet was lysed at high pressure using an Avestin EmulsiFlexC3, clarified by centrifugation, and filtered before loading to 24 ml SP-sepharose chromatography
column (GE Healthcare) equilibrated with lysis buffer. After washing, a linear salt gradient
chromatography was run from 0.2 M to 1.0 M NaCl in 20 mM Tris-HCl (pH 7.4), 0.01% NaN3
buffer by 5 volume of Heparin-Sepharose column (120 ml). The salt gradient buffer was mixed
from buffer A5 (20 mM Tris-HCl (pH 7.4), 0.01% NaN3) and buffer B5 (1.0 M NaCl in 20 mM TrisHCl, pH 7.4, 0.01% NaN3). T7 ligase peak fractions were pooled (total 24 ml).
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4 ml of the peak was diluted with five volume of buffer A5 and loaded again to SPsepharose chromatography column for next step purification. A linear salt gradient
chromatography was run from 0.05 M to 1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 0.01% NaN3 and
5 mM MnCl2 buffer by 5 volume of SP column (120 ml). The salt gradient buffer was mixed from
buffer A6 (20 mM Tris-HCl (pH 7.4), 5 mM MnCl2, 0.01% NaN3) and buffer B6 (20 mM Tris-HCl
(pH 7.4), 5 mM MnCl2, 0.01% NaN3, 1.0 M NaCl). T7 ligase peak pooled from HeparinSepharose was also further purified by EDTA method.
4 ml of the peak was diluted with five volume of buffer A5 and loaded again to SPsepharose chromatography column for next step purification. A linear salt gradient
chromatography was run from 0.05 M to 1.0 M NaCl in 20 mM Tris-HCl, pH 7.4, 0.01% NaN3 and
0.5 mM EDTA buffer by 5 volume of SP column (120 ml). The salt gradient buffer was mixed
from buffer A7 (20 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.01% NaN3) and buffer B7 (20 mM TrisHCl, pH 7.4, 0.5 mM EDTA, 0.01% NaN3, 1.0 M NaCl). In all steps of chromatography, Phage
T7 ligase purity was monitored by SDS-PAGE.
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Data files
E.coli RuvC gene and protein primary sequences
RuvC gene and protein sequence (cloned from BL21(DE3)):
Gene sequence of E.coli RuvC:
ATG•GCT•ATT•ATT•CTC•GGC•ATT•GAT•CCG•GGT•TCG•CGC•GTG•ACC•GGC•TAC•GGC•
GTC•ATC•CGC•CAG•GTA•GGT•AGG•CAA•CTG•TCC•TAC•CTG•GGT•AGC•GGA•TGC•ATC•
CGC•ACC•AAA•GTG•GAT•GAT•TTA•CCG•TCT•CGT•CTG•AAA•CTC•ATC•TAT•GCG•GGC•
GTG•ACG•GAA•ATC•ATC•ACC•CAG•TTC•CAG•CCT•GAT•TAT•TTC•GCC•ATT•GAA•CAA•
GTC•TTT•ATG•GCA•AAG•AAC•GCT•GAC•TCA•GCC•CTG•AAA•CTG•GGC•CAG•GCG•CGC•
GGC•GTG•GCG•ATT•GTG•GCG•GCG•GTG•AAT•CAG•GAG•TTG•CCA•GTA•TTT•GAA•TAC•
GCG•GCA•CGT•CAG•GTA•AAG•CAA•ACG•GTG•GTA•GGT•ATT•GGC•AGT•GCC•GAA•AAA•
AGC•CAG•GTG•CAG•CAT•ATG•GTC•CGC•ACC•TTG•CTG•AAA•CGG•CCC•GCT•AAT•CCA•
CAG•GCG•GAT•GCC•GCC•GAT•GCG•CTG•GCG•ATT•GCT•ATC•ACC•CAC•TGC•CAC•GTT•
AGT•CAG•AAT•GCG•ATG•CAG•ATG•AGC•GAA•TCG•CGG•CTG•AAC•CTG•GCG•AGA•GGG•
CGA•CTG•CGT•TAA
Primary sequence of E.coli RuvC:
MAIILGIDPGSRVTGYGVIRQVGRQLSYLGSGCIRTKVDDLPSRLKLIYAGVTEIITQFQPDYFAIEQ
VFMAKNADSALKLGQARGVAIVAAVNQELPVFEYAARQVKQTVVGIGSAEKSQVQHMVRTLLKRPANP
QADAADALAIAITHCHVSQNAMQMSESRLNLARGRLR
Gene sequence of E.coli RuvC (consistent with E.coli RuvC: NP_416377.1)
ATG•GCT•ATT•ATT•CTC•GGC•ATT•GAT•CCG•GGT•TCG•CGC•GTG•ACC•GGC•TAC•GGC•
GTC•ATC•CGC•CAG•GTA•GGT•AGG•CAA•CTG•TCC•TAC•CTG•GGT•AGC•GGA•TGC•ATC•
CGC•ACC•AAA•GTG•GAT•GAT•TTA•CCG•TCT•CGT•CTG•AAA•CTC•ATC•TAT•GCG•GGC•
GTG•ACG•GAA•ATC•ATC•ACC•CAG•TTC•CAG•CCT•GAT•TAT•TTC•GCC•ATT•GAA•CAA•
GTC•TTT•ATG•GCA•AAG•AAC•GCT•GAC•TCA•GCC•CTG•AAA•CTG•GGC•CAG•GCG•CGC•
GGC•GTG•GCG•ATT•GTG•GCG•GCG•GTG•AAT•CAG•GAG•TTG•CCA•GTA•TTT•GAA•TAC•
GCG•GCA•CGT•CAG•GTA•AAG•CAA•ACG•GTG•GTA•GGT•ATT•GGC•AGT•GCC•GAA•AAA•
AGC•CAG•GTG•CAG•CAT•ATG•GTC•CGC•ACC•TTG•CTG•AAA•CTG•CCC•GCT•AAT•CCA•
CAG•GCG•GAT•GCC•GCC•GAT•GCG•CTG•GCG•ATT•GCT•ATC•ACC•CAC•TGC•CAC•GTT•
AGT•CAG•AAT•GCG•ATG•CAG•ATG•AGC•GAA•TCG•CGG•CTG•AAC•CTG•GCG•AGA•GGG•
CGA•CTG•CGT•TAA
Primary sequence of codon changed E.coli RuvC):
MAIILGIDPGSRVTGYGVIRQVGRQLSYLGSGCIRTKVDDLPSRLKLIYAGVTEIITQFQPDYFAIEQ
VFMAKNADSALKLGQARGVAIVAAVNQELPVFEYAARQVKQTVVGIGSAEKSQVQHMVRTLLKLPANP
QADAADALAIAITHCHVSQNAMQMSESRLNLARGRLR
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E.coli RuvC properties
10
20
30
40
50
60
MAIILGIDPG SRVTGYGVIR QVGRQLSYLG SGCIRTKVDD LPSRLKLIYA GVTEIITQFQ
70
80
90
100
110
120
PDYFAIEQVF MAKNADSALK LGQARGVAIV AAVNQELPVF EYAARQVKQT VVGIGSAEKS
130
140
150
160
170
QVQHMVRTLL KLPANPQADA ADALAIAITH CHVSQNAMQM SESRLNLARG RLR
Number of amino acids: 173
Molecular weight: 18746.7
Theoretical pI: 9.59
Amino acid composition:
Ala (A)
22
12.7%
Arg (R)
12
6.9%
Asn (N)
5
2.9%
Asp (D)
7
4.0%
Cys (C)
2
1.2%
Gln (Q)
14
8.1%
Glu (E)
6
3.5%

Gly
His
Ile
Leu
Lys
Met
Phe

(G)
(H)
(I)
(L)
(K)
(M)
(F)

13
3
13
16
7
5
4

7.5%
1.7%
7.5%
9.2%
4.0%
2.9%
2.3%

Pro
Ser
Thr
Trp
Tyr
Val

(P)
(S)
(T)
(W)
(Y)
(V)

6
10
7
0
5
16

3.5%
5.8%
4.0%
0.0%
2.9%
9.2%

Total number of negatively charged residues (Asp + Glu): 13
Total number of positively charged residues (Arg + Lys): 19
Atomic composition:
Carbon
C
826
Hydrogen
H
1359
Nitrogen
N
241
Oxygen
O
241
Sulfur
S
7
Formula: C826H1359N241O241S7
Total number of atoms: 2674
Extinction coefficients:
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
Ext. coefficient
7575
Abs 0.1% (=1 g/l)
0.404, assuming all pairs of Cys residues form cystines
Ext. coefficient
7450
Abs 0.1% (=1 g/l)
0.397, assuming all Cys residues are reduced
Estimated half-life:
The N-terminal of the sequence considered is M (Met).
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 34.35
This classifies the protein as stable.
Aliphatic index: 104.91
Grand average of hydropathicity (GRAVY): 0.085
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E.coli RNaseH properties
10
20
30
40
50
60
MLKQVEIFTD GSCLGNPGPG GYGAILRYRG REKTFSAGYT RTTNNRMELM AAIVALEALK
70
80
90
100
110
120
EHCEVILSTD SQYVRQGITQ WIHNWKKRGW KTADKKPVKN VDLWQRLDAA LGQHQIKWEW
130
140
150
VKGHAGHPEN ERCDELARAA AMNPTLEDTG YQVEV
Number of amino acids: 155
Molecular weight: 17596.9
Theoretical pI: 8.43
Amino acid composition:
Ala (A)
14
9.0%
Arg (R)
10
6.5%
Asn (N)
7
4.5%
Asp (D)
7
4.5%
Cys (C)
3
1.9%
Gln (Q)
8
5.2%
Glu (E)
12
7.7%

Gly
His
Ile
Leu
Lys
Met
Phe

(G)
(H)
(I)
(L)
(K)
(M)
(F)

14
5
7
12
11
4
2

9.0%
3.2%
4.5%
7.7%
7.1%
2.6%
1.3%

Pro
Ser
Thr
Trp
Tyr
Val

(P)
(S)
(T)
(W)
(Y)
(V)

5
4
10
6
5
9

Total number of negatively charged residues (Asp + Glu): 19
Total number of positively charged residues (Arg + Lys): 21
Atomic composition:
Carbon
C
776
Hydrogen
H
1215
Nitrogen
N
227
Oxygen
O
228
Sulfur
S
7
Formula: C776H1215N227O228S7
Total number of atoms: 2453
Extinction coefficients:
Ext. coefficient
40450
Abs 0.1% (=1 g/l)
2.299, assuming all Cys residues are reduced
Estimated half-life:
The N-terminal of the sequence considered is M (Met).
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 17.12
This classifies the protein as stable.
Aliphatic index: 73.68
Grand average of hydropathicity (GRAVY): -0.631
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3.2%
2.6%
6.5%
3.9%
3.2%
5.8%

Phage T7 ligase properties
10
MMNIKTNPFK
70
PALEHLNGFD
130
HEELFVEPIR
190
LQEYFPEIEW
250
PENEADGIIQ
310
SQWGFFSPYG

20
AVSFVESAIK
80
VRWKRLLNDD
140
KKDKVPFKLH
200
QAAESYEVYD
260
GLVWGTKGLA
320
IGDNDACTIN

30
KALDNAGYLI
90
RCFYKDGFML
150
TGHLHIKLYA
210
MVELQQLYEQ
270
NEGKVIGFEV
330
PYDGWACQIS

Number of amino acids: 359
Molecular weight: 41133.0
Theoretical pI: 5.27
Amino acid composition:
Ala (A) 18
5.0%
Arg (R) 13
3.6%
Asn (N) 18
5.0%
Asp (D) 22
6.1%
Cys (C)
6
1.7%
Gln (Q) 11
3.1%
Glu (E) 32
8.9%

Gly
His
Ile
Leu
Lys
Met
Phe

40
AEIKYDGVRG
100
DGELMVKGVD
160
ILPLHIVESG
220
KRAEGHEGLI
280
LLESGRLVNA
340
YMEETPDGSL

50
NICVDNTANS
110
FNTGSGLLRT
170
EDCDVMTLLM
230
VKDPMCIYKR
290
TNISRALMDE
350
RHPSFVMFRG

(G)
(H)
(I)
(L)
(K)
(M)
(F)

7.8%
2.5%
5.6%
9.2%
7.8%
3.9%
4.5%

28
9
20
33
28
14
16

60
YWLSRVSKTI
120
KWTDTKNQEF
180
QEHVKNMLPL
240
GKKSGWWKMK
300
FTETVKEATL
TEDNPQEKM

Pro
Ser
Thr
Trp
Tyr
Val

(P)
(S)
(T)
(W)
(Y)
(V)

14
16
17
9
13
22

3.9%
4.5%
4.7%
2.5%
3.6%
6.1%

Total number of negatively charged residues (Asp + Glu): 54
Total number of positively charged residues (Arg + Lys): 41
Atomic composition:
Carbon
C
1847
Hydrogen H
2846

Nitrogen
Oxygen

N
O

482
543

Sulfur

S

20

Formula: C1847H2846N482O543S20
Total number of atoms: 5738
Extinction coefficients:
Extinction coefficients are in units of M-1 cm-1, at 280 nm measured in water.
Ext. coefficient
69245
Abs 0.1% (=1 g/l)
1.683, assuming all pairs of Cys residues form cystines
Ext. coefficient
68870
Abs 0.1% (=1 g/l)
1.674, assuming all Cys residues are reduced
Estimated half-life:
The N-terminal of the sequence considered is M (Met).
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Instability index:
The instability index (II) is computed to be 40.00
This classifies the protein as stable.
Aliphatic index: 80.36
Grand average of hydropathicity (GRAVY): -0.400

143

Using hydroxyapatite chromatography to purify CPV resolvase
After first step of regular protocol, the CPV resolvase peak fractions were pooled (total 24ml). 12
ml of them was diluted with equal volume of buffer A1 and loaded to the HAP chromatography
column. After washing, a linear phosphate gradient was run from 0.05 to 1.0 M in 6 volume of
column volume (48ml). The CPV peak was eluted at 34 ml, corresponding of 0.3M phosphate.
Most of impurity bands appear in the later fraction, but a few bands are co-eluted with CPV
resolvase peak. These results are shown in following figure A and B.

HAP chromatography to purify CPV resolvase. (A)shows the phosphate gradient elution profile. (B) shows the SDS-PAGE
results of different fractions. Lane1: Ladder marker; Lane 2: CPV resolvase peaks pooled from SP-sepharose elution;
Lane 3 to 14 are evenly sampled from 32 ml to 54 ml.

Buffer A: 15% Glycerol, 10mM Na/K phosphate, pH 7.0.
Buffer B: 15% Glycerol, 1.0M Na/K phosphate, pH 7.0
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Typical nucleic acid enzymes and their divalent ion binding sites*
Enzymes

M2+ binding sites

Enzymes

M2+ binding sites

Taq DNA polymerase

2

Restriction enzymes

4

Pfu DNA polymerase

4

Ligase (dimer)

4

E.coli DNA polymerase I

6

RNaseH

2

Poxvirus DNA polymerase

4

Cas9

4

Retroviral transcriptase

6

Argonaute

4

Retroviral integrase

4

Dicer

4

RNA polymerase
2
* Only divalent ion binds to active sites are counted. Divalent ions number is calculated by active
sites multiplying by two. Divalent ions, such as Zn2+ forming Zinc finger, which don’t bind at the
active sites and only play a role to stabilize the protein structure, are not included in the
calculation.
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